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1 INTRODUCTION 
The treatment and prevention of cardiovascular disease is one ofthe triumphs of modern 
medicine but we have a long way to go before this success is completed. Heart attack 
and stroke are still common and, in the western world, cardiovascular disease remains 
the main cause of morbidity and mortality. 
A major player in cardiovascular homeostasis is the renin.angiotensin system (RAS), 
and the growing knowledge of this system has led to the development of agents that 
specifically interact with components that are part of the RAS. 'Anti-RAS' drugs are 
now widely used in the management of hypertension, heart failure and diabetic 
nephropathy. However, as is true for cardiovascular medicine in general, many problems 
remain to be solved. Our understanding of how the RAS works and how to modify its 
actions is still far from complete. 
One century ago Tigerstedt and Bergmann coined the name 'renin' for a hypertensive 
factor in rabbit kidney. I They showed that this factor was present in renal cortex and that 
it was secreted into renal venous blood. It was retained by dialysis membranes and sensitive 
to heat, which suggested its protein. nature. After these initial observations renin sank 
into oblivion for a few decades until interest flared up after the experiments by Goldblatt 
et al.2 who showed that clamping a renal artery in a dog caused hypertension. They 
believed a humoral factor to be the hypertensive principle, which was shown to be renin 
by Pickering et al.3 From then on unraveling of the structure of what nowadays is known 
as the RAS made steady progress, culminating in the cloning of the genes of its 
constituents (for a thorough review of renin's history see ref. 4). 
The Renin-Angiotensin System and its Components 
The RAS is a proteolytic cascade, connected to a signal-transduction system (Fig. 1) in 
which renin (EC 3.4.23.15) cleaves off the decapeptide angiotensin I (AngI) from the N-
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Figure 1. Schematk; outline of the renin-angiotensin system. 
Double arrow Indicates a proteolytic event. 
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terminal part of angiotensinogen. AngI is proteolytically converted to AngII by angiotensin 
converting enzyme (ACE). AngII acts through two kinds of receptors, the A T j and AT2 
receptor (A TlR and AT2R). Most effects of AngII are mediated through the ATlR. The 
AT2R is mainly expressed during ontogeny, and although no clear functions have been 
elucidated yet, it may be associated with cell differentiation and regeneration." 6 
Not shown in Fig. 1 is prorenin.lt was discovered in 1971 when Lumbers found that 
amniotic fluid, left at low pH in the cold, gained renin activity.7 Later asimilar phenomenon 
was described in plasma by Skinner.8 Acidification was not strictly necessary for activation, 
since incubation at low temperature also increased renin activity, albeit to only 15 percent 
of activity after acidification. Soon it was postulated that this inactive, but activatable 
'big' renin -its molecular weight was 5 kD higherthan thatof renin- was the biosynthetic 
precursor of renin. Hence, it was named prorenin.9 Only with the cloning of the renin 
gene in 1984,10 prorenin was definitively proved to be the precursor of renin. In normal 
human plasma prorenin circulates at a level of on average 9 times that of renin. Prorenin 
has also been demonstrated in plasma andlortissues of cat, II dog,12 cattle,13 pig, 13 horse,13 
sheep, 14 rabbit, 15 rat, 16 and mouse,I7 
Synthesis and Biochemistry of Renin and Prorenin 
The renin gene, spanning 12 kb, is located on chromosome 1 and consists of 10 exons 
with a coding sequence of 1218 bases. The initial translation product of the renin gene is 
preprorenin, consisting of 406 amino acids. The signal, 'pre' ~peptide of 23 amino acids 
targets the nascent protein into the endoplasmatic reticulum and is cleaved off upon 
entering. 1s Pro renin (M:r 47,000) enters either a regulated or a constitutive secretory 
pathway. 19 In the regulated pathway, which in humans has only been demonstrated in the 
juxtaglomerular cells of the afferent arterioles in the kidney, prorenin is converted 
proteolytically to renin (M, 40,000). This process takes place in dense secretory granules 
where a processing enzyme cleaves off the 43 amino acid N-terminal prosegment.19 
Release of stored renin from these secretory granules occurs after appropriate stimuli 
(see below). In the constitutive pathway, which is present in the kidney as well as at 
extrarenal sites of renin gene expression, there is a continuous flow of pro renin to the 
cell membrane and release into the extracellular space. 19 
Renin and prorenin are glycoproteins and belong to the class of aspartic proteases. 
These are characterized by two aspartic residues in their active center, which is located in 
a cleft between two homologous lobes.20 Aspartic proteases are secreted as zymogens, 
which have an N-terminal propeptide obstructing the active site-cleft, thereby inhibiting 
enzymatic activity. Well-known examples of aspartic proteases are pepsin, cathepsin D, 
chymosin and HIV protease. 
Proteolysis of angiotensinogen by renin is a first-order, one~substrate reaction. 
Angiotensinogen concentration in human plasma is about 1500 nM,21 which is near the 
Michaelis constant. This means that AngI and AngII generation are determined not only 
by the renin concentration but also by angiotensinogen concentration. 
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Prorenin is proteolytically converted to renin in vitl'O by the addition of proteases like 
trypsin or plasmin. In plasma the conversion is caused by endogenous kallikrein that is 
generated from prekallikrein after destruction of the natural inhibitors of contact 
activation of the coagulation cascade by exposure of plasma to low pH or to low 
temperature.22 This highly interesting in-vitro connection between the coagulation and 
renin-angiotensinogen system, however, has not been demonstrated to operate in vivo, 
although patients with prekallikrein deficiency have an increased prorenin·to·renin ratio 
in their plasma.2l Purified prorenin from either amniotic fluid or plasma, or recombinant 
prorenin may also be activated by exposure to low pH (acid-activation) or to cold (cryo-
activation), but in this case the activation is non-proteolytic and rapidly reversible during 
incubation at neutral pH and 37 'c. 24 It is assumed that this activation is caused by a 
conformational change of the molecule by which the propeptide moves out of the 
enzymatic cleft, thus permitting entry of the scissile bond of angiotensinogen into the 
catalytic center. 21 
Regulation of Renin and Prorenin in Health and Disease 
Renin secretion by the kidney is determined by various factors. First, there is a 
baroreceptor mechanism in the afferent artery that stimulates renin secretion from 
juxtaglomerular cells in case of low perfusion pressure." Second, the delivery of sodium 
chloride to the distal tubule is sensed in the macula densa; low levels stimulate renin 
secretion, high levels inhibit." The third factor is ~,-adrenoreceptor-mediated: 
stimulation causes renin release, inhibition decreases renin outpUt.l7 Humoral factors 
may also influence renin secretion. The most important is AngII itself, which inhibits 
renin secretion.28 A summary of various clinical conditions and pharmacological 
interventions that may change renin secretion can be found in Table 1. 
Many of these interventions cause increases in plasma renin within minutes. Because 
prorenin is not stored, but secreted continuously by the kidney, it can not respond to 
acute stimuli." Only when a stimulus persists will prorenin levels rise. Most stimuli that 
acutely raise renin secretion will also raise prorenin levels in the long run, probably through 
increased gene transcription. 
Fig. 2 shows renin/total renin ratios as a function of total renin in various chronic 
clinical conditions. It appears that total renin is determined by the underlying stimulus 
and that the conversion of prorenin to renin increases with increasing total renin levels. 
There are some exceptions to the rule, like pregnancy and diabetes mellitus with 
microvascular complications. Also subjects with prekallikrein deficiency (own 
observation),23 or heterozygous for a renin gene mutation causing a premature stop 
codon30 have relatively high prorenin levels. There is no clear explanation for this 
phenomenon. One can hypothesize that as long as the renin and total renin levels conform 
to a curve defined by points 1 through 9 in Fig. 2, the kidney is responding physiologically 
to a disturbance of homeostasis, through one of the aforementioned regulatory 
mechanisms of renin and prorenin release. If the reninltotal renin ratio is off the line, 
there may be some disturbance in the renin and prorenin synthesis machinery, probably 
at the level of extrarenal renin gene transcription or intrarenal prorenin-renin conversion. 
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Table 1. Clinical conditions affecting plasma renin levels. 
Stimulus to juxtaglomerular Decreased plasma renIn 
cell 
l'or .J, perfusion pressure sodium loads 
l'or -.!t sodium delivery 
to macula densa 
PI stimulation or inhibition 
Angiotensin II 
Unknown 
mineralocorticoid excess 
liddle's syndrome 
Cushing's syndrome 
sodium loads 
autonomic dysfunction 
beta blockade 
adrenergic neuronal 
blockade 
hyporenlnemic 
hypoaldosteronism 
low-renIn hypertension 
Prorenin as Pro·enzyme or Prohormone 
Increased plasma renin 
renovascular hypertension 
malignant hypertension 
cirrhosis with ascites 
hemorrhage 
diuretics 
gaslrolntestinalloss 
upright posture 
heart failure 
nephrotic syndrome 
sodIum restriction 
direct vasodilator therapy 
pheochromocytoma 
hypoglycemia 
hyperthyroidism 
sympathicomImetic agents 
ACE Inhibllor 
angiotensIn II receptor 
antagonist 
acute glomerulonephritis 
high·renln hypertension 
Prorenin is a most unusual precursor in that no evidence exists that it is activated to renin 
in the circulation. Other proteolytic enzymes also circulate in a precursor form, a good 
example being coagulation factors, which belong to the group of serine proteases. But in 
contrast with pro renin, coagulation factors are activated continuously at sites where a 
trigger is present. The concentration of circulating activated coagulation proteases is 
always very low, much lower relative to their precursor than the concentration of renin 
relative to that of prorenin. The activity of coagulation factors is also heavily restrained 
by the presence of inhibitors, whereas for renin no circulating inhibitor is known to exist. 
If one considers renin as a hormone and prorenin as a prohormone (see below), there is 
a peculiarity that contrasts with the proenzyme! enzyme relationship of circulating serine 
proteases. Where prorenin levels relative to renin levels appear not high enough to regard 
prorenin as a typical circulating protease precursor, they are not low enough for a typical 
prohormone. Peptide pro hormones usually circulate at lower levels than their active 
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counterpart. For instance, insulin circulates together with its precursor proinsulin, but 
proinsulin concentration is at most 70% of insulin concentration. Moreover, proinsulin 
has some insulin-like action of its own, in contrast with prorenin, which has not (yet) 
been shown to possess any activity in the circulation. 
Although prorenin's role as the renin precursor in the kidney is clear, its function, if 
any, in the circulation or at other sites remains an enigma despite an estimated one 
thousand" published papers. 
Thinking on prorenin can be facilitated when we are aware of paradigms that were 
developed for the RAS and aspartic proteases. I shall discuss these first before elaborating 
on hypotheses concerning the role of prorenin. 
The Paradigm of {Pro )Renin as an Aspartic Protease 
Although the structure of pro renin has not been determined directly by X-ray diffraction 
analysis, it is very likely from computer simulation studies that it has the geometry 
common to other aspartic protease zymogens (pro-enzymes).",Jl The single polypeptide 
chain is arranged in two homologous lobes with a deep cleft in between, which contains 
the active site. This cleft is covered by a propeptide, which is the N-terminal part of the 
polypeptide chain and blocks the access of substrate and hence renders the molecule 
enzymatically inactive.34 
Aspartic proteases have low substrate specificity, are inhibited by the statin-containing 
peptide pepstatin and usually have a low pH optimum ( < 3). They are synthetized as 
zymogens and are then transported to asite with low pH. At this low pH, the propeptide 
renin/total renin 
(x100%) 1 Anephrics 
2 Conn syndrorre 
3 Essential hypertension 
4 N:mrotensive subjects 
5 Essential hypertension treated with enalapril 
6 Renovascular hypertension 
70 
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10 
o 
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Figure 2. Relationship between renin/tolal renin ratio (ordinate, mean±SD) and total renin 
(=renin+prorenln) (abscissa, geometric mean, 95% GI) in various clinical conditions. Data 
kindly provided by F. Derkx, published In: Delnum et ai, Textbook of Hypertension, Eds 
Weber&Oparil, WB Saunders, 1999, Ch. 7,with permission. 
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unfolds and is subsequently cleaved off by intra· or intermolecular proteolysis.2o In view 
of the low substrate specificity, the secretion as zymogen, the activation at low pH and 
the low pH optimum can be seen as effective safeguards against inappropriate proteolysis 
at the physiological pH of blood. For instance, pepsinogen secreted in the stomach is 
only activated when it reaches the acidic environment of the stomach. Likewise, 
procathepsin D will not become enzymatically active until it reaches the acidic pre· 
lysosomes. 
Despite its similar structure, prorenin does not fit in nicely with the picture of an 
aspartic protease. First, there is no evidence that prorenin is capable of auto-activation. 
This is explained by the exclusive dedication of the active site of the renin molecule to 
one substrate, angiotensinogen. This mono-specificity is another deviation of the general 
aspartic protease scheme. In humans, angiotensinogen is cleaved at the fairly high pH 
optimum of 5.6, with still 50% activity at pH 7.4.35 This relatively high pH optimum is 
a third difference with other aspartic proteases. Furthermore, transport is not to the 
exterior Qike pepsinogen) or to intracellular organelles like lysosomes (cathepsin D), but 
to the blood. Finally, part of prorenin, after its synthesis in the kidney in specialized cells, 
is activated in these cells to renin, before it is secreted into the blood. This is unusual for 
extracellular aspartic proteases and, for that matter, as mentioned above, unusual for 
any circulating proteolytic enzyme. 
Although prorenin appears to be an exception arnongthe aspartic protease zymogens, 
one wonders whether it has retained some of the typical features of this class of proteolytic 
enzymes. For instance, is prorenin secreted into the blood in order to be transported to 
its site of action, presumably outside the intravascular compartment, where it is then 
activated to renin? Does prorenin assume an enzymatically active conformation in vivo 
by unfolding of its prosegment, like other aspartic proteases do at low pH? Is its site of 
action a place where pH is closer to the renin pH optimum and where spontaneous 
activation may take place? 
The Paradigms of Local Tissue Renin.Angiotensin Systems 
Classically the renin-angiotensin system is seen as an endocrine system. Circulating renin 
splices AngI from angiotensinogen and AngI is converted to AngII by ACE in the 
pulmonary circulation. AngII is then transported to its target sites. Although strictll semll 
renin is not a hormone, it can be considered as such, because its concentration is rate-
determining in AngII generation and subject to tight control. Hence, according to this 
concept, the level of renin in plasma is thought to be an adequate measure of RAS 
activity. 
In the past years another concept has emerged in which so·called local or tissue RASs 
are postulated. The essence of this paradigm is that these systems produce AngII outside 
the circulating blood and that AngII acts in a paracrine or autocrine way, i.e. binds to 
receptors on neighbor cells or on the very cell where AngII is formed. The concept is 
based on several observations. Pharmacologic interference with the RAS by renin inhibitor 
causes changes in blood pressure that in magnitude and duration are discrepant with the 
concentration of plasma AngII or with plasma renin activity,36, 37 which is well explained 
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by a selective interference of the renin inhibitor with tissue RASs. More direct evidence 
for the existence ofRASs is provided by measurements of tissue concentrations ofRAS 
components showing that these concentrations are too high to be accounted for by plasma 
contamination and by demonstration of messenger RNA of components of the RAS.J8 
This evidence supports the hypothesis that a local RAS is not only present in the kidney 
but also in some extrarenal tissues like brain, adrenal gland and gonads."'" An exhaustive 
summary of the evidence for local RASs can be found in ref. 40 . In these organs there is 
evidence oflocal production of prorenin and possibly renin, and this raises the possibility 
that angiotensin formation in those tissues is regulated independently of kidney renin. 
The paradigm of kidney-independent RASs has been extended to the heart and blood 
vessels but renin mRNA is very low in these tissues. Extensive studies in humans and in 
pigs by Admiraal and Danser et al.41 using systemic infusions of radio labeled Angl and 
l! and measurements of the blood plasma levels of both radiolabeled and endogenous 
angiotensins, in different regional vascular beds, demonstrate that part of AngI in the 
circulation is indeed produced at tissue sites and that this locally produced Angl makes 
a significant contribution to thecirculatoty level of Angl!. However, the local angiotensin 
production appeared to be dependent on kidney-derived renin. Similar studies in pigs, 
but now with measurements of tissue levels of radiolabeled and endogenous angiotensins, 
showed that most of the Angl! present in cardiac tissue is not derived from the circulation 
but is produced in the tissue and this locally produced Angl! is derived from Angl that is 
also produced in the tissues.42 It is therefore possible that a significant proportion of the 
cardiac AT-receptors are activated by this in·situ produced Angl!, rather than by Angl! 
from the circulation. The cardiac production of angiotensins, however, depended on 
kidney-derived renin; after bilateral nephrectomy the tissue levels of Angl and II fell to 
undetectably low levels.43 In human hearts, both under normal and pathological 
conditions, the tissue levels of renin were directly correlated with the levels in blood.44 
The fact that the angiotensin formation in cardiac tissue depends on kidney-derived 
renin does not mean that changes in circulating Angl! always lead to parallel changes in 
tissue Angl!. There is evidence to suggest that most of locally generated tissue Angl! 
that is derived from in-situ produced tissue AngI, does not enter the circulation. 
Experiments in pigs showed that suppressed production of plasma Angl! following 
treatment with the ACE-inhibitor captopril, had little effect on the level of Angl! in 
cardiac tissue.42 
Hypotheses Concerning Prorenin 
Various hypotheses have been put forward to provide a role for prorenin and, hence, to 
justify its existence.'" 45 Most of these hypotheses remain within the framework of the 
aforementioned paradigms. They are summarized in Table 2. Some of them are quite 
obvious, others are highly speculative. 
What evidence do we have to prove or disprove any of these hypotheses? 
Let us first consider observational data. Anephric subjects have vety low, although 
not zero, 46 circulating levels of renin, Ang! and Angli in the presence of near~normal 
levels of prorenin and high levels of angiotensinogen. 47 This indicates that prorenin is 
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Table 2, Hypotheses concerning profenln 
1 
2 
Only the kidney processes profenln to renin 
Proreoin is a source of renin, by conversion to renin in the 
circulation 
Reference 
45 
31 
3 Profenin could playa direct role, not mediated by renin and 31 
not necessarily related to fluid, electrolyte and blood 
pressure homeostasis 
4 Profenln can mImic the function of renin In\~ivo without 43 
cleavage of Its prosegment 
5 Profenin could be the transporter of potential renIn activity to 31 
various target organs, where it acts directly 
6 Circulating profenln Is a "spill-over" from renal and (or) 31 
extrarenal sources, where renin or profenin functions within 
those tissues or organs and not in the circulation 
7 The tissue renin systems function via profenin 43 
8 Circulating renin and prorenln may bind to tissue by specific 45 
binding sites. 
9 Prorenln may displace renin from binding sites and thus 54 
decrease local renin activity 
10 Prorenin Is an Idiosyncratic by~product of renin synthesis 
and, In fact, redundant, and not worthy of any further study 
not activated in the circulation and, hence, hypothesis (2) in Table 2 is unlikely. Hypothesis 
(1) may be restated as: circulating renin is derived from the kidney. 
Experimental evidence against hypothesis (2) has also been obtained from infusion 
studies of pro renin and from observations in transgenic animals. Short-term infusion of 
recombinant human prorenin in monkeys did not lead to higher renin, Ang! or AngII 
levels.48• 49!f any change was observed, it was a slight decrease in blood pressure. This 
argues against hypothesis (2). On the other hand, infusion experiments of radio-labeled 
prorenin showed binding of prorenin in the liver and kidney and conversion to renin.so 
This argues against hypothesis (1). Binding of prorenin to tissues or cells has been 
demonstrated,51.53 although not necessarily to cells derived from kidney or liver. 
Activation of prorenin to renin by extrarenal cells has also been confirmed.52 The 
physiological significance of renin binding was investigated in an experiment by Hu et aI. 
who infused either renin or AngII in rats to the extent that both regimens yielded identical 
plasma levels of Ang II. 54 !flocal renin activity after renin binding would be important 
renin infusion would be expected to have additional hemodynamic and hormonal effects. 
This appeared not to be the case. This argues against hypothesis (9). Hypothesis (9) was 
also challenged in a study by Muller et aI. who infused human prorenin and renin in a rat, 
transgenic for human angiotensinogen.5S Infusion of prorenin alone or in combination 
with renin did not affect blood pressure or AngII levels. 
An interesting transgenic rat model has been developed by Mullins et al.56 They 
inserted the murine Ren2-renin gene in the genome of a rat strain. Transgenic rats 
developed an AngII-dependent hypertension with grossly elevated plasma prorenin levels. 
The renin gene wasoverexpressed in adrenals, but not in kidney. Although the mechanism 
by which hypertension is caused in these rats is still elusive, the model raises the possibility 
14 
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that renin or perhaps prorenin may cause hypertension independently of the plasma 
RAS. On the other hand, transgenic rats, overexpressing rat prorenin in the liver, showed 
normal blood pressure. In spite of the absence of hypertension, however, cardiomegaly 
and severe renal lesions were present.57 Plasma prorenin levels in these transgenic rats 
are increased 400-fold. This suggests that (circulating?) prorenin has a role in the 
development of cardiac and renal pathology and refutes hypothesis (10). To my 
knowledge, animals whose renin gene has been knocked out have not been constmcted, 
but then, would any change observed in such an animal be due to the absence of renin or 
the absence of prorenin or both? 
The picture that emerges is that prorenin is unlikely to playa role in the circulation, 
but may have a role in local RASs. 
Studies that appear to refute definitively one hypothesis or the other are scarce. The 
main obstacle is probably the fact that it is nearly impossible to study prorenin in animals 
in the absence of renin. Any change in the level of prorenin is usually accompanied by a 
change in the level of renin. Infusion studies as mentioned above were performed with 
heterologous prorenin and renin, and this leads to suppression of endogenous pro renin 
and renin. Results may therefore not be extrapolated to the physiology of homologous, 
endogenous prorenin. Furthermore, in humans, prorenin and renin may only be studied 
in blood, whereas it may well be that tissue concentrations are more important. Osmond 
et al. have pointed out that another and main obstacle to further progress is the difficulty 
in measuringprorenin.31 I shall now first address this issue. 
Measurements of Renin and Prorenin 
Measurement of pro renin is intimately linked to how renin is measured. In contrast with 
many other proteins, there is no generally accepted standard method to determine renin. 
It istherefore no surprise that the question of which method to use for renin measurement 
has been subject to hot debate,58 and it still is. 
The most widely employed way to measure renin is through its enzymatic activity. 
This indirect way of quantification is performed by incubating renin with its substrate. 
Angl is then quantitated by radioimmunoassay and this gives an estimate of the amount 
of renin. 
Many groups advocate the use of the plasma renin activity (PRA) assay which uses 
the endogenous angiotensinogen, present in the plasma sample, as substrate. In most 
plasma samples the concentration of endogenous angiotensinogen is close to the Km of 
the renin-substrate reaction, so that results of the PRA assy are determined by the plasma 
concentration of renin as well as by that of angiotensinogen. Only when the concentration 
of endogenous angiotensinogen is elevated, as is the case in pregnancy, following the use 
of oral contraceptives or a high dose of glucocorticoid, and in hyperthyroidism, PRA 
results are mainly determined by the plasma concentration of renin. PRA usually 
correlates well with the asssay ofPRC (plasma renin concentration), in which exogenous 
angiotensinogen is added in order to obtain zero-order kinetics of AngI generation. 
Both in the PRA and PRC assays, the AngI-to-AngII converting activity and the Angl-
15 
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and AngII-degrading activity have to be removed from the plasma sample before the 
AngI-generating step. This is done by methods that destroy these enzymes or remove 
them from plasma or by the addition of the appropriate enzyme inhibitors. 
Prorenin cannot be measured via its enzymatic activity, but must be converted to 
renin by limited proteolysis. This can be achieved by either trypsin or by acidification of 
plasma to pH 3.3 and subsequent incubation at 4°C and pH 7.4. The difference in 
enzymatic activity before and after activation is then a measure of prorenin concentration. 
These enzymatic methods have several drawbacks. First, protee-lytic activation may not 
be complete, which leads to underestimation of prorenin. Second, the proteolysis may 
be too extensive and lead to destruction of renin and prorenin and hence to 
underestimation of prorenin. Third, in some assays, acidification of plasma has been 
used to destroy angiotensin-degrading enzyme activity. At the time such assays were 
performed, it was not known that plasma contained pro renin and that pro renin was 
activated by acidification. The use of an acidification step in assays of plasma renin leads 
to the co-measurement of prorenin, and this has been the cause of much confusion. For 
instance, there has been controversy about whether or not plasma renin is reduced 
following treatment of hypertension with b-adrenoceptor blocker, whether or not renin 
suppression contributes to the decrease in blood pressure. Eventually, with the use of 
better assays that do not co-measure prorenin, it has been established that beta-blocker 
treatment lowers plasma renin effectively, whereas prorenin is unaltered or elevated.59 
Finally, it has been described that, during the proteolytic activation step in rat plasma, 
trypsin may splice the N-terminal14 amino acid-peptide from angiotensinogen, which 
then acts as a substrate for renin. 60 
Recently, direct immunoradiometric assays (IRMAs) specific for human renin have 
become available"!' 62 These offer speed and reliability and can be routinely standardized. 
These IRMAs, however, are somewhat less sensitive and probably less suitable in low 
renin states.58 Another problem of theIRMAs may be that a small percentage of prorenin 
is co-measured as renin in these assays. Because of the relatively high prorenin levels, this 
may influence the results, especially in plasmas with a low renin level'" These assays, 
however, are well suited for most clinical purposes.62 Prorenin can also be measured by 
these IRMAs after the proteolytic conversion of prorenin to renin. This, however, is 
associated with the same potential problems as encountered in the assays that rely on 
renin's enzymatic activity. 
It has been argued, probably rightly so, that the lack of standardization is one of the 
reasons why still so much remains to be discovered about the renin-angiotensin system.' 
63 A WHO renin standard is available," established in 1974, derived from human kidney 
# This has been pointed out eloquently by Sir George Pickering. At a meeting in 1963 he said: 
.. Another method is the hillbilly method. You take the unknown in one hand and put stones in 
a bucket in the other hand until the bucket feels the same weight as the unknown. Then you 
guess the weight of the stones. Sometimes the methods used to assay renin and angiotensin 
seem to me to be very much like the hillbilly method. Even today we have no agreed unit for 
the assay of renin. Many workers do not even use a standard. You cannot compare results 
from day to day, from one laboratory to another, from country to country ... 
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and defined by its hypertensive action in a bioassay. It seems that efforts have been made 
to establish a purer standard,6s based on recombinant human renin. However, little 
progress has been made, and it is impossible or at least hazardous at present to compare 
renin values obtained in one laboratory with those from another. 
Scope of the Thesis 
As pointed out above, it is still very difficult to verify or falsify hypotheses concerning 
prorenin's physiology by rigorous experiments. We have to rely on observational studies. 
This thesis is no exception to the rule and in a largely phenomenologic approach we will 
adress three issues, namely reversible activation of prorenin and its implications for 
measurement methodology, deranged plasma levels of prorenin in diabetes mellitus and 
finally tissue levels of prorenin. 
Chapter 2 is concerned with structural aspects of prorenin during its non·proteolytic 
activation. What are the characteristics of prorenin activation in vitro and can we generate 
from these characteristics a hypothesis of how prorenin activation occurs in vim? Chapter 
3 is concerned with the methodology of renin and prorenin measurements. The 
observations described in chapter 21ed to new assays of renin and prorenin, which lack 
some of the drawbacks of older methods, and may set a new, so much needed, standard 
in renin and prorenin measurement methodology. 
Certain pathological states in which prorenin regulation is altered, may provide clues 
to the physiology of prorenin. Diabetes mellitus, complicated by microvascular 
complications is such a condition (Fig. 2). In chapter 4 we studied how plasma prorenin 
is related in time to the development of microalbuminuria (chapter 4.1). Since the 
development of albuminuria in diabetes mellitus probably is also determined by genetic 
factors we investigated whether renin gene variants are associated with either the 
development of nephropathy or plasma prorenin levels (chapter 4.2). Thirdly, we studied 
prorenin in tissues. Observations in pathological human eye fluids (chapter 5.1) were 
corroborated by prorenin and renin measurements in normal bovine eyes (chapter 5.2). 
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CHAPTER 2 STRUCTURE OF PRO RENIN 

2.1 NON-PROTEOLYTIC' ACTIVATION' OF PRO RENIN BY ACTIVE SITE-
DIRECTED RENIN INHIBITORS AS DEMONSTRATED BY RENIN-SPECIFIC 
MONOCLONAL ANTIBODY 
Summary 
Incubation of human plasma prorenin (PR), the enzymatically inactive precursor of renin, 
with a number of non-peptide high-affinity active site-directed renin inhibitors induces a 
conformational change in PR, which was detected by a monoclonal antibody that reacts 
with active renin but not with native inactive PRo This conformational change also 
occurred when inactivePR was activated during exposure to low pH. Non-proteolytically 
acid-activated PR, and inhibitor-'activated' PR, as well as native PR, were retained on a 
blue Sepharose column, in contrast to proteolytically activated PR. Kinetic analysis of 
the activation of plasma prorenin by renin inhibitor (lNH) indicated that native plasma 
contains an open intermediary form of pro renin, PRoil in which the active site is exposed 
and which is in rapid equilibrium with the inactive closed form, PR . PR . reacts with 
, 00 
inhibitor to form a reversible complex, PR .. INH, which undergoes a conformational 
change resulting in a tight complex of a modified open form of prorenin, PRo' and the 
inhibitor, PR .. INH~PR ·INH. The PR .-to-PR conversion leads to the expression 
0' 0 Y' 0 
of an epitope on the renin part of the mo ecule that is recognized by a renin-specific 
monoclonal antibody. Presumably, PRo corresponds to the enzymatically active form of 
PR that is formed during exposure to low pH. Thus, it seems that the propeptide ofPR 
interacts with the renin part of the molecule not only at or near the enzyme's active site 
but also at some distance from the active site. Interference with the first interaction by 
renin inhibitor leads to destabilization of the propeptide, by which the second interaction 
is disrupted and the enzyme assumes its active conformation. The results of this study 
may provide a model for substrate-mediated prorenin activation and increase the 
likelihood that enzymatically active prorenin is formed in vitro. 
Introduction 
The conversion, by limited proteolysis, of the inactive proenzyme form of serine 
proteinases into their active counterpart has been extensively studied. Pro renin, the 
enzymatically inactive proenzyme form of the aspartic proteinase renin is also activated 
by limited proteolysis, which causes the prosegment to be cleaved from the prorenin 
polypeptide chain. '·5 The spatial conformation of the folded renin polypeptide chain 
shows a bilobar structure, the two lobes being separated by a cleft containing the enzyme's 
active site.' Presumably, in prorenin the cleft is covered by the prosegment (closed form 
of prorenin).7, 8 
Prorenin can also be activated without proteolysis, by exposure to low pH or low 
temperature.9.B Probably the non-proteolytic activation of prorenin involves a 
conformational change by which the cleft is uncovered (open form of prorenin), so that 
the scissile peptide bond of angiotensinogen can get access to the active site of the 
enyme. It is generally assumed that prorenin's physiological function depends on its 
conversion to renin. However, since studies with purified recombinant human prorenin 
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provided some evidence for its spontaneous activation, the possibility arises that apart 
from renin, prorenin itself may have some physiological role.7, 14 
Here we report on evidence that the native closed form of prorenin, without any 
pretreatment, is in rapid equilibrium with an open form that is capable of reacting with 
a number of high-affinity active site-directed renin inhibitors. This reaction leads to a 
conformational change of the prorenin molecule, which is recognized by a monoclonal 
antibody that binds to renin but not to the closed form of prorenin. These in·vitro 
observations raise the possibility that an enzymatically active form of prorenin may 
exist in vivo. 
Materials and Methods 
Chemicals 
Two monoclonal antirenin antibodies were used. They were obtained from Pasteur 
Diagnostics, Marnes de Coquette, France. Their characteristics have been described in 
detail. 1s.t7 
Monoclonal antibody 3E8 (mAb3E8) binds prorenin as well as renin, and does not 
inhibit renin's enzymatic activity. This antibody was coupled to polyacrylamide-agarose 
beads (diameter, 60-170 I'm) containing ferrous oxide (Magnogel, Diagnostics Pasteur, 
Marnes La Coquette, France), as described elsewhere." The beads with coupled antibody, 
1.3 mg of antibody per of Magnogel, were obtained from Pasteur Diagnostics. The 
second monoclonal antibody, mAb4G1, which was labeled with 1251 (925 kBeq/l'g 
antibody), recognizes an epitope of renin and inhibits renin's enzymatic activivity but 
does not cross· react with inactive prorenin. 15 
Human kidney renin standard, MRC 68/356, was obtained from the Medical Research 
Council Institute for Biological Standards and Control, Potters' Hill, Hertfordshire, 
United Kingdom. Plasmin (EC 3.4.21.7) was obtained from Kabivitrum. Soybean trypsin 
inhibitor (SBTI) 19 was obtained from Sigma. 
The following active site-directed renin inhibitors were studied: remikiren (Hoffmann-
La Roche, Basel, Switzerland),2o A-64662 (enalkiren, Abbott Laboratories, Abbott Park, 
IL)," and CGP 38560A (Ciba Geigy, Basel, Switzerland)." 
A plasma pool from healthy subjects (n = 14) was used as a source of renin and 
prorenin. Blood from these subjects was collected into polystyrene tubes containing 
trisodium citrate solution (0.2 mL in 10 mL blood, final citrate concentration 13 mM), 
and immediately centrifuged for 10 min at 3,000 x g and room temperature. The plasma 
was stored at -70°C. 
Binding of Prorenin to Gel Beads by Immunoadsorption_ mAb3E8 coupled to 
Magnogel beads was used to trap renin and pro renin from plasma. The beads were 
suspended in 0.2 mM imidazole-HCI buffer containing 0.25% gelatin and 15 mm sodium 
azide. The suspension (250 I'L), which contained 4% Magnogel, was added to plasma 
(250 I'L), and the mixture was incubated for 2 h at room temperature, while the tubes 
containing the mixture were placed in a horizontal rack shaker to keep the beads in 
suspension. At the end of the incubation period, 2 mL of phosphate-buffered saline 
(PBS, 0.1 M sodium phosphate buffer pH 7.4, containing 0,05 M NaCl) was added, and 
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the tubes were shaken for 2 min. The beads were then separated from the buffer solution, 
without removing them from the tubes, by means of a magnetic ruler placed in close 
contact with the tubes, and the supernatant was discarded. Again 2 mL of PBS was 
added, and after 2 min of shaking, the separation procedure was repeated, and the washed 
beads were resuspended in PBS. 
Proteolytic Activation of GeI·bound Prorenin by Incubation with Plasmin. 
Magnogel·mAb3E8 beads with bound prorenin from 250 p,L of plasma were suspended 
in 250 p,L of PBS containing 0.2 p,M plasmin, and incubated for 24 h at 4 oC, while the 
tubes were continuously shaken. This procedure caused complete activation of prorenin, 
as was demonstrated by measuring the enzymatic activity of the beads and by comparing 
the results with those from OUf routine enzyme-kinetic assay of renin and prorenin.23 24 
Magnogel·mAb3E8 beads with bound renin from the MRC human kidney renin standard 
did not show a change in enzymatic activity after treatment with plasmin. Complete 
activation of prorenin by plasmin and the absence of any effect of the plasmin treatment 
on the MRC human kidney renin standard was also demonstrated with the 
immunoradiometric assay, in which the washed plasmin.treated beads were incubated in 
a buffer containing 125I·labeled mAb4G 1 and the quantity of antibody bound to the 
beads was measured after incubation, byycounting (tmmunoradiometricassay, see below). 
Non.proteolytic 'Activation' of GeI·bound Prorenin by Incubation with Renin 
Inhibitor. Magnogel.mAb3E8 beads with bound prorenin from 250 p,L of plasma were 
suspended in 250 p,L of PBS containing renin inhibitor in concentrations ranging from 
10.8 to 104 M. The mixture was incubated for periods ranging from 30 min to 24 h, 
while the mixture containing the beads was continuously shaken. During this procedure 
the prorenin molecule undergoes a conformational change, by which it becomes 
recognizable by the antibody mAb4Gl. Because this antibody recognizes renin but not 
inactive prorenin, the effect of renin inhibitor on the binding of prorenin to the antibody 
is referred to as 'activation'. The quantity of 125I·labeled mAb4G 1 bound to the beads 
after incubation with this antibody was used as a measure of the activation of prorenin 
by renin inhibitor (immunoradiometric assay, see below). 
Non·proteolytic Activation of Prorenin in the Fluid Phase in Complete Plasma by 
Incubation with Renin Inhibitor or by Acidification. To study the effect of renin 
inhibitor on prorenin in complete plasma, normal plasma pool (6 mL) to which 60 p,L 
of the serine protease inhibitor SBTI (final concentration, 50 p,M) and either PBS alone 
or PBS containing remikiren (60 p,L) had been added was incubated for 24 h at 4 °C, at 
room temperature, or at 37°C. The final concentration of remikiren was 10 p,M. Samples 
were taken at different time intervals for immunoradiometric assay of renin (see below). 
It is known that prorenin is reversibly activated after acidification. II, 12 After restoration 
of pH prorenin again assumes its inactive form. To study the effect of renin inhibitor on 
the inactivation of acid·activated plasma prorenin, plasma was diluted with an equal 
volume of 0.05 M glycine HCI buffer, pH 2.5, containingO.l M NaCI, and dialyzed at 4 
°C for 24 h against 0.05 M glycine HCI buffer, pH 3.3, containing 0.1 M NaCL 13 The 
plasma was then neutralized by adding an equal volume of 0.1 M PBS, pH 8.0, containing 
0.05 M NaCL Fine adjustment of pH to 7.4 was made by adding 1 M NaOH or 1 M 
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HC!. AfterpH adjustment, which took less than 5 min, either PBS alone or PBS containing 
remikiren was added (10 p.L in 1 mL of pH-adjusted plasma). The final concentration of 
remikiren was 10 p.M. Renin was measured by immunoradiometric assay (see below) 
either immediately after pH adjustment or after a l-h incubation 37°C. 
Inununoradiometric Assay of Proteolytically Activated and Renin Inhibitor-
Activated Gel-bound Prorenin. The assay was carried out according to Refs. 16 and 
17. Magnogel-mAb3E8 beads with bound prorenin from 250 p.L of plasma were treated 
with plasmin or renin inhibitor, as described above. The beads were then washed in PBS 
and resuspended in 250 p.L of 0.05 M Tris-HCI buffer, pH 7.4, containing "'I-labeled 
mAb4Gl (approximately 100,000 cpm), 10% horse serum, and 15 mM sodium azide. 
The mixture was incubated for 3h at room temperature, while the tubes containing the 
beads were continuously shaken. After incubation the beads were washed three times 
with PBS, and radioactivity was counted. Nonspecific binding of radiolabeled antibody 
was less than 0.2%. Results are expressed as nglliter, using highly purified human renin 
as the standard. 15 
Enzyme.kinetic Assay of Gel-bound Renin and Proteolytically Activated Gel·bound 
Prorenin. To measure the binding of renin and prorenin to the Magnogel-mAb3E8 
beads, the enzymatic activity of the beads was determined as the quantity of AngI that 
formed during incubation with sheep angiotensinogen (1 p.M) at 37°C for up to 1 h. The 
beads with bound renin and prorenin were incubated with angiotensinogen before and 
after treatment with plasmin 4°C, in order to convert prorenin into renin. AngI generation 
rates by the beads were compared with the results of our routine enzyme-kinetic assays 
of renin and prorenin in plasma, which were carried out under comparable conditions 
and which also made use of sheep angiotensinogen as the substrate.22 It appeared that 
more than 90% of the renin and prorenin present in plasma was trapped by the Magnogel-
mAb3E8 beads. 
In order to measure K. of the renin inhibitor remikiren, Magnogel beads with bound , 
kidney renin from MRC standard 38/356 were also incubated with sheep angiotensi-
nogen (1 p.M), in the presence of the renin inhibitor in concentrations ranging from 10.10 
to 10.5 M. Km for the reaction of gel·bound kidney renin with sheep angiotensinogen was 
also measured. It was 0,24 p.M (mean of triplicate measuremen which is similar to Km 
(0.21-28 p.M) for fluid phase renin." A plot of V/W; -1) against inhibitor concentra-
tion was made (Va and V; are the enzymatic activities in the absence and presence of 
inhibitor, respectively. The slope of this line equals I/K;(, r K; was calculated according 
to the equation K; - K;(, /Q + [S)/ KJ, in which[S) is tlie angiotensinogen concentra-
tion. K; of remikiren app~ared to be 8 nM (mean of triplicate measurement). 
Separation of Proteolytically Activated and Renin Inhibitor-Activated Prorenin 
by Dye Ligand Chromatography. Plasma was treated with Sepharose-bound trypsin 
as described by Derkx et al.22 or by incubation with the renin inhibitor remikiren (fmal 
concentration, 50 p.M) for 48 h at 4°C. Native plasma or trypsin- or inhibitor-treated 
plasma (2 mL) was applied to a 1 x 16·cm column of blue Sepharose (pharmacia LKB 
Biotechnology Inc.). The column had been equilibrated with 20 mM sodium phosphate 
buffer, pH 7.2. Elution was performed in two steps, Le. with the equilibration buffer and 
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same buffer containing 1.4 M NaCl. 1l The flow rate was 60 mL/h and 2.Q.mL fractions 
were collected. Equilibration and elution were carried out at room temperature. The 
renin content of the fractions was determined with the immunoradiometric assay, both 
before and after incubation of the fractions with plasmin, 0.2 I'M final concentration, for 
24 h at4 °C. 
Kinetic Analysis of Renin Inhibitor-Induced Activation of Prorenin.We assumed 
the renin inhibitor to interact with prorenin in the manner of active site-directed 
irreversible inhibitors24 as follows. 
K; k 
E +INH~ reversible ~ irreversible complex 
complex 
The first step is the formation of the reversible E· INH complex that is in rapid 
equilibrium with E and INH, K, being defined as follows. 
K - [E]-[INHJl(E-INHJ , 
The second step is the formation of the irreversible E·INH complex, which is a first 
order reaction with the rate constant k . This first order reaction is the rate-limiting 
mu 
step. This reaction sequence implies that the inhibition rate is saturable with respect to 
the concentration of enzyme-inhibitor complexes. 
We further assumed the existence of closed and open forms of prorenin. In the 
closed form, PRo' the cleft is covered by the prosegment so that the inhibitor cannot 
reach the active site of pro renin. Our results (see later) indicated that the irreversible 
E·INH complex but not the reversible E·INH complex, could be recognized by the 
monoclonal renin antibody mAb4G I. This implies the existence of two open forms of 
prorenin. Both can bind active-site ligands but one form, PRo is recognized by the 
antibody, whereas the other, an intermediary open form, PR ., is not. PR . is assumed to 
01 01 
be in rapid equilibrium with PR,. The anticipated reaction sequence is then as follows. 
~ knul( 
P~i + INH () PRoi• INH --)- PRo °INH 
K, tt 
PI\ 
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K. and K are defined as follows. , , 
K=[pR ][INH]/[pR .. lNH] 
I 01 01 
K = [PR y[PR , 
a Oi c.l 
(1) 
(2) 
CPR ], CPR .], [INH] and CPR .·INH] are the concentrations of PR ,PR ., INH, and 
C Oi 01 COl 
PR .·INH complex. The anticipated reaction scheme leads to the following. 
m 
·d[PR]/dt=[pR .·INHl'k 
m nux 
(3) 
[PRJ is defined as follows. 
[PR]- [PR '+ [PR .]+ [PR .. lNH] 
c-' OJ 01 
(4) 
On the basis of equations 1,2, and 4, [pRo;'INH]can be expressed as a function of [PR], 
[INH], K and K as follows. , , 
CPR .. INH]= [INH]/Kj . [PRJ 
01 1+ 1IKa +[INH]/Kj 
(5) 
The solution to equation 3 is 
[PR], =[pRVAxknuxx, (6) 
in which 
A [INH]/Kj 
1 + 1/ Ka + [INH]/ Kj 
(7) 
and [PRJ, and [PRLare the concentrations of PR at t = t and t = O. From equations 6 and 
7 it follows that 
[INH]/K, .k 
1+ 11K, +[INH]/K, ~ 
(8) 
(9) 
in which k b is the first-order rate constant for PR ·INH complex formation. 
o , 0 
By plotting 11k ob, on the y-axis against l/[INH] on the x-axis, a straight line is 
obtained intersecting the x-axis at -l/[K,(l + 11K)] and the y-axis at 11 km",' Assuming 
K. for prorenin to be the sarne as for renin, K can be calculated. , , 
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Results 
Proteolytic Activation of Gel-bound Plasma Prorenin by Plasmin and Non-
proteolytic Activation by Renin Inhibitors. Incubation of gel-bound kidney renin 
with plasmin or with the renin inhibitors remikiren, A 64662, or CGP 38-560A for 24 h 
at 4 °C did not alter the binding of renin to the radio labeled monoclonal antibody 
mAb4GI, an antibody that specifically reacts with renin and not with native inactive 
prorenin. In contrast, not only plasmin but also the renin inhibitors increased the binding 
of plasma prorenin to this antibody (Table 1 and Fig. 1). When gel·bound plasma 
prorenin was activated with plasmin and then incubated with the renin inhibitors, the 
binding of the activated prorenin to the antibody was not altered by the renin inhibitors 
(data not shown). 
Apparently, complex formation with the renin inhibitors is associated with a 
conformational change in prorenin, by which it becomes recognizable by the antibody. 
Because this conformational change also occurs when inactive pro renin is converted by 
plasmin to enzymatically active renin, the effect of the renin inhibitors on the binding of 
prorenin to the renin-specific monoclonal antibody is designated here as activation. The 
activated prorenin, which is detected with the reninspecific monoclonal antibody 
mAb4G1, cannot be detected via its enzymatic activity, because of the presence of renin 
inhibitor. 
Activalion 100 0.2 
of prorenin 0.1 percent 
80 renikiren 
60 
40 
20 
0 
0 8 16 24 0 8 16 24 
hours at 4 °c hours at4 °C 
Figure 1. Proteolyllc activallon of gel·bound plasma prorenln by plasmin (0.004-0.2 ~M)(A) 
and nonproteolytcacUvalion byvartous renin Inhibitors (10 ~M) (B) at 4 ·C. Activated prorenln 
was measured with the Immunoradlometrlcassay using the monocional anllbody mAb4G1 
that recognizes renin but not native Inactive prorenln. Results (mean, n = 3) are expressed as 
percentage of maximal activation by plasmin. 
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Table 1. Proteolytic activation of gel-bound profenln by plasmIn and nonproteolyUc activation 
by renin Inhibllors 
RenIn and activated prorenln expressed as renin equivalents 
Immunoradlometric assay Enzyme·klnetlc assay 
Kidney renin Plasma Kidney renin Plasma 
ngJ/iler 
PBS 29±2 31±3 33±3 34±2 
Plasmin, 0.2 ~M 32±2 312±18 30±3 304±19 
Remlkiren, 10 ~M 32±1 301±14 <0.25 <0.25 
A 54·662, 10 ~M 29±3 149±11 <0.25 <0.25 
CGP 38·560A, 10 ~M 32±2 298±3 <0.25 <0.25 
Results (mean±SD, n=5) of both assays are expressed as renin equivalents (ng/llter) 
In a separate series of experiments we added to the renin inhibitor solution, EDT A 
(final concentration,S mM) or the serine proteinase inhibitors phenylmethanesulfonyl 
fluoride (1.4 mM), or SBn (50 I'M). These additions had no effect on the activation of 
prorenin by the renin inhibitors. A serine proteinase appears not to be involved. 
Fig, 2 shows the activation at 4°C of gel· bound plasma prorenin over time at different 
concentrations of the renin inhibitor remikiren. The reaction of gel-hound pro renin 
with the inhibitor followed first·order kinetics. The data are in good agreement with the 
anticipated reaction sequence. They support a rapid equilibrium between PR and PR . 
, m 
Remaining 100 11k"" 50 
Prorenin 80 0.100 • 
percent 81 40 80 
30 
'.8)) 
0.700 30 
40 
1.(1)) 
• 
• 
30 20 • 
'I)) 
20 / 
0 2 4 6 8 12 ·4 ·2 0 2 4 6 8 10 
hpurs al4 °c 1/[INHI 
Figure 2. Kinetics of activation of gel-bound plasma profenin by the renin inhibltorremlklren 
at 4 °C. Activated prarenln was measured with Ihe Immunorad!omelric assay using Ihe 
monoclonal antibody mAb4G1 that recognizes renin but not native Inactive prorenin. Results 
are expressed as percentage of the lotal prorenln concentration as measured after activation 
by plasmIn. The observed first·orde rate constant, kObS (expressed In h'l), at various 
concentrations of the Inhibitor (0.1·100 ~M), are given by the slopes of the lines (A). The 
reciprocal of kObS plotted against the reciprocal of the Inhibitor concentrations (expressed 
In ~M) gives a straight line (B). The line is the least·square fit for 1/ kObO at concentrations 
ofthe renin Inhibitor ranging from 0.100 to 3 ~M. Results for the concentrations 10, 30, and 
100 ~M were close to the Intercept with the y·axls, which Is at 1/ k
m
". The intercept with 
the x·axls Is at -1IIK,(1 +1/K,)]. 
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and between PR ., inhibitor and a complex ofPR . with inhibitor. The subsequent slow 
01 01 
conversion ofPR . to PR in this complex is associated with a conformational change 
J' ° that is recognize by the monoclonal renin antibody mAb4G 1. That the first step, 
PRo ~PROi' is not rate-limiting, is also supported by experiments in which gel-bound 
plasma prorenin or prorenin in whole plasma was incubated for up to 24 h at 4 °C (in the 
presence of 50 I'M SBTI to prevent proteolytic activation) prior to the addition of the 
renin inhibitor remikiren (10 ftMJ. These experiments demonstrated that the preincubation 
did not modify the rate of prorenin activation. As shown in Fig. 2, the rate of pro renin 
activation by remikiren increases with increasing concentrations of this inhibitor until a 
maximum was reached. These findings are compatible with the assumption that 
irreversible binding of the inhibitor to prorenin does not take place directly but via the 
formation of a reversible complex. 
Kinetic analysis according to Equation (9) gave a value of 0.1 h·1 for k
mu
' and a value 
of 330 nM for Ki(l + 11K). K, of remikiren for gel.bound kidney renin was 8 nM. If Ki 
for gel-bound prorenin is the same as for gel-bound renin, K, equals 40, which would 
mean that 2.5% of native prorenin is in the open form. 
Activation 100 
of Prorenin A 4' 8 
percent 
80 ~22' 
/,37' 
60 / 4°C 
22°C 
40 ~37'C L 20 =82~g 4'C 0 =822 ,C ~37° 
------IJ. 37 °C 
I! >-'- II >-'-
0 2 4 6 8 24 0 2 4 6 8 24 
hours hours 
FIG. 3. Influence of temperature on the nonproleolyl!c activation of gel-bound plasma 
prorenin (A) and of prorenin In the fluid phase In whole plasma (B) by the renin Inhibitor 
remiklren (10 ~M). Activated profenin was measured with the immunorad!ometric assay 
using the monoclonal antibody mAb4G1 that recognIzes renIn but not native Inactive 
profenin. Results for control incubations without renin inhibitor are Indicated by open 
symbols. Results (mean, n=3) are expressed as percentage of maximal activation by 
plasmin (for gel·bound plasma prorenln)or by Sepharose·bound trypsin (for plasma) (22. 
23). 
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Fig.3 shows that prorenin activation by renin inhibitor not only occurs at 4 DC but 
also at room temperature and at 37 DC. In fact, the rate of activation of gel-bound 
plasma prorenin these higher temperatures was hardly different from the rate at 4 DC. 
Non-proteolytic Activation of Prorenin in the Fluid Phase in Whole Plasma by 
Renin Inhibitor or by Acid and Prevention of Inactivation of Acid-activated 
Prorenin by Renin Inhibitor. Prorenin activation by the renin inhibitors, as detected 
with the monoclonal antibody mAb4GI, could not only be demonstrated for gel-bound 
plasma prorenin but also in the fluid-phase in whole plasma. Fig. 3 shows the activation 
by the renin inhibitor remikiren. The rate of activation was lower than for gel. bound 
plasma prorenin. This is probably due to the fact that more than 90% of the inhibitor is 
bound to plasma protein," so that the effective inhibitor concentration is lower in plasma 
than in the buffer solution in which the gel beads are suspended. Activation in whole 
plasma occurred at 4 DC and also at room temperature and at 37 DC. 
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FIG. 4. SeparaUon by blue Sepharose oolumn chromatography 01 naturally occurring 
plasma renin and renIn Inhibitor-activated plasma prorenln. A, native plasma; S, plasma 
after incubation with the renin Inhibitor remiklren (10 ~M) lor 24 h at 4 ·C. Elution 
buffer. 20 mM sodium phosphate buffer. pH 7.2. The arrow indicates change 01 buffer: 
20 mM sodium phosphate buffer. pH 7.2, oontalnlng 1.4 M NaCI. Native renin, native 
Inactive profenln, and renin InhibItor-activated profen'n were measured, before (closed 
circles) and after (open circles) plasmin treatment 01 the eluate, with the 
Immunoradiometrlc assay using the monoclonal antibody mAb4G1 that reoognlzes 
renin but not native Inactive profenln. 
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Treatment of plasma at pH 3.3 at 4 °C for 24 h is known to cause reversible activation 
of prorenin; the acid-activated prorenin is inactivated after restoration of pH. II, 12 \Y/e 
found that this reversibly acid-activated form of prorenin was not only detected by the 
kinetic assay but also by the direct radiometric assay, which measures the binding to the 
monoclonal antibody mAb4Gl that recognizes renin but not native prorenin. With this 
direct assay we observed that treatment of the normal plasma pool at pH 3.3 at 4 °C for 
24 h caused 94% (mean, n - 3) activation of prorenin, which was not different from 
results obtained with the indirect kinetic assay. After rapid restoration of pH to 7.4 and 
incubation at 37°C for 1 h at this pH (in the presence of 50 I'MSBTI to prevent proteolytic 
activation), most of the activated prorenin was inactivated. The immunoradiometric 
assay demonstrated that only 8% (mean, n - 3) of prorenin was in the activated form, 
and again similar results were obtained with the kinetic assay. By using the radiometric 
assay it could be demonstrated that the inactivation during l-h incubation at pH 7.4 at 
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nglL 
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Fig. 5. Change in chromatographic behavior of renin Inhibitor-activated plasma prorenin after 
proteolytic conversion to renin by plasmin. The second peak of Fig. 4 indicated by the 
horizontal line In B, was divided Into two portions. One portion was rechromatographed on 
a blue Sepharose column without prior treatment with plasmin (A). The other portion was 
rechromatographed after treatment with plasmin, 0.2 VM. for 24 h at 4 'C (B). Elution buffer: 
20 mM sodIum phosphate buffer, pH 7.2. The arrow indicates change of buffer: 20 mM 
sodium phosphate buffer, pH 7.2, containing 1.4 M NaCI. Both forms of activated prorenln 
were measured wilh the Immunoradiometrlcassay usIng the monoclonal antibody mAb4G1 
that recognizes renIn but not native inactive prorenln. 
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37 °C was completely prevented by the addition of the renin inhibitor remikiren (final 
concentration in incubate 10 /tM); after incubation in the presence of remikiren, 91% 
(mean, n ~3) was still in the activated form. 
Separation of Plasmin-activated and Renin Inhibitor-activated Prorenin. Naturally 
occurring renin and pro renin can be readily separated by blue Sepharose column 
chromatogra-phy. It is known that, under the conditions we used (20 mM sodium 
phosphate buffer, pH 7.2), naturally occurring plasma renin appears in the pass-through 
fractions, whereas native prorenin or reversibly acid-activated prorenin are retained and 
can be eluted by adding 1.4 M Nael to the elution buffer." Fig. 4 shows the separation 
of inhibitor-activated pro renin and naturally occurring renin, when plasma is subjected 
to chromatography after it has been incubated with the renin inhibitor remikiren (final 
concentration, 10 I'M) for 24 h at 4 °C. Like native prorenin and reversibly acid-activated 
pro-renin, renin inhibitor-activated pro renin was retained on the column and was eluted 
at 1.4MNaCl. 
The fractions containing naturally occurring renin, native prorenin, and renin inhibitor-
activated pro renin were incubated with plasmin (0.2 I'M) for 24 h at 4 °C. 
Rechromatography after plasmin treatment showed that renin inhibitor-activated prorenin 
was not bound to blue Sepharose anymore; it appeared in the pass-through fractions, as 
did plasmin-treated renin and plasmin-activated prorenin (Fig. 5). 
DisclIssion 
This study describes a specific interaction of enzymatically inactive prorenin with a number 
of nonpeptide high-affinity active site-directed renin inhibitors. Because this interaction 
was observed in fresh plasma without pretreatment, we assume that native plasma contains 
an open form of prorenin, in which the active site is exposed. Our kinetic analysis supports 
the hypothesis that this open form of prorenin, PRop is in rapid equilibrium with the 
closed form, PRo' 
PRoi differs from the open form of prorenin that is generated by exposing PRo to 
low pH (non-proteolytic acid activation), because acid-activated prorenin isslowly formed 
and slowly returns to the closed form when pH is restored. ll 12 Moreover, non· 
proteolytically acid-activated prorenin is recognized by the monoclonal renin antibody 
mAb4Gl, whereasPR .isnot. 
0' Our kinetic analysis implies that PRoi rapidly binds to renin inhibitor to form a 
reversible complex, PR .. lNH, and that this is followed by a slow conformational change 
0> 
resulting in a tight complex of the inhibitor with a modified open form of prorenin, 
PR .·lNH...,PR ·lNH. Thisslow conformational change is associated with the expression 
0' 0 
of an epitope on the renin part of the molecule that is recognized by the mAb4G 1 
antibody. Binding studies with the nonpeptide activesite-directed renin inhibitor U-71038 
also provided evidence for the slow formation of a tight prorenin-inhibitor complex.7 
This may be comparable to the slow PR .·INH-to-PR ·INH conversion we describe 
0> 0 
here. 
We found that both PRo; and non-proteolytically acid-activated prorenin reacted with 
the monoclonal renin antibody mAb4Gl. Moreover, both the PR ·lNH complex {with 
o 
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the renin inhibitor remikiren} and the enzymatically active form of prorenin generated at 
low pH were bound to a blue Sepharose column, in contrast to proteolytically activated 
prorenin, and both forms of non-proteolytically activated prorenin could be eluted with 
1.4 M NaCI. The binding of the PRo'INH complex to the column was probably not due 
to the presence of remikiren, because the chromatographic behavior of naturally 
occurring renin or plasmin-activated pro renin was not altered by this inhibitor. \VIe 
therefore tentatively assume that PRo corresponds to the enzymatically active open form 
of prorenin that is generated during exposure to low pH. 
Our findings suggest that one or more interactions of the propeptide with the renin 
part of the molecule, at sites different from the active site, are essential for keeping 
pro renin enzymatically inactive. Studies with peptides containing amino acid sequences 
of prorenin's prosegment have shown that the sequence from -p32-Phe to -p27-Pro of 
the propeptide in human prorenin is capable of inhibiting human renin.! Cleavage of the 
prosegment of human prorenin between residues-p34-Arg to -p30-Lys yields an active 
enzyme.7 Site-directed mutagenesis of human prorenin has demonstrated that positively 
charged residues located near the amino terminus, -p34-Arg, -p29-Arg, and -p24-Arg, 
rather than -p12-Arg and -p1-Arg, of the propeptide contribute to its correct folding 
and to the blocking of prorenin's enzymatic activity.2 Since it is thought that a positively 
charged residue located near the carboxyl terminus rather than the amino terminus is 
interacting with Asp residues of the enzyme's active site,3 the studies cited above also 
support the view that interactions of the propeptide with the renin part of the prorenin 
molecule at some distance from the active site are essential for keeping the molecule 
enzymatically inactive. 
If this is true, how then to explain the effects we observed on prorenin of low-
molecular weight ligands that are specifically directed toward renin's active site? 
Apparently, an additional interaction of the propeptide with the renin part olthe prorenin 
molecule near or, in fact, at the active site also contributes to the stabilization of prorenin 
in the inactive form. By interfering with this interaction, the active site-directed ligands 
may trigger further destabilization of the propeptide, so that the prorenin molecule will 
assume its active configuration. 
Sealey14 has argued that the presence in extrarenal tissues of in sitll synthesized renin, 
as opposed to prorenin, has not been unequivocally proven. She made the suggestion 
that local angiotensin production in these tissues might be due to the fact that part of the 
in situ synthesized pro renin is in an open and enzymatically active conformation. Our 
results would then indicate that the PR, -->PRoi-->PRo reaction sequence, as described in 
this paper, is responsible for this local production of angiotensins in extrarenal tissues. 
Transgenic rats harboring the mouse Ren-2 renin gene develop severe hypertension, 
which can effectively be treated with angiotensin-converting enzyme inhibitor. The 
hypertension is thought to be due to the high expression of the Ren-2 gene in the adrenal 
gland.' The plasma levels of renin and AngII are low in these animals but plasma prorenin 
is grossly elevated, presumably due to hypersecretion of pro renin by the adrenals. The 
present study may help to explain these surprising observations. Our results may provide 
35 
a model for substrate-mediated activation of prorenin ill vivo, and lend support to the 
hypothesis that prorenin, apart from renin, may have some (patho)physiological role. 
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2.2 PROBING EPITOPES ON HUMAN PRORENIN DURING ITs 
PROTEOLYTIC AND NON-PROTEOLYTIC ACTIVATION 
Summary 
The conformational changes of prorenin (PR) that are associated with its reversible 
non-proteolytic activation and irreversible proteolytic activation were monitored with 
immunoradiometric assays, using antibodies against epitopes belonging to the propeptide 
or the renin-part ofPR_ BindingofPR to the renin inhibitor remikiren or protonation 
ofPR resulted in the slowly progressive and simultaneous expression (t'I2=3.5-5_0 hours 
at 4'C) of epitopes of the N-terminal and C-terminal halves of the propeptide and an 
epitope that is manifest on renin but not on native non-activated PRo During reversible 
PR activation-inactivation, expression and disappearance of these epitopes coincided 
with the appearance and disappearance of enzyme activity. Cleavage of the propeptide 
from the renin-part of PR by plasmin, as demonstrated by the failure of remikiren to 
unmask the N-terminal and C-terminal propeptide epitopes, was, with some time lag, 
followed by the simultaneous expression (t'I2=60 minutes at 4'C) of the renin-specific 
epitope and enzymatic activity. Based on these findings we propose a model for the non-
proteolytic activation of PR that involves the formation of an intermediary form of 
activated PR with the following properties: 1) the covalently bound prop tide has moved 
out of the active-site cleft, so that binding sites are exposed to active-site ligands, 2) the 
propeptide is still not in the' relaxed'conformation that is characteristic for fully, non-
proteolytically, activated PR, and 3) the N-terminal part of the renin polypeptide chain 
has not yet attained the proper location that is required for enzymatic activity. 
Introduction 
Prorenin is the enzymatically inactive biosynthetic precursor of the aspartic protease 
renin (EC 3.4.23.15), which serves important functions in blood pressure regulation and 
body fluid homeostasis. Prorenin is converted to renin by cleavage of the N-terminal 
propeptide. Inactive prorenin is also activated non-proteolytically during exposure to 
low pH (acid-activation)'" or low temperature (cryoactivation).3,4 Activation also occurs 
when prorenin reacts with active-site-directed ligands.s Despite the fact that the complexes 
of activated prorenin with the ligands are devoid of enzymatic activity, the term 
'activation' is used here to indicate that the ligands induce a conformational change of 
pro renin that also occurs during acid-activation and cryoactivation. This change in 
conformation is slowly reversible, so that pro renin remains active for some time after 
pH or temperature have been restored. 
Aspartic proteases like renin have a bilobal three-dimensional structure with a deep 
cleft between the lobes, in which the active site is located. In the enzymatically inactive 
aspartic protease zymogen pepsinogen the propeptide is in the cleft, so that substrates 
cannot reach the active site. Acid-activation of pepsinogen is initiated by a reversible 
conformational change of the propeptide, by which the enzyme's active site becomes 
exposed.6 The active site then takes part in the intra- and intermolecular proteolytic 
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reactions by which the propeptide is removed from the pepsin-part of the molecule. 
The initial reversible phase of pepsinogen activation may well be analogous to the 
reversible non-proteolytic activation of prorenin. 
It has been reported that acid-activated prorenin reacts with antibodies directed against 
epitopes of the propeptide, whereas native pro renin does not.7, 8 We therefore decided 
to use monoclonal antibodies directed against epitopes of the propeptide to monitor 
the conformational changes that occur during acid-activation and cryoactivation and 
during activation with an active-site-directed renin inhibitor. We also used a monoclonal 
antibody directed against an epitope that is present on the renin-part of prorenin but is 
not manifest on native, enzymatically inactive, prorenin. The rate of expression of these 
epitopes during activation was determined and compared with the increase in enzymatic 
activity over time. 
Materials 
Antibodies. Five mouse anti·human (pro)renin monoclonal antibodies were used. These 
antibodies (mAbs) were > 98% pure, as determined by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis. mAbs RJ-36-16 and RJ·27-5 were a gift from Drs. J. 
Wood and M. de Gasparo (Novartis, Basle, Switzerland). Biotinylated mAb R3-36·16 
and Il5I-Iabeled mAb RI-20-5 were purchased as part of a commercial kit from Nichols 
Institute Diagnostics, Wijchen, The Netherlands. mAbs F257-16-2C3 andF258·37-Bl 
were kindly provided by Dr. S. Mathews (Novartis, Basle, Switzerland). Some 
characteristics ofthese mAbs are presented in Table I.' mAbs R3-36-16 and R 3·27-5 
do not interfere with each other's binding to renin or prorenin and mAb R 1-20-5 does 
not inhibit the binding of R3-36-16 to renin. mAb F257-16-2C3 was raised against a 
synthetic peptide with the same sequence as the 23 amino acid N-terminal fragment of 
the propeptide of prorenin (-p43·Leu to -p21-Leu). mAb F258-37-Bl was raised against 
Table 1. Characteristics of monoclonal anti-human renin and prorenln monoclonal antibodies 
Monoclonal Localization of binding epltope Inhibition of Ang 1-Antibody generating activity of renin 
R3-36-16 on renin and native prorenin yeg9 
R3-27-S on renin and native prorenln yes,partlal,9 
R1-20-S on renin but not manifest on native yes9 prorenln (renin-specific epilope) 
F2S7-16-2C3 on propeptide of prorenin, N-termlnal no part (prorenin·specific epltope) 
F2S8-37-B1 on propeptide of prorenin,C-terminal no part (prorenln-speclfic epltope) 
• R3-27-Slnhlblls enzymallc acUvity of renin to a fixed degree (30%). This Is probably caused 
by partial steric hindrance or by an ~lIosterlc effect, which in both cases would result In a 
reduction of the substrate turnover. 
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a synthetic peptide, consisting of the-p24-Arg to -p1-Argsequence of prorenin, i.e. the 
C-terminal part of the propeptide. 
Renin and Prorenin. Renin is the WHO human kidney renin standard, lot 68/356 
(National Institute for Biologic Standards and Control, Potters Bar, Hertfordshil'e, UK). 
Recombinant human prorenin was a gift by Dr. Fischli (Hoffmann-La Roche, Basle, 
Switzerland). It was produced in CHO cells transfected with a vector containing human 
pro renin eDNA. It was partially purified from culture medium by chromatography on 
blue Sepharose (pharmacia LKB Biotechnology Inc.). Briefly, a 26x1.5 cm column of 
blueSepharose was equilibrated at room temperature with a 20 mmol!L sodiumphosphate 
buffer, pH 7.1. Culture medium with recombinant pro renin (9.6 mL) was applied to the 
column. Elution was performed in two steps i.e. with equilibration buffer and with the 
same buffer containing 1.4 mollL NaCI. The flow rate was 1 mL/min and 2.0-mL 
fractions were collected. Renin content of the fractions was measured by 
immunoraruometric assay (see below). Pro renin content was determined with the same 
assay after activation with remikiren. Prorenin eluted in the step with NaCI. Pro renin· 
containing fractions were pooled and dialysed against a 100 mmollL sodiumphosphate 
buffer, pH 7.4, and stored at -80°C. This preparation contained approximately 8.5 x 
lQ'"UI mL renin after proteolytic activation with plasmin (0.5 casein units/ mL, 48 h at 
4 0C).' The intrinsic AngI-generating activity of the non-activated prorenin preparation 
was less than 0.4 % ofthe fully activated prorenin. The intrinsic activity rose upon storage 
to maximally 2 %. The prorenin preparation did not contain prorenin-ac.tivatingproteases; 
no activation was observed after 3 hours of incubation at 37°C. 
Chemicals and 'Dilution' Buffer. Remikiren, an active site-directed renin inhibitor, 
was provided by Dr. Fischli (Novartis, Basle, Switzerland). It is a non-peptide transition-
state-analogue with a M, of 726. The ICso for purified human renin is 0.7x10·
9 M.l0 The 
K. forthe reaction with human renin is 3x 10.10 mollL. ll Only freshly prepared solutions , 
in dilution buffer (see below) were used. Plasmin was from Chromogenix, Miilndal, 
Sweden. Aprotinin was obtained from Bayer, Germany. 'Dilution buffer' is a 100 mmoll 
L sodium phosphate buffer, pH 7.4, containing 75 mmol /L NaCI and 0.1 % human 
serum albumin. 
Assays 
Table 2 shows some characteristics of the immunoradiometric assays (lRMAs) we used. 
IRMA-R was carried out as described earlier. 11 In this assay biotinylated mAb R3-36-16 
was the primary antibody, which was bound to an avidin-coated bead. The secondary 
(developing) antibody was 125I-labeled mAb Rl-20-5 (2.5x105 cpm/assay tube, specific 
activity 740 kBq/ mg). The assay was carried out with 200 "I sample or standard and 100 
"I labeled antibody. Incubations were performed at 4 °C and incubation time was 6 
hours. 
The other assays were developed in our laboratory for the purpose of this study. 
mAbs R3-36-16, F257-16-2C3 and F258-37-B1 served as primary antibodies and were 
immobilized in Maxisorp Startubes (Nunc, Denmark). To this end 1.5 mg of R 3-36-16 
or F 258-37-B1 or 3 mg of F257-16-2C3 were added per Startube and then incubated 
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Table 2. Characteristics of renin and proren!n Immunoradlometric assays 
Type of Immobilized Method of Developing mAb 1) Specificl!r. of 
IRMA mAb Immobilization assay l 
binding of R : yes biolinylated 
R R3·36-16 mAb to avidln- Rl-20-5 PRn: no 
coated bead PR,,: yes 
R : yes 
PR R3-36-16 coating to R3-27-5 PRn: yes 
Startube PR,: yes 
R:no 
PR-N F257-16-2C3 coaling to R3-27-5 PRn: no 
Startube PRa: yes 
R: no 
PR-C F258-37-Bl coating to R3-27-5 PRn: no 
Startube PRa: yes 
1) The developing monoclonal antibodies were labeled with 125,. 
2) This column shows whether or not renin or profen!n are recognized by the 
assay and which form of profen!n is recognized; R, renln;PRn• native Inactive 
profenln; PRa. reversibly activated profenin 
for 2 hours at 37 'C in 150 "I of a coating buffer (50 mmollL sodiumcarbonate, 150 
mmollL NaCI and 0.02 % sodium azide, pH 8.6)." Tubes were then washed five times 
with phosphate-buffered saline (PBS, 150 mmoIlL NaCI, 10 mmoIlLsodium phosphate, 
pH 7.4). Any remaining adsorption sites in the tubes were blocked by incubation for 1 
hour at 37 'C in PBS/1 % bovine serum albumin. Tubes were stored at 4 'C in this 
blocking buffer until use. Blocking buffer was then removed by five times washing with 
PBS. The secondary, developing antibody was labeled with 125r by the rodogen method 
according to the instruction of the manufacturer (pierce, Rockford, IL, USA). Specific 
radio-activity was 360 kBq/"g. 
IRMA-PR, IRMA-PR-N and IRMA-PR-C were carried out in the antibody-coated 
Startubes with 100 "I sample and 50 "I labeled antibody (2.5x10' cpm/tube). The samples 
were not pre-incubated with the immobilized antibody before the radiolabeled antibody 
was added. Incubation was at 4 'C for 6 hours. Then, the Startubes were washed three 
times with 2 mL dilution buffer. The remaining radioactivity in the Startubes was measured 
in a gamma counter. 
Prorenin that is 'activated' by the renin inhibitor remikiren expresses all five epitopes 
against which the monoclonals were directed. We therefore used the recombinant prorenin 
preparation after it had been activated by remikiren as a standard in each IRMA. For this 
purpose the prorenin preparation was incubated at 4 'C for 48 hours with remikiren in a 
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Figure 1. Calibration curves for the Immunoradiometric assays used in this study. For 
characteristics and abbreviations, see Table 2. 
final concentration of 100 nmol! mL, This causes complete activation of prorenin.' The 
remikiren-activated prorenin was calibrated against the WHO human kidney standard 
with the use ofIRMA-R. This means that all IRMA results could be expressed as microunit 
equivalents of the WHO renin standard, Typical examples of standard curves are shown 
in Fig,!. The interassay variability was 8 % for IRMA-R and 20% for IRMA-PR-N and 
IRMA-PR-C (standard deviation of 8 assays of a standard sample of remikiren-activated 
prorenin at a concentration of 1500 !'V/ mL), 
Renin and acid-activated prorenin were also measured by the enzyme-kinetic assay,B 
In this assay, renin or activated pro renin were incubated with saturating concentrations 
of sheep angiotensinogen at pH 7.4 and 37 'C in the presence of inhibitors to block 
AngI-convertingenzyme, AngI-degrading enzymes and serine proteases. The incubation 
time was reduced to 5 minutes, in order to minimize the inactivation of acid-activated 
prorenin during incubation at pH 7.4. The AngI that was generated was quantitated by 
radioimmunoassay. Again, calibration was against the WHO human kidney renin standard, 
so that results of the enzyme-kinetic assay could be directly compared with the IRMA 
results. 
Experimental protocols 
The following procedures of reversible non-proteolytic activation of prorenin were 
studied: cryoactivatiofi, acid-activation and activation by remikiren. Prorenin in the 
activation experiments had a concentration between 8x103 and 14x103 !,V/mL. 
Cryoactivation was performed by incubation of the prorenin-containingsamples at 4 
'C. Acid-activation was performed by incubation with one volume 0.05 mol!L glycin 
buffer, pH 3.3, containingO.1 mo1!L NaCI and 5 mmo1!L EDT A, at 4 'c.2 The activated 
prorenin samples were immediately assayed with the IRMAs. One-mL aliquots were snap-
frozen and stored at -70 'C for later enzyme-kinetic assay. 
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Activation of prorenin was also studied by incubating one volume pro renin with 0.1 
volume remikiren in dilution buffer at 4'C (final concentration of remikiren 100 nmoV 
mL). Irreversible proteolytic activation of prorenin was studied by incubating one volume 
prorenin with 0.1 volume plasmin in dilution buffer at 4'C (final concentration of plasmin 
0.5 casein units/ mL). At the end of the incubation with plasmin ice-cold aprotinin (final 
concentration 1000 kallikrein-inibiting units/mL) was added. This was sufficient to stop 
the proteolytic activation of pro renin. 
In the activation experiments with remikiren, prorenin is exposed to the inhibitor not 
only during the incubation period prior to the IRMAs (pre-incubation) but also during 
the IRMAs themselves. In order to correct for the assay-related activation, we used the 
following calculations. The amount of activated prorenin that is measured (PRme.uu,J is 
given by the equation: 
PRmeasured= PRpr~incubj1tion + Ix (PR;uax- PRpre.iqcubatioJ (1) 
In this equation PR . b' is the amount atp Iforenm that has been activated by pre·mcu atlon 
remikiren in the pre-incubation period, PR ax is the amount of activated prorenin that is 
measured after all prorenin has been activated by remikiren. The amount of non-activated 
prorenin that has remained after the pre-incubation with remikiren, is given by the term 
PR -PR . b' • A proportion/of this remaining non·activated prorenin is activated 
nux pre-mC\! ltlOn 
duringtheassay,andisgivenbythetermfx(pR -PR . b' \. Thefactorfcanbe 
nux pre-Illcu auorY 
measured by omitting the pre-incubation step and performing theIRMAs in the presence 
of remikiren;/is then the ratio between the measured amount of activated prorenin and 
PRnux· 
Results 
Table 3 shows the effects of non·proteolytic and proteolytic activation of prorenin 
on enzyme activity and the expression of the various epitopes. Incubation of pro renin 
with 100 nmoll mL remikiren at 4 'C for 48 hours causes full expression of the renin-
specific epitope recognized with IRMA-R. Here, this result is taken as 100 percent 
activation. The term (activation) is used to indicate that this epitope) which is not manifest 
on native enzymatically inactive prorenin, is also expressed on renin as well as acid~ 
activated orcryoactivated prorenin) which possess enzymatic activity. Uniform expression 
of the results of the renin assays as microunits of the WHO renin standard enabled us to 
make quantitative comparisons between these assays in terms of degrees of activation. 
IRMA-R indicated that both acid and plasmin caused complete activation of prorenin 
and this was confirmed by the enzyme-kinetic assay. IRMA-PR, which recognizes two 
epitopes that are both present on native prorenin as well as renin, showed that the 
activation procedures we used did not affect the assay results. Thus, it appears that these 
activation procedures did not lead to destruction of prorenin. Remikiren as well as acid 
caused full expression of the N-terminal and C-terminal pro peptide epitopes that were 
recognized by IRMA-PR-N and IRMA-PR·C respectively. These epitopes were not 
manifest on plasmin-activated prorenin, which lacks the propeptide part of the molecule. 
The results of IRMA-R and the enzyme· kinetic assay obtained after incubation of 
prorenin for 48 hours at 4 'C, were compatible with the well known fact that exposure of 
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Table 3. Effects of different activation procedures on the prorenin assay results 
Pretreatment Type of IRMA Enzyme-
of prorenln kinetic 
PR·N PR·C R PR assay 
None 10±5 2±3 12±3 74±7 2±1 
Remikiren 
100 ~moUI 127±29 98±31 100 101:!:7 1±1 
48 h, 4 'c 
Plasmin 
0.5 CU/ml 7:,:8 O±O 131±8 111±2 120:,:17 
48 h, 4'C 
pH 3.3 88±22 92±22 128±11 118±17 87±6 
48 h, 4 'c 
pH 7.4 12±4 10±1 20±2 80±3 7±2 
48h,4'C 
Data (mean .± SO, n=3) are expressed as percentage of the results obtaIned In the IRMA-
R after maximal activation with remikiren. CU, casein-units. 
pro renin to cold causes a small proportion of the pro renin molecules to attain an active 
conformation that is similar to the conformation of acid-activated prorenin.3 Surprisingly 
the results obtained with IRMA·R without any pretreatment of prorenin also indicated 
some degree of activation, which was not seen with the enzyme-kinetic assay. The 
activation may have occurred during the incubation step of the assay. This is supported 
by the results ofIRMA·PR·N. This assay, which recognizes theepitope on the N·terminal 
part of the propeptide, showed some degree of expression of this epitope on prorenin 
that had not been subjected to any form of pretreatment. An alternative explanation 
might be that antibody Rl·20-5 is not completely renin·specific but crossreacts, to a 
small degree, with native, enzymatically inactive prorenin. 
Results of kinetic studies are shown in Figs, 2·5. We detected no marked differences 
in activation kinetics between the results ofIRMA.R, IRMA·N and IRMA·C, both during 
treatment of prorenin with remikiren (Fig, 2) or with acid (Fig, 3). There was some 
indication that, with acid-activation, the C-terminal propeptide epitope might be 
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Figure 2. Progression curves for the expression of epltopes on recombinant human 
prorenln during Incubation with the renin Inhibitor remikiren (final concentration 100 
nmol/ml) at 4oC. Results are means of 3 experiments. No enzymatic activity could be 
detected, For abbreviations, see Table 2. 
expressed at a higher rate than the N-terminal propeptide epitope, but the reproducibility 
of our assay is not high enough to establish whether this difference is real. Results of the 
enzyme-kinetic assay showed kinetics of acid-activation that were very similar to those 
seen with the IRMAs. Kinetics of inactivation (PH 7.4, 37'C) of acid-activated prorenin 
are shown in Fig. 4. Epitope expression as determined by the IRMAs and enzymatic 
activity of acid-activated prorenin decreased at similar rates. 
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Figure 3. Progression curves for the expression of epitopes on recombinant human proren!n 
and the development of enzymatic activity during acid-activation (Incubation at pH 3.3 
and 4°C). Results are means of 3 experiments. For abbreviations, see Table 2, 
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Figure 4. Disappearance of the expression of epitopes and enzymatic activity of acld-
activated recombinant human prorenin at pH 7.4 and 37°C. Results are means of 3 
experiments. For abbreviations, see Table 2. 
Duringproteolytic activation by plasmin, the appearance of the renin-specific epitope 
coincided with the appearance of enzymatic activity (half-time approximately 60 minutes) 
fig. 5, left). Our experiments, in which we used the propeptide antibodies and in which 
the propeptide epitopes were unmasked by remikiren after the incubation with plasmin 
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Figure 5. Activation of human recombinant prorenln by plasmin (final concentration 0.5 
casein unlts/ml) at 4 ce. Left: progression curves for the expression of renin-specific and 
propeptlde epltopes and the development of enzymatic activity. Right: same as left. 
however, the propeptlde epllopes that were present In the remaining uncfeaved prorenln, 
were unmasked with remlkiren (final concentration 100 nmol/ml, 24 hours at 4 ee). For 
abbreviations, see Table 2. 
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(Fig. 5, right), indicated that the N- and Gterminal propeptide epitopes are cleaved off 
by plasmin at similar rates (half-time approximately 10 minutes). Apparently the cleavage 
of the propeptide by plasmin proceeds at a higher rate than the appearance of the renin-
specific epitope and the appearance of enzymatic activity. We also used the propeptide 
antibodies in experiments in which pro renin was first treated with remikiren and then 
with plasmin. Both the N-and Gterminal propeptide epitopes disappeared rapidly (half-
time approximately 10 minutes, results not shown), as they did when prorenin was first 
treated with plasmin and then with remikiren. 
Discussion 
Pro renin antibodies against peptide sequences of the N-terminal part of the pro peptide 
fail to bind native prorenin,l·14 but recognize acid-treated prorenin.7 Antibodies against 
the C-terminal sequences of the propeptide may8, 15·19 or may noe, 16 recognize native 
prorenin. Pro renin recognition by these antibodies is enhanced by acid treatmene· 18 or 
renin inhibitor.'6 The pro renin antibodies we used had been elicited with the N-terminal 
(-p43-Leu to -p21-Leu) and C-terminal (-p24·Argto -pl-Arg) halves of the propeptide. 
Our experiments show that these antibodies bound very little, if any, native prorenin but 
reacted well with acid-activated prorenin and with prorenin that had been treated with 
the renin inhibitor remikiren (remikiren-activated prorenin). This is fully compatible with 
the view that in native prorenin the propeptide is located in the active-site cleft and that 
for activation to occur, the propeptide has to move out of the cleft. 
The propeptide antibodies we used proved most helpful to our study, because they 
enabled us to monitor the kinetics of the conformational changes of the propeptide 
during the non-proteolytic activation of prorenin and to do this independently of 
measurements of enzymatic activity. Such kinetic studies with the use of immunological 
methods are often not possible, because the conformational changes proceed rapidly 
relative to the binding rates of the monoclonal antibodies. The pro peptide antibodies 
were also helpful to monitor the cleavage of the propeptide during the proteolytic 
activation of prorenin. 
Our observations suggest a common rate-determining process for both the expression 
of the propeptide epitopes and the renin-specific epitope and the appearance of 
enzymatic activity, during activation with acid as well as during activation with remikiren. 
The activation with remikiren and acid-activation are known to be slow processes. 1, 5 
The remikiren concentration and the pH in our experiments were chosen in such a way 
that the rate of activation was close to the maximum rate, which is 0, 14-0,20/hour for 
both procedures.,,5 We had expected that the binding of the active-site ligand remikiren 
to prorenin, which displaces the propeptide from its original position in the cleft, would 
lead to the immediate unmasking of the propeptide epitopes. This apparently is not the 
case. We therefore assume that, after displacement, the propeptide is still held, for some 
time, in a 'stressed' conformation that somehow prevents its epitopes to be expressed 
on the surface of the prorenin molecule. 
It has been reported that plasmin cleaves prorenin between -p2-Lys and _pl_Arg.2o 
This, however, may not be the only site of cleavage by plasmin. The pro peptide contains 
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a number of peptide bonds adjacent to lysyl and arginine residues that could be susceptible 
to serine protease attack (-p12, 18,20,24,29,30,34,35). The possibility that N-terminally 
truncated prorenin forms are generated by plasmin needs therefore to be addressed. 
Full-length prorenin is inactive but truncation may result in partial or full expression of 
enzymatic activity. \Y/e cannot exclude that our prorenin preparation contained some 
truncated prorenin, but, if it did, the truncation was not extensive, since our results 
showed that the whole C-terminal half of the propeptide and at least part of the N-
terminal half were still present in prorenin. The intrinsic artgotensin I-generating activity 
of our prorenin preparation was less than 2 % of fully activated prorenin. This may 
indicate that the amount of truncated prorenin, if present, is very small but it is also 
/~'" interrr.ediary 
" ..,_>' ~ /' "m •• "_ 
A-orenin open 
interrrediary 
enin closed Renin interrrediate Renin 
o First strand of six-stranded .. Second strand of six-stranded 
anti-parallel p-sheet of profenin anti-paranel p-sheet of renin and prorenin 
.. First strand of six-stranded M Activation site 
ant"'para!lel p-sheet of renin 
Figure 6. Cartoon depicUng various steps In the activation of prorenln. (Upper panel) Proposed 
model for non-proteolytic activation of profenln. Two altemative Intermediary open pro renin forms 
are shown, the upper one with the first p-strand of the propeptide In situ In the six-stranded p-
sheet, the lower one with an incomplete p-sheet.ln both forms the propeptlde Is not accessible 
to propeptide-speclflc monoclonal antibodies. (Lower panel) Proposed model for proteolytic 
activation of profenln.ln both panels p-strands are only shown when they are embedded In the 
six-stranded antiparallel p-sheet. 
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Table 4. Some characteristics of various conformational species of renin and profenln 
Profen!n Prorenln Profenin Renin Renin 
closed open open Intermediate 
Intermediate 
(PRe) (PRo,) (PRo) (R,) (R) 
Conformation folded In out of cleft out of cleft cleaved from cleaved 
of propeptide enzyme 'stressed' 'relaxed' enzyme from 
cleft enzyme 
Enzymatic absent absent present absent present 
activity 
Binding of no yes yes yes yes 
renIn inhibitor 
ExpressIon of 
renin-specific 
epilope on no no yes no yes 
surface of 
enzyme 
Expression of 
propepllde- no no yes no no 
specific epitopes 
on surface of 
enzyme 
possible that the truncated form of prorenin has very little enzyme activity_ Plasmin at 
the concentration we used, caused rapid disappearance of the N- and C-terminal 
propeptide epitopes. The disappearance rates were not different between the two epitopes 
and there was no evidence for the formation of a stable truncated form of prorenin 
lacking the N-terminal epitope. 
The disappearance rate ofthe propeptide epitopes following treatment with plasmin, 
was similar for native prorenin and remikiren-activated prorenin, which indicates that in 
native pro renin the activation site is not hidden in the cleft in the same way as the two 
propeptide epitopes are. X-ray-diffraction analysis of the three-dimensional structure 
of pepsinogen supports that the cleavage site for the non-intramolecular proteolytic 
activation of pepsinogen is also located on the surface of the rnolecule.6 Our results 
further suggest that proteolytic cleavage at the activation site of pro renin is not 
immediately followed by the appearance of enzymatic activity. A rate-determining 
conformational change seems to be required after the propeptide has been cleaved from 
the renin part of the molecule. 
On the basis of our results we propose the sequence of events as presented in Fig. 6 
and Table 4. This scheme also incorporates the knowledge abollt the structure and 
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activation of other aspartic proteases. From studies of pepsinogens and pepsin-like 
enzymes it is inferred that in these enzymes, which have a bilobal three-dimensional 
structure, a six-stranded antiparallel p-sheet is situated at the centre where the two lobes 
are connected; three strands belong to the N-terminallobe and three to the Gterminal 
lobe_" The proper three-dimensional conformation of this p-sheet is thought to be 
essential for enzymatic activity. In the zymogen conformation, the first strand of this 
sheet belongs to the N-terminal part of the propeptide_ In the active enzyme conformation, 
the first strand of this sheet is formed by amino acid residues in the N-terminal part of 
the enzyme part of the molecule_ In the scheme of Fig_ 6, it is assumed that the proper 
positioning of the N-terminal part of the propeptide in the six-stranded p-sheet, is 
important for keepingprorenin inactive, and that the proper positioning of the N-terminal 
part of the renin polypeptide chain to form the six-stranded p-sheet, is important for 
prorenin to attain its active conformation. The difference betweeen the two alternative 
pathways of non-proteolytic activation shown in Fig_ 6, depends on whether or not the 
intact propeptide can move out of the active-site cleft while the N-terminal part of the 
propeptide remains in its original position in the six-stranded beta-sheet and is still in the 
'stressed' conformation_ These alternative pathways correspond with the pathways 
proposed for the early stages of the non-proteolytic activation of pepsinogen at low 
pH_6 In pepsinogen, the eight N-terminal residues (-p44-Leu to -p37 -Arg) form the first 
strand_ Sequence alignment indicates that in prorenin the residues -p36-Phe to -p29-Arg 
form the ftrst strand?' The assumption that residues belonging to tlus strand are important 
to keep prorenin inactive, is supported by studies of truncated forms of prorenin_ In 
these studies it was found that prorenin missing the first 9 N-terminal amino acids had 
little enzyme activity, whereasprorenin missing the first 14 N-terminal amino acids was 
fully active_'O Further support is provided by studies on inhibition of active aspartic 
prot eases by synthetic peptides corrresponding to the first p-strand of the propeptide_ 
For instance, porcine pepsin is strongly inhibited by a peptide consisting of the first 11 
amino acids of the propeptide (-p44-Leu to -p34-Ser)_'" 2l Similarly, human renin is 
inhibited by the peptide -p38-Thr to -p27-Pro, which includes the first beta-strand of 
the propeptide_",24 
OUf results provide more insight into the processes involved in the reversible activation 
of prorenin_ This may help to answer the question of whether the open, enzymatically 
fully active, form of prorenin exists in vivo and whether the closed, enzymatically inactive, 
form of prorenin is reversibly activated in vivo_ More detailed knowledge ofthe molecular 
basis of the reversible activation of prorenin might eventually lead to the development 
of agents that prevent the activation. Based on Figure 6 for instance, one can envisage 
that peptides or non-peptide analogs corresponding with amino acid sequences of the 
N-terminal part of the propeptide can act as activation inhibitors_ Finally, a better insight 
into the reaction mechanisms that lead to the non~proteolytic activation of prorenin 
might be applicable to other asparticproteases including human immunodeficiency virus 
protease. 
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2.3 MOLECULAR MECHANISM OF PRORENIN ACTIVATION. STUDIES 
WITH A SITE-DIRECTED MUTANTS AT THE PROLINE-4 POSITION 
Summary 
We hypothesized that the proline residue at the -4 position in the propeptide of human 
prorenin is involved in a conformational change of the proptide. probably a cis-trailS 
isomerization, which is a prerequisite for both non-proteolytic and proteolytic activation 
of prorenin. A prorenin mutant in which the proline residue at the -4 position in the 
propeptide had been replaced by glycin, was compared with wild type prorenin as to its 
susceptibility to (non~)proteolytic activation. This mutation is expected to preserve the 
tertiary structure of the propeptide, whilst making any movement at the preceding peptide 
bond impossible. There was, however, no important difference in activation characteristics 
between wild-type and mutated prorenin, irrespective of activation mode. The hypothesis 
that cis·trans isomerization at the -4 position is important in prorenin activation has thus 
been refuted. 
Introduction 
The aspartic protease renin is produced in juxtaglomerular cells of the kidney. In the 
dense core granules in these cells, renin is generated from its precursor pro renin by 
proteolytic removal of a 43 amino acid N-terminal propeptide. The activating protease 
has not been identified with certainty although various candidates have been proposed. l . 
3 By site·directed mutagenesis of the region around the processing site in prorenin chu 
et aI. have shown that the pair of basic amino acids at position -1 and -2 (i.e. in the 
propeptide) is important for correct processing as well as the proline residue at position 
-4.' Substitution of the proline residue at position -4 by alanine or phenylalanine caused 
a substantially reduced proteolytic activation of prorenin in mouse pituitary AtT-20 cells 
that had been transfected with mutated prorenin eDNA. By contrast, AtT20 cells 
transfected with wild·type pro renin eDNA correctly process prorenin to renin. Alanine 
or phenylalanine at the -4 position may destroy a reverse turn, which, according to 
computer calculations, is present at this site. The absence of this reverse turn may cause 
a conformation of the polypeptide chain that is unfavorable to either binding of a 
processing enzyme or proteolysis by this enzyme. Substitution of proline at -4 by glycine 
is expected to conserve this reverse turn, but nevertheless also resulted in reduced prorenin 
processing in transfected AtT20 cells. This appears to refute the hypothesis that the reverse 
turn at position -4 per se is essential for the processing enzyme. 
Prorenin may also be activated non.proteolytically by acid, cold or incubation with a 
renin inhibitor (see chapter 2.1 and 2.2.). Kinetic experiments reported in these chapters 
suggest that activation by renin inhibitor occurs by interaction of the renin inhibitor with 
an intermediary, open form of prorenin that has no enzymatic activity, does not express 
renin or propeptide-epitopes, but allows access of the renin inhibitor to the active site in 
the enzymatic cleft of renin. This intermediary form is in equilibrium with the native 
form. It is not known if this intermediary form is also the physiological substrate for 
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pro renin processing enzymes) rather than the closed, native, conformation of prorenin. 
It could be that the importance of the proline-4 residue for prorenin processing is 
determined by the cis-trans isomerization it may allow in the peptide bond.5 The postulated 
intermediary, open prorenin conformation may he a form in which the chain direction 
has changed at the -4 position. If this is true then this intermediary form is expected not 
to occur if another residue than proline is present at this site. Non-proteolytic as well as 
proteolytic activation of prorenin would then be seriously hampered. 
In this study we assessed kinetics of non-proteolytic and proteolytic activation of 
wild type pro renin and a prorenin mutant with the proline residue at -4 replaced by 
glycin. 
Materials and Methods 
Materials 
Prorenin Variants_ Recombinant human prorenins were a gift by Dr. T. Reudelhuber 
(University of Montreal, Montreal, Canada). They were wild-type human prorenin (\VT) 
and prorenin with glycine instead of proline at the -4 position (P IG-4), i.e. the fourth 
position preceding the cleavage site between the propeptide and the renin-body of the 
molecule. In AtT-20 cells this mutated prorenin is not processed to renin as is WT human 
prorenin.4 Construction of vectors containing prorenin cDNAs has been described 
previously.' Rat pituitary GH4 CL cells had been transfected with these vectors and 
culture supernatants were used forthe experiments. WT andP/G-4 prorenin were partially 
purified from these culture supernatants by Blue-Sepharose chromatography as described 
in chapter 2.2. Stock solutions of both prorenins contained about 150,000 and 80,000 
I'VlmL respectively and were kept in aliquots at - 80 'C. Spontaneous renin activity of 
the stock was 2.4% and 0.6% respectively. 
Chemicals and 'Dilution' Buffer. Remikiren, an active site-directed renin inhibitor, 
was provided by Dr. Fischli (Hoffmann- LaRoche, Basle, Switzerland). It is a non-peptide 
transition-state-analogue with a M, of 726. The IC50 for purified human renin is 0.7xl0 
9 M.6 The KJorthe reaction with human renin is 3x 10.10 mol/L,6 Only freshly prepared 
solutions in dilution buffer (see below) were used. Plasmin was from Chromogenix, 
Molndal, Sweden. Aprotinin was obtained from Bayer, Germany. 'Dilution buffer' is a 
100 mmol IL sodium phosphate buffer, pH 7.4, containing 75 mmol IL NaCl and 0.1 
% human serum albumin. 
Assays 
Active prorenin and renin were measured by IRMA as described earlier.' In this assay 
biotinylated mAb R3-36-16 is the primary antibody, which was bound to an avidin-
coated bead. The secondary (developing) antibody is 125I-labeled mAb RI-20-5 (2.5xI05 
cpm/ assay tube, specific activity 740 kBq/ "g). The assay was carried out with 200 "I 
sample or standard and 100 "I labeled antibody. Incubations were performed at 4 'C 
and incubation time was 3 hours. 
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Activation Protocols 
WT and P /G-4 prorenin were activated by four activation methods. Concentration of 
prorenin in the experiments was about 10,000 I' U/ mL. Proteolytic activation was 
performed by incubation with plasmin at a final concentration ofO.5 CU/mL. Activation 
was at pH 7.4 and incubation temperature was 37 'c. At 0, 2, 5, 7, 10, 15,20,30,45, 60, 
90 and 120 minutes an aliquot was taken and proteolysis was stopped by addition of 
aprotinin (final concentration 1000 kallikrein inhibitingunits/mL). Activation at low pH 
was performed by addition of 9 volumes 0.05 mol/L glycin buffer, pH 3.3, containing 
0.1 moIlL NaCl and 5 mmol/L EDT A, and subsequent incubation at 4 'c. At regular 
time intervals an aliquot was taken, neutralized in dilution buffer and immediately assayed. 
Remikiren activation was at 100 J!mol/L final concentration at 4 ce. In the activation 
experiments with remikiren, pro renin is exposed to the inhibitor not only during the 
incubation period prior to the IRMAs (pre-incubation) but also during the IRMAs 
themselves. In order to correct for the assay-related activation, we used the following 
calculations. The amount of activated prorenin that is measured (pRme.uure) is given by 
the equation: 
PRmeasured = PRpre-incubation + f x (PROIax- PRpre-incubatio) 
In this equation PR . b' is the amount of prorenin that has been activated by pre-meu atlOn 
remikiren in the pre-Incubation period, PR is the amount of activated prorenin that is 
measured after all prorenin has been activatedby remikiren. The amount of non-activated 
prorenin that has remained after the pre-incubation with remikiren, is given by the term 
PRnux-PRpre-incubation' A proportion/of this remainingnon·activated prorenin is activated 
during the assay, and is given by the termlx (PR -PR. . \, Thefactor/can be 
fThlX pre-mcupauon' 
measured by omitting the pre-incubation step and performing the IRMAs in the presence 
of remikiren;fis then the ratio between the measured amount of activated prorenin and 
PRnw, 
Cryoactivation was performed for 24 h at 4 'C and pH 7.4. 
Results 
Both WT and P/G-4 prorenin could be activated by remikiren, acidification, incubation 
at 4'C and plasmin. Fig.1 shows typical progression curves for activation of prorenin 
WT and mutants by plasmin, remikiren and acidification. Activation appeared first-order. 
From these curves activation rate constants were calculated. Results are shown in Table 
1. For cryoactivation the percentage active prorenin after 24 h is given. The rate constants 
for the WT andP/G-4 did not differ importantly for plasmin activation. Activation by 
acid or remikiren was slightly slower. Inactivation of prorenins at 37 'C and pH 7.4 after 
acid activation was similar for both prorenins. 
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Table 1. Aclivalion rale of hUman prorenin, wild·lype (WT) and Ihe Pro·Gly mUlanl 
(P/G·4) by various melhods 
Melhod of aclivallon 
Degree or rate of 
WT P/G·4 
activation 
CryoactlvaUon %ln24 h 8.4 6.6 
acld~activation k (h") 0.219 0.167 
Remlklren k (h") 0.194 0.099 
Plasmin k (min") 0.019 0.023 
Data are means of three experiments 
Discllssion 
Although non-proteolytic activation (by acid, cold or remikiren) was slightly slower in 
the P/G-4 mutant compared with \'(IT PR, these findings do not support the hypothesis 
that the proline residue at the -4 position in prorenin is involved in a cis·trans isomerization 
that induces a conformational change, preceding the transition to an active form of 
prorenin. In other words, the intermediary, open form of prorenin, postulated in chapter 
2.1 is not likely to be caused by an isomerization of the propeptide at the proline-4 
position. 
The proteolytic processing of prorenin is a puzzling subject. According to computer 
calculation of pro renin structure,8 the activation site of prorenin is located deep in the 
active site cleft. It is not sure how proteases reach this site, but a simple explanation may 
be that the activating site is brought to the surface before cleavage. Hints at this mechanism 
have been found in experiments which show that acid·treated prorenin is converted to 
renin by serine proteases at a faster rate than native prorenin.9 Although the P/G-4 
mutant is not processed to renin in the AtT20 expression system, plasmin was able to 
activate this mutated prorenin fully, indicating that plasmin's mode of activatingprorenin 
is probably different from that of the activating enzyme in AtT20 cells. 
Study of prorenins, mutated in their propeptide, have yielded some insight into the 
problem why prorenin is inactive. Change of arginine residues at the positions -33, -27 
and -22 to glycin but not to lysin yielded fully active prorenins, indicating that positive 
charges of these Arg residues are important to maintain prorenin in an inactive state. to 
Mutations in the propeptide of pro renin that are closer to the processing site, like 
the mutants we used in this study, may be useful to identify the processing enzyme that 
converts prorenin into renin in juxtaglomerular cells. TillS is illustrated by a recent study" 
that demonstrated that it is not likely that cathepsin B is the processing enzyme, as had 
been suggested earlier by \'(lang et al.2 Identification of the processing enzyme is important, 
because in the age of transgenesis, it may be possible to knock-out the gene coding for 
this protease in a kidney-specific manner. This would permit to cortstruct an animal 
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model that is essentially a renin-knock out, in which pro renin synthesis is normal, Such 
an animal would be an excellent tool to study prorenin physiology. 
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2.4 CRYOACTIVATION OF PRORENIN IS DUE TO INHIBITION OF 
INACTIVATION 
Summary 
We studied the so·called cryoactivation of prorenin, a process in which prorenin slowly 
acquires up to 20% of maximal enzymatic activity at low temperature and pH 7.4. 
Subsequent incubation at 37°C causes a rapid return of pro renin to the inactive state. \Yfe 
incubated recombinant human prorenin at pH 3.3, which causes reversible activation of 
prorenin (acid-activation), which is similar to cryoactivation. In contrast with 
cryoactivation, however, acid-activated prorenin is fully activated. We then neutralized 
acid-activated prorenin at various temperatures and followed inactivation by either an 
enzyme-kinetic assay for AngI generation or an immunoradiometric assay specific for an 
epitope of renin and activated prorenin. We also studied activation kinetics of prorenin 
using a renin inhibitor, remikiren, which induces a conformation of prorenin that is 
indistinguishable from reversibly activated prorenin. 
From our experiments we conclude that the inactivation rate is highly temperature 
dependent. At 37'C the inactivation rate constant amounts to 5.6 h· l , compared to 0.032 
h-1 at 4°C. The maximal activation rate is much less dependent on temperature with 
values of 0.2 h·1 at 4'C and 0.15 h·1 at 37'C. Thus, cryoactivation is due to slow 
inactivation. Inactivation of reversibly activated prorenin occurs 5 times slower in the 
presence of angiotensinogen. Reversible activation of prorenin at physiological conditions 
may well be possible, provided that inactivation can be inhibited. A likely candidate for 
inactivation inhibition is angiotensinogen. Tissue binding may also keep prorenin in an 
activated state, although this remains to be proven. 
Introduction 
So-called cryoactivation of pro renin occurs when prorenin is incubated at neutral pH 
and low temperature (-4 to +4 'Cl. I It is a slow process, taking seven days to activate up 
to 26% of prorenin.' In plasma cryoactivation is thought to be proteolytic and therefore 
irreversible. This proteolysis comprises deavingof the propeptide of prorenin that covers 
the enzymatic deft of the renin body of the molecule, thus rendering prorenin 
enzymatically inactive. Proteolysis depends on the serine proteases kallikrein and factor 
XII that are activated in the contact activation pathway of the coagulation system." 4 At 
low temperature endogenous plasma protease inhibitors lose their inhibitory activity on 
these proteases.5 In the absence of these proteases, e.g. in solutions of purified or 
recombinant prorenin, activation after exposure to cold also occurs, but this activation 
is reversible.6 It is thought that this non-proteolytic activation consists of aconformational 
change, in which the propeptide moves out of the enzymatic deft, which is located between 
the two lobes of the renin molecule. Reversibly cryoactivated pro renin is rapidly 
inactivated again by incubation at neutral pH and 37 'C.' 
The mechanism of reversible cryoactivation is not known and has not been studied 
extensively. Pitarresi et al. suggest that hydrophobic interactions between the propeptide 
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and the renin part, which keep the molecule inactive, are disrupted at low temperature.6 
Another model to understand non·proteolytic cryoactivation, suggested by the 
experiments in chapter 2.1, is that inactive prorenin is in equilibrium with a small amount 
of active pro renin, and that this equilibrium shifts to active prorenin because the rate 
constants of activation and inactivation have different sensitivities to temperature. 
The purpose of this study is to investigate the kinetics of non·proteolytic cryoactivation 
of prorenin. A simple model is assumed in which porenin is at an equilibrium between 
an open, active form (pRJ and a closed, inactive, form (PRJ, in which the propeptide 
blocks the enzymatic cleft. 
Materials and Methods 
Prorenin and Renin. Recombinant prorenin was a kind gift by Dr. W. Fischli (Hoffmann-
La Roche, Basle Switzerland). It had been synthetized in CHO cells, which were stably 
expressing human prorenin after transfection with a vector containing human prorenin 
cDNA. Partial purification of the prorenin from culture medium was performed by 
chromatography on blue Sepharose (pharmacia LKB Biotechnology Inc) as described 
in chapter 2.2. The aliquotted stock of partially purified prorenin had a concentration of 
1,6x10' mUlL and was kept at -SOOC. Its AngI generating activity was less than 0.4 % of 
maximal activity after complete proteolytic conversion of pro renin to renin by plasmin. 
Renin is the WHO human kidney renin standard, lot 6S/3S6 (National Institute for 
Biologic Standards and Control, Potters Bar, Hertfordshire, UK). Angiotensinogen was 
from plasma from nephrectomized sheep.' 
Chemicals. Remikiren, an active site-directed renin inhibitor, was provided by Dr. Fischli 
(Novartis, Basle, Switzerland). It is a non·peptide transition·state-analogue with a M, of 
726. The IC50 for purified human renin is 0.7x10·
9 M.8 TheKJor the reaction with human 
renin is 3x 10.10 mollL.9 Only freshly prepared solutions in dilution buffer were used. 
Dilution buffer is a phosphate-buffered saline solution at pH 7.4. 
Methods 
Assays. Active prorenin was measured directly in an immunoradiometric assay (IRMA? 
and indirectly in an enzyme-kinetic assay (EKA). In the IRMA the biotinylated monoclonal 
antibody (mAb) R3-36·16 against renin and prorenin is immobilized on an Smm 
polystyrene bead coated with avidin. MAb Rl-20-S, which is specific for renin and active 
prorenin but does not recognize inactive prorenio, is the free radio·iodinated antibody. 
Incubation volume was 400 "L consisting of 100 "L sample or standards, 200 "L 
incubation buffer containing 1.5 "g of mAb R3·36-16 and 100 "L of 125I-Rl-20-S 
(approximately 2,5 x 105 cpm/tube). The pH was 7.4 and incubation time was 4 hours at 
4 'c. Standards for a calibration line were from a WHO human kidney renin standard in 
concentrations ranging from 0 to 16000 "UI mL. The indirect, enzyme-kinetic assay uses 
partially purified sheep angiotensinogen. In brief, samples were incubated with near-
saturating concentrations (0.6"M of sheep angiotensinogen, Km 0.2"M~ at 37 'C, pH 
7.4 for 2-5 min in the presence of AngI·degradingenzyme inhibitors (S·hydroxy quinoline, 
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phenyl methonsulphonyl.fluoride, disodium EDT A and aprotinin~. Ang! was quantitated 
in a radioimmunoassay,IO 
Generation of Active Prorenin. Non.proteolytic, reversible activation of recombinant 
human prorenin was brought about by dialysisis against a 0.05 M glycin buffer pH 3.3 
for 24 h at 4 °e. This causes a reversible activation of all pro renin, since enzymatic 
activity was identical to that ot a sample with the same prorenin concentration after 
exhaustive proteolytic activation by plasmin (not shown). Final concentrations of prorenin 
ranged from 8000 to 14000I'V/mL 
Experitnental Protocols. For experiments of inactivation, acid-activated prorenin was 
neutralized in a 0.15 M sodium phosphate buffer, pH 7.4 at the temperature of the 
experiment. At various time points during each experiment samples were drawn and 
active prorenin was measured in the EKA and the IRMA. For experiments of activation 
prorenin was first incubated at 37°C for 1 h to inactivate any active prorenin. Incubations 
were then started at the appropriate temperatures. For experiments in the presence of 
remikiren, prorenin~containing samples were diluted 1: 1 in an appropriate remikiren 
solution. Inactivation in the presence of angiotensinogen was performed by adding 
reversibly activated pro renin at t=O to a mixture, containing sheep angiotensinogen (0.6 
I'M final concentration) and protease inhibitors like described above for the EKA. The 
mixture was incubated at 37°C. At regular time interval a sample was taken and assayed 
for AngI content. The disappearance rate of AngI generation was compared with the 
disappearance rate of Ang! generating activity of reversibly activated prorenin, incubated 
at 37°C in dilution buffer, from which at regular time intervals samples were taken that 
were assayed in the EKA. 
Analysis of the Results 
During incubation at 4 °C in the IRMA ongoing inactivation or activation may occur, 
but this is small compared to the total prorenin concentration (maximally 5% of fully 
activated or fully inactived pro renin respectively), so we ignored this. Likewise, in the 
EKA there will be inactivation at 37°C but with the very short incubation times we also 
ignored this. \Xlhen prorenin is activated with the renin inhibitor remikiren there is 
substantial ongoing activation during the IRMA step, but this was corrected for by the 
following formula: 
PR ~PR. b' +j(PR ·PR . b· \ measured pre-mcu allOn max pre-mcu allon' 
in which PR d is the amount of reversibly activated prorenin after pre-incubation 
measure 
and incubation in the IRMA (4 hours at 4°C). PR . b' is the amount of prorenin pre-Ipcu auon . 
that is activated during the incubation step preceding the IRMA·incubation. PRnux IS the 
total amount of prorenin that can be activated. This is found by incubatingprorenin for 
48 hours with remikiren (100 nmol! mL final concentration). The factor f determines 
the fraction of inactive prorenin that is activated during the IRMA step. It is found by 
immediate IRMA incubation of inactive pro renin in the presence of remikiren for 4 h at 
4°C and dividing this value by PR . 
nux 
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Kinetic Analysis 
Results were analysed according to a simple model: 
k, 
PRe .... PRo 
k, 
(Scheme A) 
An equilibrium is assumed between an open and a closed form of prorenin (resp. PRo 
and PRJ Open and closed refer to the enzymatic cleft being accessible (open) or not 
(closed) to substrate and hence, prorenin being active or not. We presume that opening 
of prorenin is caused by the prosegment moving out of the cleft. The equilibrium between 
the two states is determined by an activation fate constant kl and an inactivation fate 
constant k2' Progression curves for activation and inactivation of renin are described by 
the following equation 
(1) 
PR is the total amount of pro renin (i.e. PR plus PR \. PR is the amount of PR at 
o d ot 0 
time t and p is the fraction of prorenin that is in the closed fonn (pRJ at time 0 (i.e. PR/ 
PRJ. 
The rate constants were estimated by fitting the equation to the progression curves 
for either activation or inactivation of prorenin using a PowerMac computer and 
Graphpad Prism software (Graphpad Software, Inc., San Diego, CAl. 
Scheme A is a simplified scheme. From the results in chapter 2.1 it can be refined to: 
~ PRai ~,n"" 
PR., <11<111----:---k, 
(Scheme B) 
PRa 
Ka is an equilibrium constant. The activating reaction and inactivating reaction in the 
presence of remikiren ~NH) may be dissected as follows: 
Forward (activating) reaction 
(SchemeC) 
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Reverse (inactivating) reaction 
PR"oINH 
(SchemeD) 
The rate constants for the activating (k j b' based on scheme C) and inactivating (k, b' ~ s ~ 5 
based on scheme D) reaction are given by the following equations: 
k - 1+ [INHVK, xk 
1.,b, - 1 + 1/ K, + [INHV K, 1._ (2) 
k = 1 xk 
,.,b, 1 + [INHV K, '.= 
(3) 
Even without knowing the exact values of K or K (estimated to be - 8 and - 40 nM , , 
respectively, see chapter 2.1) it can be seen easily that at high inhibitor concentration 
equation (2) reducestok j ,b, - k, nux' Likewise, atINH-O, equation (3) reducestok ,b,-
k'm, . If at different temperatures the proportional change in k, is similar at different 
remihlren concentration, then the term 1/(1 + [INHVK) remains constant. This means 
that Ki remains constant at different temperatures. The values of kl obs and k2 bs were 
estimated by fitting the progression curves at a remikiren concentraiion of 10~ M and 
zero respectively, to equation (1). 
Results 
Activation of Native Recombinant Prorenin and Inactivation of Reversibly 
Activated Prorenin. Active and inactive prorenin were incubated at pH 7.4 at three 
temperatures, 37 'C, 22 'C and 4 'c. Progression curves for the fraction of PRo are 
shown in Fig. 1. From these curves k, and k, were calculated. This proved to be 
impossible for the curves at 22 'C and 37 'C, because hardly any activation was measurable 
(resp. 3 % and 1% of total PR after 24 h). Table 1 shows the values of k, and k, when 
Table 1. k, of the fOlWard reaction and k2 of the reverse reaction at various temperatures as 
calculaled from dala shown In Flg.1 
k, k, 
Temperature PRo=O at toO PRc=O at toO PRo=O at toO PRc=O at toO 
4'C 0.0141h 0.0121h 0.034/h 0.0321h 
22°C Not measurable not measurable not measurable 0.78/h 
37'C Not measurable not measurable not measurable S.71h 
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:: ,.-"' l~. l .. ~_ 
o 12 24 36 48 024 6 0.0 0.5 1.0 
hours pH 7.4 
37 "C 
Fig.1. Progression curves for activation (PR/PR =0 at t=o, square symbols) and inactivation 
(PR,IPR=1 at t=O, circles) of recombinant human prorenln at 4, 22 and 37 'C. Resulls 
were obtained by enzyme kinetic assay. 
derived from either an activation or an inactivation progression curve. The inactivation 
constants are resp. 0.032, 0.78 and 5.7 h·1 at 4, 22 and 37 'C respectively. Therefore, 
inactivation appears to be highly dependent on temperature. The results shown in Fig. 1 
were obtained using an EKA for active prarenin. Results with the IRMA were not 
different. 
Influence of Remikiren on Inactivation Rate Constant k,. When remikiren at various 
concentrations is incubated with active prorenin at pH 7.4 inactivation is slower depending 
on remikiren concentration (Fig. 2 and Table 2). This effect is not caused by alterations 
of Ki at different temperatures, since the fractional increase of observedk2 with decreasing 
Table 2. k2 of the reverse reaction at various remikiren concentrations and temperatures 
k, 
temperature remikiren remikiren remikiren 
OM 5x10" O M 10.9 M 
4 'e 0.0321h 0.0151h 0.011th 
22'e 0.79th 0.39th 0.241h 
37'e 5.6th 2.81h 1.8th 
Oata are means of 3 experiments 
Table 3. Fractional Increase of k2 with increasing temperature at 
various remiklren concentrations 
Remlklren k2, 370C k2,220C k2, 40C 
concentration 
OM 176 25 
5xl0" 0 M 188 26 
10.9 M 171 22 
10.6 M 135 19 
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D 10.8 M 
,. 10·9M 
A 5x10. 10 M 
o 12 24 36 48 
4°C 
6 
• 0 
0,0 0.5 1.0 
o hours pH 7.4 
37 C 
Flg.2. Progression curves of Inactivation of recombinant human profenln at various 
remikiren concentrations and at 4, 22 and 37 ·C. Results were obtained by IRMA. 
remikiren concentration was similar at each temperature (fable 3). The results depicted 
in figure 2 were obtained by IRMA. 
Activation Rate Constant k, Increases with Increasing Remikiren Concentration 
but not with Increasing Temperature. At high concentrations of remikiren pro renin 
inactivation is blocked. This may be used to study the activation rate constant. From 
Fig. 3 it can be seen that with increasingremikiren concentration faster activation occurs. 
Influence of temperature on progression curves and, hence, on activation rate constant 
o 12 24 36 48 
4°C 
o 12 24 36 48 
22°C 
o 12 24 36 48 
hours 
Fig. 3. Progression curves of activation of recombinant human prorenin at various (high) 
remikiren concentrations at 4, 22 and 37 ·C. Results were obtained by IRMA. 
Table 4. k1 of the forward reacllon at various remiklren concentrations and temperatures 
k, 
Temperature rem!~I(en rem!~iren reml~lren 
10 M 10 M 10 M 
4'C 0.0271h 0.127/h 0.2261h 
22°C 0.0071h 0.051h 0.1071h 
37'C 0.0071h 0.0341h 0.1541h 
Data are means of 3 experiments. The kl values In the rightmost column are i'll kf ,max values at 
the three temperatures 
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k1 is present but to a much smaller extent than influence on pro renin inactivation (fable 
4). 
Active prorenin {PRJ was determined by IRMA in the experiments with remikiren, 
because the EKA can not be used in the presence of a renin inhibitor. 
Inactivation of Reversibly Activated Prorenin in the Presence of Angiotensinogen. 
Inactivation of prorenin, as evidenced by a decrease in Angl generating activity, proceeded 
with a rate constant ofa.oJ min'! when angiotensinogen was present. In a purified system, 
inactivation rate was 0.15 min'l (results flot shown). 
Discussion 
Our study confirms the finding ofPitarresi et alhhat recombinant human prorenin can 
be activated at low temperature. This cryoactivation is a slow process and is rapidly 
reversed at 37 "C. Wle studied the temperature dependency of this prorenin activation 
and inactivation separately. Time course of inactivation was studied by incubation of 
fully activated prorenin at different temperatures at neutral pH. Inactivation rate constants 
were highly dependent on temperature, with a 17O-fold difference between inactivation 
rates at 4 °C and 37°C. Inactivation in the presence of low concentrations of remikiren 
showed that the interaction between prorenin and renin inhibitor was not temperature-
dependent. Activation was studied at high concentrations of remikiren, and the results 
suggest that temperature has little impact on activation rate constants, in contrast with 
the effect of temperature on inactivation rate constants. 
We assumed that the form of prorellin induced by incubation at pH 3.3 is the same at 
the moment of neutralization as the form of active prorenin that is generated during 
cryoactivation at neutral pH. This is likely from studies in which we incubated 
cryoactivated prorenin at 37 °C. Inactivation rate was identical to inactivation rate of 
acid-activated pro renin (not shown). Also, epitope expression on cryoactivated prorenin 
is proportionally identical to acid-activated recombinant prorenin (see chapter 1.1)_ 
Nevertheless, we do not have definite proof that our assumption is correct. 
From our experiments we conclude that the phenomenon of cryoactivation can be 
understood as caused by a decrease in the inactivation rate and not by an increase in 
activation rate. In fact, the activation rate constant is relatively temperature-independent. 
This is an important insight, because this means that in vivo activation will occur at 37 °C 
at neutral pH provided inactivation of active prorenin can be blocked. One obvious 
candidate for blocking inactivation of pro renin would be angiotensinogen. Indeed, 
inactivation of acid-activated pro renin proceeded at a 5 times lower rate in the presence 
of angiotensinogen. Activation of inactive prorenin by angiotensinogen, however, does 
not occur at physiological pH, temperature and concentrations of angiotensinogen (not 
shown), refuting the proposition at the end of chapter 2.1 that angiotensinogen may 
induce an active from of prorenin. The probable reason for this is that the intermediary 
form of prorenin, postulated to explain the effect of remikiren (see chapter 2.1), is not 
accessible to angiotensinogen or that affinity or angiotensinogen concentration are too 
low. Activation could also occur if some other factor would bind to the prosegment and 
in this way inhibit prorenin to assume its native conformation. H this inactivation-inhibiting 
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factor exists, it is probably present at the level of the tissues, because no evidence has 
been found for such a factor in plasma. It cannot be excluded that the recently described 
cell· binding of prorenin 11, 12 induces and/or fixes such a conformationally changed 
pro renin. The concept of a tissue factor causing nonenzymatic activation of pro renin is 
also supported by a recent article that reports in·vivo enzymatic activity of prorenin. B 
Transgenic mice expressing human prorenin and angiotensinogen exclusively in the 
somatotrophic cells of the pituitary gland, demonstrate angiotensin I production in the 
pituitary gland. This phenomenon appears to be specific for the extracellular space in 
tissues, since prorenin catalytic activity is not detectable in the circulation or in supernatants 
of ceUs cotransfected with pro renin and angiotensinogen. 1l 
The maximal activation rate constant is about O.2/h ('fable 4). This is a low value for 
a conformational change. If activation of pro renin indeed plays a role in vivo, then this 
relatively slow activation would be a safeguard against very rapidly increasing angiotensin 
production. On the other hand, it can also be proposed that pro renin activation is not 
very important in vivo, because it is too slow a process. 
The phenomenon of cryoactivation, however intriguing, has met relatively little 
interest, probably because of its slowness and because in vivo low temperatures do not 
occur, makingitssignificance for physiology questionable. Cryoactivation would indeed 
deserve oblivion if activation rate constants would depend on temperature. The results 
we now present, however, suggest that prorenin activation is not limited by temperature, 
provided inactivation is precluded. Further understanding of these processes may 
therefore yield information on a role of prorenin in vim other than the intrarenal percursor 
of renin. 
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CHAPTER 3 RENIN AND PRO RENIN MEASUREMENTS 

3.1 IMPROVED IMMUNORADIOMETRIC ASSAY FOR PLASMA RENIN 
Sununary 
In a previous report we described new IRMAs to measure the plasma concentration 
of the enzyme renin and its inactive precursor prorenin. Compared to the enzyme~ 
kinetic plasma renin concentration (pRe) assay, the level of renin was overestimated 
by IRMA, particularly in plasmas with a high prorenin-to-renin ratio. Here we 
demonstrate that the overestimation of renin was caused not so much by cross· 
reactivity of the renin-specific antibody with prorenin, but rather by an inadvertent 
conformational change of prorenin into an enzymatically active form during the 
assay. The inactive form of prorenin is known to pass slowly into an active form at 
low temperature_ We therefore raised the assay-temperature from 22°C to 37 °C, 
and shortened the incubation time from 24 to 6 h. With these modifications, the co-
measurement of pro renin as renin was eliminated. Reagents were stable at 37 oc, 
and IRMA 37°C, 6h and IRMA 22°C, 24h were comparable in terms of precision 
and accuracy. The functional lower limit of the assay (4 mUlL) was well below the 
lower reference limit (9 mU/L)_ Results of the modified IRMA in clinical samples 
with low, medium and high levels of renin showed excellent agreement with the 
levels measured by enzyme-kinetic assay_ The IRMA results were not influenced by 
the plasma concentration of angiotensinogen and were, in plasmas with a normal 
angiotensinogen level, closely correlated with the results of the classical enzyme-
kinetic assay of plasma renin activity (PRA)- The modified IRMA takes less than 
one working day and is simple to perform. Its results are expressed in terms of the 
internationally recognized human renin standard and, therefore, permit ready 
comparison between different laboratories. 
Introduction 
The aspartic protease renin is rate-determining in the proteolytic cascade that leads 
to generation of Ang II, a key factor in the regulation of blood pressure and the 
maintenance of water and salt homeostasis. I Renin is produced exclusively in the 
kidney from its enzymatically inactive precursor prorenin. Prorenin is not only 
produced in the kidney, but in other organs, like adrenal gland,' ovary,3 testis,' and 
the uteroplacental unit,5 as well. Its secretion into the blood is continuous, in contrast 
to the tightly controlled release of renin. The level of pro renin in normal plasma is 
about 9 times that of renin and is much less subject to short-term fluctuations than 
renin.6 
Enzyme-kinetic measurements of the so-called plasma renin activity (PRA) are often 
used to assess the in·vivo activity of the renin-angiotensin system, instead of the difficult 
and labor-intensive AngII measurement. In the PRA assay plasma is incubated at 37 'C. 
During the incubation renin acts on endogenous renin substrate, angiotensinogen, to 
generate AngL Conversion to Angll and degradation of AngI are blocked by protease 
inhibitors that have been added to the plasma_ The in-vitro generated Ang I is quantitated 
by radioimmunoassay. Because angiotensinogen circulates at a concentration that is about 
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equal to Km' the rate of Ang I generation in the PRA assay is as much dependent on the 
concentration of renin as on that of angiotensinogen. Plasma angiotensinogen levels 
may vary, and PRA is therefore not always a good measure of renin release by the kidney. 
To overcome this problem, exogenous angiotensinogen can be added to the incubation 
mixture at a saturating concentration. This is the principle of the enzyme-kinetic plasma 
renin concentration (PRe) assay. 
Recently our group described the clinical validation of an immunoradiometric assay 
(IRMA) of plasma renin.7 This assay measures renin directly, is better to standardize and 
is less laborious than the classical enzyme-kinetic PRA and PRC assays. Our paper, 
however, sparked a polemic on the specificity of the new assay,'·10 because in the IRMA 
some prorenin is measured as renin' so that the reliability of the assay at low renin levels 
might be insufficient. We therefore set out to improve our method, in order to minimize 
the co-measurement of prorenin. 
We assumed that the problem was caused not so much by cross-reactivity of the 
renin-specific antibody with native, enzymatically inactive, pro renin but rather by 
inadvertent activation of prorenin during the assay procedure. It is known that 
prorenin spontaneously undergoes a conformational change by which it becomes 
enzymatically active (active prorenin). This change does not require the proteolytic 
cleavage of the prosegment and does not necessarily lead to generation of renin. The 
non-proteolytic activation of prorenin is time-and temperature-dependent. It occurs 
mainly at low temperature 4 'C.u Our original IRMA was carried out at room 
temperature. Spontaneous activation of prorenin over time has been detected at 
room temperature, and is virtually absent at 37 'cY We therefore attempted to 
prevent the inadvertent activation of pro renin by shortening the incubation time of 
the assay) and by raising the incubation temperature to 37°C. 
Materials and Methods 
Antibodies. The monoclonal antibodies (mAbs) R3·36·16 and R 1-20-5 against renin 
and prorenin were purchased in a kit by Nichols Diagnostics (San Juan Capistrano, 
CAl. Briefly, the primary mAb, R3-36·16, is a biotinylated monoclonal mouse anti· 
human antibody) which binds renin as well as active and inactive prorenin. The 
secondary mAb, RI-20-5, is radio·iodinated (1251) and only binds renin and active 
prorenin. Detailed information on the antibodies is given in ref. 13. mAb F258-37-
Bl was provided by Dr. S. Mathews (Hoffmann-LaRoche, Basle, Switzerland). It 
was elicited against the C-terminal part of the propeptide of prorenin. The epitope 
of this part of the propeptide is hidden in native, enzymatically inactive prorenin, 
but is expressed on the active form of prorenin.14 Like R-3-36-16 it was biotinylated. 15 
Avidin-coated Plastic Beads, Washing Bnffer and Sheep Serum. Biotinylated bovine 
serum albumin was coupled to 8-mm-diarneter polystyrene beads (precision plastic Balls 
Co., Chicago, IL), after which the beads were coated with avidin 15 and stored at 4'C. 
Washing buffer, phosphate buffered saline with 0.01% Triton X-loo, was provided by 
Nichols Diagnostics. Serum from normal sheep was heat-inactivated for 1 h at 56°C. 
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Renin Standards. Recombinant human renin was provided by Nichols Diagnostics. We 
calibrated this renin preparation against the \Y/HO human kidney renin standard, the 
International Reference Preparation (IRP), lot 68/356 (National Institute for Biologic 
Standards and Control, Potters Bar, Hertfordshire, UK)" in the enzyme-kinetic PRC 
assay (see below). Serial dilutions of human recombinant renin to be used for constructing 
the calibration line were made up in undiluted sheep serum. Sheep serum content of the 
renin standards was therefore near 100 %, contrary to what was stated in our previous 
pape? on a renin IRMA. Renin standard-dilutions were then lyophilized and stored at 4 
dc. Prior to assay, the Iyophilisates were reconstituted in distilled water. 
Renin Inhibitor. Remikiren, an active site-directed renin inhibitor, was obtained from 
Hoffmann-LaRoche (Basle, Switzerland).17 It is a non-peptide transition-state-analogue 
with a M, of 726. The ICso for purified human renin is 0.7xl0-
9 M, and the Ki for the 
reaction with human renin is 3 x 10-10 molll." Only freshly prepared solutions of 
remikiren were used. 
Angiotensinogen. Angiotensinogen was prepared from plasma of nephrectomized 
sheep.18 The partially purified preparation was dialyzed against 0.15 mollL PBS, 
pH 7.4, and neomycin sulphate was added (final concentration 2 giL). The final 
preparation had an angiotensinogen concentration of 1.2xlO·6 moUL, determined as 
described below. 
Methods 
Non-proteolyticActivation of Pro renin. Prorenin was treated with the renin inhibitor 
remikiren to change the molecular conformation from an inactive form into a form that 
is recognized by the mAb specific for renin. 19 We refer to this remikiren-induced 
conformational change of prorenin as 'activation', despite the fact that the prorenin-
remikiren complex lacks enzymatic activity. To activate all the prorenin in plasma, we 
added 1 vol of remikiren (10.3 mollL) to 10 vol of plasma, and incubated the mixture 
for24hat4°C." 
Assays 
Enzytne-kinetic Assays of Renin. To measure PRe, we used our in-house assay, as 
described peviously.2o, 21 In short, we added 250 p.L aliquots of sheep angiotensinogen 
solution to 25- 250 p.L aliquots of plasma, and adjusted the volume to 500 p.L with 
0.15 mollL PBS, pH 7.4, and added 17.5 p.Lof a protease inhibitor solution consisting 
of 2 vol 0.34 mol/L 8-hydroxyquinoline sulphate, 1 vol of 0.287 mollL 
phenylmethylsulfonyl fluoride in ethanol, 2 vol of 0.5 mollL disodium EDT A, and 
2 vol of aprotinin (10,000 kallikrein-inhibiting units/mL). We incubated the mixture 
at 37°C for at least two time periods between 0.25 and 3 h in order to verify linear 
AngI generation. The final concentration of sheep angiotensinogen in the incubation 
mixture was 6xlO-7 mol/L (Km 2xl0-7 moIlL). Only incubations in which less than 5% 
of angiotensinogen was hydrolyzed were accepted to calculate the concentration of 
naturally occurring renin. Parallel incubations at 0 °C served as blanks. The generated 
Ang I was measured by RIA." Results of the PRC measurements are expressed as m ul 
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L, as calibrated with the international renin standard. Under the conditions of the assay, 
1 mU of renin generates 163 pmol (212 ng) of AngI per hour. Thelower limit of detection 
is 1 mUlL. 
For the PRA assay we used a modification of the method proposed by Sealey et 
al."The method was modified to include blank subtraction and the 18 hour 
incubation for low renin samples was eliminated. In this assay 50 p.L of maleic acid, 
pH 5.7, and 12.5 p.L of a protease inhibitor solution consisting of 1 vol 0.287 moll 
L phenylmethylsulfonyl fluoride in ethanol, 2 vol. 0.5 mollL disodium EDT A, and 
2 vol. 10% (w/v) neomycin sulphate, were added to 0.5 mL plasma. The mixture 
was then incubated at 37°C for at least two time periods between 0.5 and 3 h to 
check for linear Ang I generation. The generated Ang I was quantitated by RIA.21 
Results are expressed as nmol Ang I/L/h. The lower limit of detection was 0.08 
nmol Ang IlL/h. 
Assay of Angiotensinogen. The concentration of angiotensinogen in plasma was 
determined as the maximal quantity of Ang I that was generated during incubation 
at pH 7.4 and 37°C of plasma to which recombinant human renin had been added 
at a final concentration of 20,000 mUlL. Results are expressed as nmollL.21 
Immunoradiometric Assays. To 200 !IL aliquots of untreated plasma, remikiren-
treated plasma or renin standards, we added 100 !\L of an equivolume mixture of 
biotinylated mAb RJ·36-16 (0.5 !lglL) and radiolabeled (approximately 250 000 cpm) 
mAb Rl-20-5. We incubated this mixture with a polystyrene, avidin·coated bead in 
duplicate for either 24 h at room temperature (IRMA22 'C, 24h) or for 6 h at 37°C 
(IRMA37 'C, 6h). After incubation we washed the beads three times and transferred 
the washed beads to a clean tube. Radioactivity of bound antibody was counted for 
5 min in a gamma-counter. The assay measures renin in the untreated plasmas and 
renin + prorenin in the remikiren-treated plasmas. Pro renin is the difference between 
the results of the two measurements. 
In order to test our hypothesis that co-measurement of pro renin as renin was caused 
by a conformational change of prorenin we also performed another, two-step sandwich 
assay. This assay is a modification of an assay we described earlier" and measures pro renin 
levels directly after remikiren activation. In this assay an avidin-bead carrying 1 p.g of 
biotinylated F258-37-B1, was incubated for 6h at 37°C or for 24h at 22°C with plasma 
from a patient with high plasma prorenin (prorenin 2757 mUlL, renin 53.1 mUlL. This 
F258-37-B1-beadcan only bind the active form of prorenin by its exposed propeptide, 14 
but will not bind renin and native, inactive prorenin. Half·time of binding of active 
prorenin to the bead at 37°C is about 12 minutes. After incubation we rinsed the bead 
three times with 2 mL of phosphate buffered saline, containing 0.1% bovine serum 
albumin, to remove all renin and inactive prorenin. Then we incubated the bead with 
sheep serum containing remikiren (10-4 M) and radio labeled R 1-20-5 for 24 h at 22°C. 
The tracer antibody binds the active prorenin trapped on the bead. We added remikiren 
in this second step to ensure that any active prorenin captured on the bead in the first 
step, is kept in its active conformation. After incubation we washed the beads with 3x2 
mL washing buffer and we counted bound radioactivity after transferral to a clean tube. 
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A standard line of remikiren-treated recombinant human pro renin in sheep serum was 
used. H The lower limit of detection of this assay is about 10 mUlL active prorenin. The 
interassay coefficient of variation at levels below 100 mUlL is about 10%. 
Collection of plasma samples 
Plasma samples were from normal subjects, patients with essential hypertension 
without therapy or on enalapril, patients with renovascular hypertension without 
therapy or on enalapril, patients with hepatic cirrhosis and patients with primary 
aldosteronism (Conn's syndrome). Individuals with conditions where a high prorenin. 
to-renin ratio is not unusual, i.e. pregnant women, women with ovarian 
hyperstimulation, women with preeclampsia, women taking oral contraceptives and 
patients with diabetes mellitus, were also studied. Blood sampling was performed 
according to our in-house protocol; after cannulation of an antecubital vein and 30-
45 minutes supine rest, blood was collected into tubes containing 0.2 mL of 0.646 
mol/L citrate per 10 mL blood. The blood was immediately centrifuged at room 
temperature, and plasma was stored at -20°C. Shortly before each assay plasma 
samples were rapidly thawed and kept at room temperature. 
Results 
Performance characteristics of the renin IRMA at 37°C 
Calibration line. Fig. 1 depicts a comparison of the calibration line of IRMA 37°C, 6h 
with the calibration lines of IRMA 37°C, 24 h, and of IRMA 22°C, 24h. Results, expressed 
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Figure 1. Calibration lines of IRMAs. Ordinate: total binding of labeled 
antibody. Abscissa: renin concentration. The shaded area represents the 
normal range. Inset: low range of the calibration line of IRMA 37 oC, 6h 
(mean ± 3 SD). 
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Figure 2. Plasma dilution tests for plasmas from a patient with renal artery 
stenosIs, treated by enalaprll (A). a patient wIth renal artery slenosls, 
untreated (.), a pregnant woman (D), a patient with low-renin hypertension 
('7) and a paUent with Conn's syndrome (III). Ordinate: results of IRMA 37 
°C, 6h. The shaded area represents the normal range. 
Table 1. Recovery of hUman kidney renin added to plasma 
Plasma Renin added Renin Renin Recovery of 
mUll concentration concentration added renin 
measured measured 
before addition after addlUon 
of renin of renin 
mUll mUll % 
A 10 7.4 17.1 97 
B 20 10.1 30.2 102 
C 50 24.5 75.6 102 
0 50 25.1 75.6 101 
E 50 28.1 80.1 107 
F 10 37.0 46.5 95 
G 20 42.3 61.9 98 
H 70 53.1 115.4 89 
H 130 53.1 203.9 116 
I 130 155 265.5 85 
I 260 155 446 110 
/;fPROVED RENIN IRMA 
as counts per minute, were linear over a wide range of renin concentrations. IRMA 37°C, 
24h and IRMA 22°C, 24h produced identical results. It appears therefore that the reagents 
were stable at 37°C. The calibration line of IRMA 37°C, 6 h was parallel to those of the 
24h·IRMAs but results were 25% lower. This difference w"; fully explained by the first-
order rate constant for the binding of the radiolabeled mAb to renin at 37°C (0.23 h-l, 
data not shown). For practical purposes we chose IRMA 37°C, 6h instead of IRMA 
37°C, 24 h as our routine assay, although the quantity of radiolabeled mAb trapped by 
renin was somewhat lower after 6 h than after 24 h. 
Linearity was tested by preparing dilutions of plasma samples with renin ranging 
from 5.7 to 2106 mUlL. Dilutions were made up in the same matrix, i.e. sheep senut!, as 
used in the calibration line. Plots of the results, expressed as mUlL, against the dilution 
factor gave straight lines with the correct slope (Fig. 2). 
Analytical recovery. The human kidney renin IRP was added to plasma samples 
with renin concentrations ranging from 7.4 to 155 mUlL. As shown in Table 1 
results of IRMA 37"C, 6h demonstrate excellent analytical recovery of both low 
and high quantities of added renin. The mAbs we used are capable of inhibiting the 
AngI-generating activity of reninY To investigate whether angiotensinogen might 
interfere with the binding of renin to these antibodies, we added the human kidney 
renin IRP to a plasma, obtained from a pregnant woman. This plasma (plasma D in 
Table 1) had an angiotensinogen concentration of 3208 nmoIlL, which is about 3 
times normal. Angiotensinogen, at this high concentration, did not influence the 
results of IRMA 37 'C, 6h (see Table 1). 
Assay variation and sensitivity. As shown in Fig. 1, the detection limit of IRMA 37°C, 
6h, defined as 3 SD above the zero-standard was 1.3 mUlL. The zero-standard of this 
standard line gave about 150 counts per minute, and the 4 mUlL-standard about 300 
counts per minute. Thus, at this low renin concentration, the result is close to the blank. 
This raises concern about the reliability of renin measurements by IRMA in the low 
E 
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Figure 3. Binding of labeled 
antibody to zero-standard-beads 
(blank) and to the lowest, 4 
mUlL, renin standard-incubated 
beads. for all 32 IRMAs, 37C.S! 
6h performed from JanuaryS!1 , 
1998 through September 1 
1998. Indicated are the mean ± 
SO on the left and right for the 
blank and the 4 mUll standard 
respectively. 
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Table 2. Intraassay and interassay CVs determined in plasma samples 
Renin Inlraassay CV (%) Interassay CV(%) 
concentration 
(Enzyme- n=6 n=10 
kinetic PRC 
assay) 
IRMA IRMA Enzyme- IRMA IRMA Enzyme-
22 "C, 24h 37"C,6h kinetic 22 "C, 24h 37"C, 6h kinetic 
PRC PRC 
mUll assay assay 
3.6 11.3 9.5 B.2 25.5 21.5 14.5 
7.3 5.9 7.6 6.2 13.5 16.4 9.6 
34.3 4.9 3.9 3.6 6.6 5.2 5.1 
154 3.9 3.B 3.7 5.7 5.3 4.6 
range of renin levels. This issue is addressed in Fig, 3 which gives the results, expressed 
as counts per minute, for human recombinant renin at a concentration of 4 mUlL (specific 
binding of radiolabeled mAb - total binding by 4 mUlL renin-standard minus the 
binding by zero-standard (blank), both as the mean value of duplicate measurements). 
Fig. 3 shows adequate separation between the 4 mUlL-standard and the blank in each 
of the 32 assays. Variability of the duplicate blanks was low compared to specific binding 
by the 4 mUlL renin-standard as depicted in Fig. 3. The difference between the duplicate 
blanks was 13.5 (1-38) cpm or 11 (1-35)% of the mean blank (median(range), n -32). 
The difference of the duplicate 4 mUlL-standard was 14{1-32) cpm or 6(0-15)% of 
specific binding. 
In Table 2 intra-assay and inter-assay evs in low-, medium- and high-renin 
concentration renin plasmas are given for IRMA 37°e, 6 h and are compared with the 
ev s for IRMA 22°e, 24 h and the enzyme-kinetic PRe assay. Intra-assay ev s were 
similar for the three types of assay in plasmas with high renin concentration as well in 
plasmas with medium or normal renin. Interassay evs in the plasmas with low renin 
Table 3. Renin concentration determIned in a pool of human plasma and In a dilution of 
human kidney rentn In sheep serum 
IRMA 22 oe, 24h IRMA 37 "e, 6h Enzyme-kinetic 
PRe assay 
mUll mUll mUll 
Normal plasma pool 30.6.:!:.3.6 24.5:tJ .5 25.1 !.1.6 
Kidney renin 50.2±.2.9 51.1!.2.8 50.0;!:.1.5 
Values are mean:t.SD. 0=3. Plasma samples from 8 normal subjects were pooled: the 
pro renIn concentration of this pool was 238.:!:.13 mUll 
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Figure 4. Comparison of IRMA 22 'C, 24 h (IRMA 22) and IRMA 37 'C, 6h (IRMA 37)wilh Ihe 
enzyme-kinetic PRC assay (EKA). Ordlnale: difference between IRMA and Ihe enzyme-
kinetic PRe assay, expressed as a percentage of the enzyme-kinetic PRe assay. Abscissa: 
profenin -to-renin ratio as measured by IRMA 37°C, 6h. Slopes of regression lines for IRMA 
22 and IRMA 37 (nol depicled) are 41 and 5.9 (p<0.001 and NS for comparison with slope=O). 
Y-Intercept is -7.2 and 3.7% resp. The x-variable is log[prorenln-fo-renin ratio]. The outlier 
most on the right was omitted from analysis 
((IRlM37-EKA)lmean renin)x100 
100 
-100 
10 100 
Mean of IRIM 3PC, 6h and EKA rrU'L 
1,000 10,000 
Figure 5. Bland-Allman plol comparing IRMA 37 'C, 6h (IRMA 37) with Ihe enzyme-kinetic 
PRC assay. Ordinale: difference between IRMA and Ihe enzyme-kinetic PRC assay (EKA), 
expressed as a percentage of the renin level (mean renln=mean of IRMA and EKA). Abscissa: 
mean of IRMA and enzyme-kInetic PRCassay. The mean aftha difference between IRMA 
37 'C, 6h and enzyme-klnellcPRC assay is 0.4%, SD =17% (n=121) 
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Table 4. Pla!lma eoneentratlons of renin. renin plus prorenin and angioten!linogen, and the level of plasma renin activity in normal !lubjects and In varlou!l 
group!l of patients 
Renin Renin plus prorenln PRA Anglo. PRA·to. 
ten!llnogen renin 
Subject group!l IRMA 22 DC. IRMA 37 DC. Enzyme· IRMA 22 DC, IRMA 37 DC, ratio 
24h , h kinetle 24 h , h 
PRe 
a!l!lay 
nmol 
mUll mUll mUll mUfl mUll Angllllh nmol/l 
Controls 10 29.7a,b 24.9 23.3 19. 202 2.01 918 0.079 
15.9_62.2 14.6.38.9 10.2·36.2 131·347 123·344 1.15·6.09 823.1003 0.064.0.118 
Essential 
hypertensives 
No treatm ent 20 11.0a,b 9.1 ,.5 139 13. 0.58 1159 0.073 
6.7·21.9 5.4·16 5.0.16.9 49·527 46·486 0.19-1.56 729.1626 0.029·0.114 
Enalaprll 3811,b 30.9 32.7 34' 330 2.42 
'" 
0.077 
20.7·73.3 17.8·58.0 13.2_68.2 213-559 219-470 1.06·5.97 627-1189 0.029.0.114 
Renovascular 
hypertension 
No treatment 100.2a,b 86.3 94.7 426 411 7.43 1334 0.079 
73.3·158 58.140 68.1.149 346-475 385-445 5.97-9.00 1189_1628 0.061_0.093 
Enalaprll 527 496 533 1233 1171 31.9 
." 0.060c 
153_1392 128_1188 124.1238 405-2034 383·1923 11.8·78.1 526_1139 0.038_0.095 
Hype ra Id 0 sle ro n Is m 2 4.4,9.4 4.1.6.4 3.4,5.4 44.0,64.1 43.7,68.2 0.33,0.57 1105.1244 0.081,0.080 
(Conn !lyndrome) 
liver cirrhosis 12 1892 1847 1777 NO 3569 27.7 252c 0.015d 
525·6821 528-7436 456·6830 807.4605 13.5·70.6 115_626 0.007-0.040 
Olabetes mellitu!l • 61.6a,b 36.8 38.3 691 '" 
3.28 903 0.076 
(In s u lin_de p e nde n t) 45.4-82.4 24.4-54.4 25.0_57.5 381_904 381-859 1.79-7.08 784.1025 0.061.0.117 
Pregnancy 10 67.7a,b 52.5 56.2 '4' ,sa 9.62 3535c 0.157d 
33.7-127 29.6-121 30.7·147 367_1609 426.1348 5.35-20.8 2631-4675 0.065·0.210 
Preecciamps'la 27.3a,b 18.5 19.8 4'4 "5 2.83 2501c 0.113d 
7.6-56.3 5.4-40.4 4.2·44.0 139.1137 129·1137 1.09-4.93 1723_3711 0.064.0.189 
Go nadolro p in -tre ate d 12 47.2a.b 27.9 27.2 NO 914 3.31 2707c 0.122d 
women 19.9_110 14.0_57.8 12.4.56.7 355-2345 1.54-7.64 1563-3961 0.076_0.161 
Women on oral 10 18.7a .b 16.9 15.9 122 130 2.01 2664c 0.133d 
contraceptives 12.1-36.8 11.0·34 9.2-33.0 95.152 101_135 0.85·4.66 1390_6776 0.092-0.187 
Values are mean and 95% confidence interval. a: Sign'iflCanlly dlffereri't-from IRMA 37-"C, 6h, p<o~oT; b: Signiflca;'-tiy different from enzyme_kinetic PRC assay, 
P<O.OI; c and d: Significantly different from eontrol subjects, P<0.05 and 0.01 re!lp. NO: not determined 
'" 
'" 
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concentration were, however, higher for the IRMAs than for the enzyme-kinetic PRC 
assay. The functional sensitivity, i.e. the minimum renin concentration that can be measured 
from assay to assay with < 20% CV, is about 4 mUlL (see Table 2). 
Co·measurement of pro renin 
Table 3 compares the results ofIRMA 37°C, 6 h, IRMA 22°C, 24 h and the enzyme-
kinetic PRC assay in a normal plasma pool. The renin concentration in the plasma 
pool measured by IRMA 37°C, 6 h was equal to that measured by the enzyme-
kinetic PRC assay and was about 25% lower than the concentration measured by 
IRMA22°C, 24h. In contrast, results obtained by IRMA 37°C, 6h and by the enzyme-
kinetic PRC assay in a dilution of the human kidney renin IRP in sheep serum were 
not different from the concentration measured by IRMA 22°C, 24 h. This is an 
indication that pro renin interferes with the measurement of renin in IRMA 22°C, 
24 h. To further prove that a conformational change of prorenin at 22°C is the 
culprit of renin overestimation, we also performed at 22 and 37 °C a two·step IRMA 
that measures the active conformation of prorenin. \Vhen in the first step of the assay 
incubation is performed at 37°C for 6h, very little active prorenin is measured in the 
second step (18 mUlL, less than 1% of total prorenin and close to the detection limit of 
the assay). In contrast incubation of the same plasma with the same beads at 22°C for 24 
h yielded a much higher level of active prorenin measured in the second step (149 mUI 
L, i.e. 504% of total prorenin). This indicates that in the course of incubation prorenin is 
activated and then captured by the F258-37-Bl-coated bead at 22°C, but not at 37°C. 
This observation could be repeated and was also made in 3 other plasmas with a high 
pro renin level. Activation of prorenin at 22 oC, but not at 37 oC, also explains the results 
presented in Fig. 4. In this figure we compare the results of IRMA 22 "C, 24 h and IRMA 
37°C, 6h with the results of the enzyme-kinetic PRC assay, in plasmas having different 
prorenin~to-renin concentration ratios. Overestimation of renin was frequent in IRMA 
22°C, 24 h, and was most pronounced at high prorenin·to-renin ratios (FigA, left-hand 
plot). Overestimation of renin was not seen in the IRMA 37°C, 6h. Fig. 5 depicts a 
Bland-Altman plot, comparing the IRMA 37°C, 6h with the enzyme-kinetic PRC assay. 
Since renin levels ranged over three orders of magnitude and differences were 
proportional to the renin level, the mean of the two assays was log-transformed and the 
difference corrected for by the renin level. The plot demonstrates good agreement between 
IRMA 37°C, 6 h and the enzyme-kinetic PRC assay, in plasmas with a renin level ranging 
from very low to very high. 
In Table 4, the results presented in Figs. 4 and 5 are grouped according to diagnostic 
categories. Table 4 also compares the three types of renin concentration measurement 
(IRMA 22°C, 24h; IRMA 37°C, 6h; enzyme-kineticPRC assay) with the measurement of 
plasma renin activity (PRA) in different patient groups. The percent overestimation that 
was seen in IRMA 22°C, 24h was most pronounced in patients with diabetes mellitus, in 
pregnant women with or without preeclampsia, and in gonadotropin·treated women. 
These are the patient groups with the highest prorenin-to-renin ratio. IRMA 22°C, 24 h 
did not overestimate renin in patients with renovascular hypertension treated with enalapril 
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Figure 6. Comparison of IRMA 37 °C, 6h with the enzyme·kinetic PRA assay in patients with 
Conn's syndrome (triangles), patients with essential hypertension (closed clrcles) and from 
control subjects (open circles). The regression line was obtained by a least-square 
regression analysis after logarithmic transformation of the resulls. The y-intercept (given as 
the antilog) is 0.056, slope Is 1.097, n=65. 
The shaded area represents the normal range. 
and patients with liver cirrhosis. In these patient groups the prorenin-to-renin ratio is 
abnormally low. 
Many laboratories measure PRA instead of renin concentration. The results of the 
PRA assay are determined not only by the concentration of renin but also by the 
concentration of angiotensinogen in plasma. We compared the results of IRMA 3rC, 6 
h with those of the PRA assay. Fig, 6 shows the results in normal subjects, in patients 
with untreated essential hypertension and in patients with Conn's syndrome. The 
angiotensinogen concentration in these plasma is normal and renin is normal or low. 
Results of the PRA assay (nmol angiotensin I1L/h)were 0.07 times those of IRMA 
37°C, 6 h (mUlL). A similar correlation was seen in other patient groups having normal 
renin and angiotensinogen concentrations in their plasma (see Table4). As expected, the 
PRA-to-IRMA ratio was higher in patients with abnormally high angiotensinogen, and 
the ratio was lower in patients with abnormally low angiotensinogen. 
Discussion 
The original IRMA of renin we described previously, was not 100% specific for renin. 7 
It also measured asmall fraction (0.5-2%) of prorenin. Measurements in plasma therefore 
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led to an overestimation of renin. In normal subjects and in patients with essential or 
renovascular hypertension, renin is overestimated by 20% or less but the deviation can 
be larger in situations in which plasma prorenin comprises more than 90% of total renin 
such as low-renin essential hypertension, pregnant women, in patients with Conn 
syndrome and in patients with diabetes mellitus. 
The present study demonstrates that this problem is solved in the improved assay. 
The tertiary structure of renin and prorenin has the form of two lobes separated by a 
cleft that contains the enzyme's active site,24,25 In enzymatically inactive, intact, pro renin 
the propeptide is folded in this cleft so that angiotensinogen cannot reach the active site. 
This so-called closed form of prorenin is in dynamic equilibrium with an open form 
where the propeptide, while still covalently linked with the renin part of the molecule, 
has been displaced from the cleft so that angiotensinogen can now reach the active site." 
The transition of the closed form into the open, active form takes hours and the 
equilibrium is shifted towards the open form by lowering the temperature 
(cryoactivation)12 or by the addition of active site-directed renin inhibitors. '9 Our results, 
especially those of the two-step IRMA that captures active prorenin, demonstrate that 
the co-measurement of prorenin we observed in the original IRMA 22°C, 24h, is caused 
by the formation of open prorenin. This is almost completely prevented in the IRMA 
3rC,6h. 
IRMAs are usually performed at room temperature. One may therefore wonder 
whether the reagents we used are stable at 3rC. Our observation that the calibration 
lines of IRMA 3rC, 24h and IRMA 22°C, 24 h were identical strongly suggests 
that the reagents are indeed stable at 37°C. 
The renin standard was diluted in sheep serum in orderto minimize unspecific binding 
of the mAbs. Theoretically, the binding characteristics in the sheep serum matrix might 
be different from those in human plasma. Additions of the renin standard to human 
plasma, however, resulted in complete recovery, and serial dilutions of human plasma 
resulted in decrements of binding that were linearly correlated with the dilution factor. 
The close agreement between the results of IRMA 37°C, 6h with those of the enzyme-
kinetic PRe assay also indicates that the difference in the reaction milieu between plasma 
samples and standards did not affect the results. 
The IRMA 37°C, 6h in plasma samples with a normal or elevated renin 
concentration was as precise as the enzyme-kinetic PRC assay (interassay CV < 10%). 
In plasma samples with a low renin concentration « 10 mUlL), the precision of 
IRMA 37°C, 6h, was less than that of the enzyme-kinetic PRe assay. The functional 
sensitivity, defined as the minimum concentration that can be measured from assay to 
assay with < 20% CV, was approximately 4.0 mUlL. Our results show this to be sufficient 
for measuring the concentration of renin in plasmas from patients with suppressed renin, 
like patients with Conn}s syndrome or low-renin essential hypertension. 
Many laboratories still use the enzyme-kineticPRA assay. From our results it appears 
that the patients who were diagnosed by IRMA 3rC, 6h as having a low concentration 
of renin in this plasma, also had abnormally low PRA. 
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The improved IRMA is specific for renin and appears to be a simple, precise and 
accurate method for measurements in clinical plasma samples. This assay is easier to 
standardize than the enzyme-kinetic assays that rely on endogenous angiotensinogen 
like the PRA-assay. Its results are expressed in terms of the internationally recognized 
human renin standard and, therefore, permit ready comparison between different 
laboratories. 
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3.2 RENIN AND PRORENIN ASSAYS: THE NEXT GENERATION 
Summary 
In search of renin and prorenin assays that (I) do not co· measure prorenin as renin, (2) 
do not use a proteolytic step, which may destroy renin or prorenin, (3) can be easily 
standardized, and (4) are easy to perform, we compared a traditional enzyme kinetic 
assay (EKA) for renin, a direct immunoradiometric assay (IRMA) for renin (R.IRMA) 
and a new, direct liMA for prorenin (pR·liMA). 
The EKA was performed by measurement of angiotensin I generation from sheep 
angiotensinogen. R·IRMA was performed by immobilization of renin and prorenin with 
a renin· and prorenin·binding monoclonal antibody (mAb) R3-36-16. Renin and prorenin 
treated with the active site·directed renin inhibitor remikiren, were detected by a 
radiolabeled mAb RI-20-5 that is specific for an epitope expressed solely on renin and 
remikiren·treated prorenill. PR·IRMA was performed by selective immobilization of 
remikiren·treated prorenin by a mAb F258-37-B I against the propeptide, followed by 
binding of the radiolabeled antibody RI-20-5. Standards in the IRMAs were the WHO 
kidney renin standard or remikiren-treated recombinant human prorenin, that expresses 
the renin·specific epitope and the propeptide.epitope, both hidden in native prorenin. 
Plasma from 6 healthy subjects and 50 with various causes of hypertension were studied 
as well as 7 patients treated by remikiren. 
EKA and R·IRMA gave identical results for renin. EKA and R·IRMA were also 
used to assess total renin after proteolytic treatment and remikiren treatment respectively. 
This was used to determine prorenin level indirectly. Comparison with direct pro renin 
quantification in the PR·IRMA gave identical results in 56 clinical samples. Patients on 
renin inhibitor therapy showed disproportionally high renin levels, probably caused by 
inhibitor-induced activation of prorenin. 
We conclude that for routine purposes the R·IRMA is reliable for direct renin and 
indirect prorenin measurement and that a new standard for both renin and prorenin 
assays could be remikiren treated recombinant prorenin. Measurement of renin and 
prorenin by both R·IRMA and PR·IRMA may become important with further clinical 
development of renin inhibitors. 
Introduction 
Renin is the regulated compound of the renin·angiotensin system, and determines the 
rate of generation of angiotensin II, the effector of the system. Therefore, plasma renin 
measurement has been important to study the physiologyofthe renin·angiotensin system 
since the early days of renin·angiotensin research.' In the clinical setting plasma renin 
measurement gained a place in the diagnostic work·up of renovascular hypertension and 
hypokalemic hypertension. Initially renin levels were estimated by the hypertensive response 
after injection of a renin-containing sample into an animal. Later 00, enzyme kinetic 
assays (EKAs) were developed that measured angiotensin I production by renin from 
angiotensinogen (for an overview of the various methods see ref. 2). Angiotensin I was 
quantitated by either bio·assay or by radioimmunoassay. A third phase in renin 
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measurement methodology was entered some fifteen years ago when antisera and 
monoclonal antibodies against renin became available, allowing development of direct 
immunoassays for renin.3 Despite the long history of renin research and the availability 
of an international reference preparation4 little consensus exists regarding which of the 
aforementioned assays is to be preferred. Because of this, methods abound and differ 
considerably. Results of renin assays are hardly ever comparable between laboratories 
and hence, reference values have never been established. 
Another problem in renin measurement is the presence in plasma of pro renin, the 
enzymatically inactive precursor of renin. Its concentration in plasma is on average 9 
times that of renin. Pro renin has a structure that is very similar to renin (see chapter 1). 
Prorenin may be co·measured as renin, either in enzyme-kinetic assays because it acquires 
enzymatic activity, e.g. a&er storage in the cold,s or in immunologic assays because of its 
considerable structural homology to renin,6 or because of, again, a change into an active 
conformation (see previous chapter). Accounting for contribution of prorenin to 
measured renin levels is difficult, because few laboratories dispose of direct prorenin 
assays. The usual way of prorenin measurement is to convert prorenin to renin by 
proteolytic removal of the propeptide and to measure the the total, i.e. renin plus prorenin 
content. The difference in renin concentration before and after proteolytic activation is 
then a measure of the pro renin concentration. 
\VIe and others' feel that there is a need for specific, standardized assays for renin and 
prorenin, that preferably avoid a proteolytic step when total renin is to be measured. In 
the present paper we compared a second-generation, enzyme kinetic assay, the plasma 
renin concentration (pRe) and two third-generation assays, an immunoradiometric assay 
for renin (R-IRMA) and a direct prorenin IRMA (PR-IRMA), for their use in renin and 
prorenin quantification. The EKAs like the PRe assay rely on proteolytic activation of 
prorenin, but the two IRMAs use remikiren-'activation' as described in chapter 2.1. The 
PR-IRMA is a new development and in this chapter we describe the performance of this 
assay. Another new feature is that for both renin and prorenin measurement by IRMAs 
an identical standard was used. Finally we discuss the application of these assays. 
Materials and Methods 
Antibodies. Three mouse anti-human monoclonal antibodies (mAbs) were used. Purity 
was more than 98%, as verified by sodium dodecyl sulphate polyacrylamide 
electrophoresis. Biotinylated mAb R3-36-16 and 125I-labeled mAb Rl-20-5 were 
purchased as part of a kit from Nichols Institute Diagnostics, \VIijchen, The Netherlands. 
mAb F258-37-Bl was from the laboratories of Hoffmann-La Roche, Basle, Switzerland. 
mAb R-3·36-16 binds to an epitope that is expressed on both renin and prorenin.8 mAb 
Rl-20-5 is able to bind to an epitope expressed on renin, but not on native, inactive 
prorenin.8 lt does, however, bind active prorenin (see chapter 2.2). mAb F258-37-Bl 
was raised against a synthetic peptide, consisting of the -p24-Leu to -p l-Arg sequence 
of the propeptide of prorenin, i.e. the Cterminal part of the propeptide. This propeptide 
is absent in renin. 
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Chemicals and Buffers. Remikiren, an active site-directed renin inhibitor, was provided 
by Dr. Fischli (Hoffmann-La Roche, Basle, Switzerland). It is a non-peptide transition-
state-analogue with aM of 726. The IC51) for purified human renin is 0.7x1O·9 M.9 The 
f\ for the reaction with human renin is 3x 10.10 mollL. Only freshly prepared solutions 
were used. Sepharose-bound trypsin was prepared by coupling trypsin (Sigma, St. Louis, 
MO) to CBr-activated Separose 4B (pharmacia, Uppsale, Sweden).lO Sheep serum was 
used as a dilution buffer in thelRMAs.1t was purchased at Biotrade, The Netherlands. In 
addition to irradiation it had been heated at 56 'C for 1 h. Washing buffer was a phosphate 
buffered saline, supplemented with 0.5% bovine serum albumin. 
Renin and Pro renin Standards. Recombinant renin standards were included in the 
Nichols Institute Diagnostics kit. They were prepared as described previously. 11 Briefly, 
recombinant renin was calibrated in an enzyme kinetic assay against the \'{fHO human 
kidney renin standard, lot 68/356 (National Institute for Biologic Standards and Control, 
Potters Bar, Hertfordshire, UK). Renin standards were made up in sheep serum. 
Recombinant human prorenin was a gift by Dr. Fischli (Hoffmann-La Roche, Basle, 
Switzerland). It was produced in CHO cells transfected with a vector containing human 
prorenin eDNA. Native pro renin is only recognized by mAb R3-36·16(see chapter 2.2). 
For use of recombinant prorenin as a calibrator in the IRMAs the renin and propeptide 
epitopes of prorenin were unmasked by preincubation with remikiren at lO~M for 48 h 
at 4'C (see chapter 2.2). Remikiren-treated prorenin stock was diluted in sheep serum, 
containing lO~M of remikiren, to establish a range of calibration samples. The renin-
specific epitope of these prorenin standards was calibrated with the reference human 
kidney standard, lot 68/356, in the renin IRMA 
Avidin-coated Plastic Beads. Polystyrene beads with a diameter of 8 mm, coated with 
biotinylated bovine albumin to which avidin was coupled, were from Precision Plastic 
Balls Co., Chicago, IL. 
Methods 
Prorenin Activation 
In order to measure plasma prorenin by IRMA, it was 'activated' prior to the assay by 
remikiren (lO~M final concentration) for 48 h at SOC. Although the complex of pro renin 
and rernikiren is enzymatically inactive we use the term' activation' to indicate that prorenin 
becomes recognizable by mAb Rl-20-5, i.e. the renin·specific mAb, after remikiren 
incubation. Plasma prorenin was also activated proteolytically by mixing 200 I'L of 
SepharosNrypsin (0.5 mg of trypsin) with 1 mL of plasma and incubation of the mixture 
for 24 h at 4 'C.10 The trypsin-Sepharose was then removed by centrifugation. 
Assays 
IRMAs. Fig. 1 depicts the principles of the two immunoradiometric assays we employed. 
R-JRMA measures renin and active prorenin. In this assay biotinylated mAb R3-36-16 is 
the primary antibody, which is bound to an avidin·coated bead. The secondary 
(developing) antibody is 125I-labeled mAb Rl-20-5 (2.5x105 cpm/assay tube, specific 
activity 740 kBq/mg). The assay was carried out with 200 1'1 sample or standard and 100 
1'1 of an equivolume mixture of biotinylated mAb R3-36-16 (0.5 mg/L) and labeled 
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Figure 1. Schematic representation of the principle of prorenin measurement In the R-
IRMA (left) and the PR-IRMA (right). The 'square' epitope is exposed on both renin and 
prorenin, The 'triangled' epitope is exposed In renin as well as in remikiren-treated prorenin, 
but is hidden in naUve prorenin. The 'dome' epitope on the propeplide is specific for prorenin 
and only exposed after remlklren incubation 
mAb Rl-20-5. Incubations were performed at 37'C and incubation time was 6 hours. 
After incubation beads were washed three times with 2 mL washing buffer. Beads were 
transferred to dean tubes and radioactivity was counted for 5 minutes in a gamma·counter. 
The characteristics of the R-IRMA are described in chapter 3.1. 
Prorenin IRMA. For the direct prorenin IRMA (PR-IRMA) Il'g of F-258-37-Bl, 
biotinylated with 11% biotin (w/w), 12 in a volume of 250 1'1 of dilution buffer with 
20%(vollvol) assay buffer, was coupled per avidin-coated bead by incubation for 48 h 
at 4 'c. To remove unbound antibody, beads were washed three times with 2 mL of 
washing buffer. Two hundred 1'1 of sample or standard and 50 1'1 of assay buffer were 
added per bead and left to incubate for 6 h at 37'C. In this step 'activated' prorenin is 
bound to the F-258-37-Bl-coated beads through its exposed propeptide (see chapter 
2.2). Then the bead was washed three times in 2 mL of washing buffer, followed by an 
incubation with 100 1'1125I-labeled RI-2Q.5 (approximately 3xl05 cpm) and 200 1'1 assay 
buffer, containing 100 I'M of remikiren, for 24 h at 22'C. Addition of remikiren in this 
second step was done to ensure that activated prorenin, if bound to the immobilized F-
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258-37-Bl was kept in the 'activated' state and hence would not dissociate from the 
bead. 
Enzyme-kinetic Assay. Plasma renin, and plasma renin plus trypsin-Sepharose-activated 
pro renin, were also measured by an EKA. In this assay, the sample was incubated with 
saturating concentrations of sheep angiotensinogen at pH 7.4 and 37 °C in the presence 
of inhibitors to block angiotensin I-converting enzyme, angiotensin I-degrading enzymes 
and serine proteases,lJ Two incubation times between 15 and 60 minutes were used in 
order to verify linear AngI generation. Generated AngI was quantitated by 
radioimmunoassay.1l Calibration was against the WHO human kidney renin standard, 
so that results of the EKA could be directly compared with the IRMA results. 
Patients. Blood was taken from an indwelling venous catheter after patients had rested 
for 45 minutes in the supine position. It was anticoagulated with trisodium citrate (0.2 
mL of 0.646 mol/L per 10 mL of blood) and centrifuged within 30 minutes from 
collection for 10 minutes at 3000 g. Plasma was stored at -20 °C in 1-mL aliquots. Just 
before the assay, samples were rapidly thawed and kept at room temperature. 
Two groups of patients were studied. The first group of 56 patients consisted of: 
healthy subjects (n ~ 6), patients with primary hyperaldosteronism (n ~ 2), renovascular 
hypertension (n~ 6), essential hypertension with either low or high renin (n ~6 and 6 resp.), 
diabetes mellitus and microvascular complications (n~6), heart failure (n~ 6) and subjects 
that either used oral contraceptives (n ~6) or were pregnant (n ~6). To illustrate a potential 
use of the IRMAs we restudied the plasmas of seven patients that had been treated by 
oral remikiren. Time course of renin or propeptide epitope after oral ingestion of 600 
mg of remikiren was followed at 0, is, 30 minutes and 1,2,4,6 hours. This study was 
performed in 1990 and has been reported in reference. 14 One patient was not included in 
the series of the present report, because of lack of plasma. Plasmas had been thawed 
once in the meantime and had been kept stored at -80 °C. 
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Figure 2, Calibration rurves for remikiren treated 
human recombinant prorenln In sheep serum, 
nallve recombinant human prorenin In sheep 
serum, and a hUman kidney renin standard (lot 
681356). 
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fable 1. Effect of dilution of plasma by sheep serum on prorenln measurement In the PR-IRMA 
Prorenln (mUll) 
sample Dilution factor Measured Expected Ratio (%) 
165.1 
2 81 82.6 98 
4 41 41.3 100 
8 16.7 20.6 81 
16 9.1 10.3 88 
2 323.7 
2 172.5 162 94 
4 83.1 81 97.5 
8 37.4 40.5 92 
16 18.7 20.3 92 
3 968 
2 475 484 98 
4 233 242 96 
8 115 121 95 
16 55 60.5 91 
Results 
Characteristics and Performance of the Direct Prorenin Assay. In preliminary 
experiments we found that plasma that had been incubated with trypsin-Sepharose did 
not elicit a detectable signal in the PR-IRMA. Pretreatment with remikiren gave values 
for prorenin that were similar to the prorenin levels estimated by the EKA after trypsin 
proteolysis (results not shown). Binding of remikiren treated prorenin to the F-258-37-
B1-coated beads occurred with a half-time of about 20 minutes at 37 "C. Fig. 2 shows 
the standard curve of the PR-IRMA. If standards were used consisting of native pro renin 
in the PR-IRMA, a parallel curve to the remikiren-treated, activated prorenin-standard 
curve was observed, indicating a cross· reactivity of native prorenin in the assay of 
approximately 0.8%. Renin standards did not produce an appreciable signal in the PR-
IRMA. Serial dilution of plasma with sheep serum, with subsequent remikiren treatment 
gave parallel, proportional decreases in prorenin content (fable 1). Prorenin added to 
sheep serum or plasma was fully recovered (fable 2). Table 3 gives coefficients of 
intra- and interassay variation. The analytical lower limit of detection, defined as the 
prorenin level at a binding level of 3SD of non-specific binding (n- 6) above the mean 
non-specific binding was 4 mUlL. It proved to be impossible to assess the functional 
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Table 2 Recovery of added prorenin In sheep serum and three plasmas 
Prorenin conc., mUll 
Inillal Added Expected Measured recovery (%) 
Sheep serum 0 157 157 182 116 
314 314 309 98 
628 628 577 92 
1256 1256 1177 94 
Plasma 1 145 157 302 290 93 
314 459 446 96 
1256 1401 1391 99 
Plasma 2 272 314 586 627 113 
628 900 1027 120 
1256 1528 1760 119 
Plasma 3 587 314 901 871 91 
628 1215 1140 88 
1256 1843 1820 98 
Plasma 4 897 395 1292 1339 112 
Plasma 5 1348 395 1743 1752 102 
lower limit of sensitivity, defined as the lowest prorenin level with an interassay coefficient 
of variation of less than 20%, because our lowest plasma pool (45 mUlL of prorenin) 
had an interassay CV of 10.5%. 
Renin and Prorenin in Clinical Samples According to Different Assay Types. R-
IRMA and EKA gave identical results in renin levels (Fig. 3). Prorenin results of the 
three assay types for 56 different plasmas were compared by a variant of the Bland-
Altman plot (Fig. 4). The difference of the result in each assay with the mean of the three 
Table 3. Coefficients of variation (CV)of the PR-IRMA 
Prorenin level (mUll) Interassay CV Inlraassay CV 
(%) (%) 
n=8 n=6 
45 10.5 4.5 
279 19.3 6.4 
559 10.9 7.5 
735 15.4 5.6 
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assays was plotted against this mean. No significant differences of the EKA, the R-
IRMA and the PR-IRMA with this mean were observed. 
Renin and Prorenin Measurements in Patients on Remikiren Treatment. The results 
of the R- and PR-IRMA of serially taken plasmas from patients that had taken the renin 
inhibitor remikiren are depicted in Figure 4. Plasma samples were studied in both assays 
before as well as after a 48 h preincubation with remikiren. There is a discrepancy between 
the renin values on one hand and the prorenin and total renin values on the other hand. 
Moreover, there appears to be expression of pro peptide epitope in the first two time-
points after administration of remikiren, even though the blood samples had not been 
preincubated with remikiren. We conclude from this observation that after ingestion 
remikiren reaches levels in circulating blood that are sufficient to 'activate' pro renin. It 
seems therefore that, contrary to earlier reports, the kidney does not respond to acute 
renin inhibition with an immediate -i.e. within minutes- release of renin, but instead, with 
a more gradual rise, and that the early peak in renin, observed with the R-IRMA, in a 
large part is remikiren-'activated' prorenin. 
Discussion 
In the preceding chapter we demonstrated the good performance of the R-IRMA for 
renin measurement. Now we demonstrate the adequacy of a direct PR-IRMAfor prorenin 
measurement. Indirect renin measurement by subtracting the PR-IRMA result from total 
renin (defined by the mean ofEKA and R-IRMA after trypsin and remikiren treatment 
respectively) gave identical results to those by the EKA or R-IRMA (results not shown), 
albeit with too large a variation to be applicable in all samples. In particular, samples 
with very low renin content often gave negative values or a relatively large overestimation 
of renin. 
A problem we anticipated but that did not surface in the PR-IRMA, was the 
phenomenon of proteoly1ic cryoactivation. The unmasking of the propeptide epitope 
of pro renin by remikiren was performed at 8'C (the temperature of our cold room) for 
48 h and since spontaneous proteolytic activation may occur in plasma at this temperature) 
a lower level of prorenin could be expected, compared to other methods. However, as 
demonstrated in FigA) there was no underestimation of prorenin. Results of 
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Figure 4. Comparison of prorenln 
measurement in 56 human plasmas, 
Indirectly by the enzyme-kinetic 
assay after Ifypsln-activatian (EKA), 
by R-IRMA after remiklren treatment 
(R-IRMA) and directly by PR-IRMA. 
PR=prorenln as measured by the 
assay. PR", ::: mean of the three 
assay types for profenln. Mean±SD 
althe diflerenceswith PR
rn 
was 1±12, 
0±11 and -1±9% lor EKA, R-IRMA 
and PR-IRMA resp. 
preincubation at higher temperatures gave identical results. The absence of proteolytic 
cryoactivation may be explained by the near absence of proteolytic pro renin-activation 
at this temperature or by only limited proteolysis that leaves the C-terminal epitope of 
the propeptide intact and attached to the renin body of prorenin. 
A direct prorenin assay has been developed before by Schumacher et al. 15 Their 
IRMA employed a polyclonal antiserum against a propeptide sequence consisting of 
amino-acids -12p-+ 3p of the prosegment. In contrast with our assay their assay could 
be performed with native prorenin, although it is not sure whether sensitiviry could have 
been improved by preincubation with remikiren.ln contrast to their assay, which found 
prorenin levels 20% lower in the direct IRMA compared to an indirect prorenin assay, 
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Figure 5. Time course of plasma levels total renin, profenln, renin and 'active' profen!n after 
oral administration of 600 mg of remikiren at t=-15 min, Shown are geometric means for 7 
subjects. Error bars have been omitted for clarity. 
our PR·IRMA had identical results to indirectly determined prorenin. Furthermore, 
our PR-IRMA appears to be a little more sensitive and permits to measure prorenin 
over a wide range of concentrations that encompasses all concentrations that are 
encountered in clinical samples. 
The three assays had an identical calibrator, recombinant human prorenin. The 
consistency in the results obtained by three assays that differ in principle, suggests that 
what is measured in either of them refers to the same molecules, with the restriction that 
PR·IRMA is not suitable for total renin measurement. It also shows the advantage of a 
universal standard. Wle would like to stress the importance and the potential of such a 
standard. The only official renin standard that is now available is the WHO standard that 
we used for calibration of our prorenin standard. This standard is defined by its blood 
pressure-increasing effect upon injection and is in fact a first-generation renin assay 
standard. OUf remikiren-treated prorenin may be an attractive alternative to this renin 
standard. It can be used in both our R·IRMA and PR·IRMA and has the potential of 
being expressed in molar units. Prerequisite is that a pro renin standard has as much renin 
epitope as prorenin epitope. This can be verified in enzymatic assays, in which the native 
prorenin standard must not have enzymatic activity. OUf preparation has an enzymatic 
activity of less than 2% which means that prorenin levels may be overestimated at most 
by 2%. We do not know, however, whether this spontaneous acitivity is due to the presence 
of renin or to the presence of active prorenin. In the latter case the propeptide is still 
present and prorenin will not be underestimated. Another check can be made if in control 
plasmas both renin and prorenin are measured directly by the R- and PR-IRMA 
respectively and total renin directly in aR·IRMA after full activation of prorenin. Directly 
measured renin and prorenin should add up to the same level as has been found in the 
total renin assays, which is the case in our assays. 
What role could direct renin and prorenin IRMAs play in the clinical and research 
setting? It is still unknown whether prorenin has any role in the (patho)physiology of 
angiotensin generation, and, therefore, the relevance of pro renin measurement may be 
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questionable. Some conditions exist in which prorenin is elevated in excess of renio, for 
instance in diabetes mellitus with microvascular complications. IO,17 It can not be excluded 
that prorenin measurement can become of interest in the management of diabetic patients 
(see chapter 4.1). 
From the present results it seems that the R-IRMA may cover all needs of renin and 
prorenin measurements in plasma, because it reliably can measure renin as well as, indirectly 
after preincubation with remikiren, prorenin. The EKA also performs well, but it is 
much more labor-intensive. Furthermore, we have preliminary evidence that the R-IRMA 
for renin and prorenin and the PR-IRMA for prorenin quantification have good 
performance in non-plasma samples, like tissue homogenates, cell culture media and 
human follicular fluid. The EKA measures renin reasonably well in these samples but 
prorenin is usually highly underestimated. Presumably this is caused because proteolytic 
activation of prorenin by trypsin-Sepharose is not complete, since measurement of trypsin-
Sepharose samples in the R-IRMA yields low concentrations unless an additional 
preincubation with remikiren is performed (unpublished observation). 
There appears to be little need for the PR-IRMA, but one can imagine situations in 
which active prorenin may be present which would normally be interpreted as renin in an 
enzyme-kinetic assay, whereas our PR-IRMA would recognize this as active prorenin. 
Evidence for active pro renin has been found,18 although in the present report we did not 
find discrepancies between direct and indirect prorenin assays in plasma. A further use 
for a direct renin and a direct prorenin assay may be in studies of renin inhibitors. As 
shown in the samples of a study performed some years ago even a direct renin assay may 
not yield reliable results, because inhibitor~activated prorenin may be measured as renin. 
Since the prorenin-'act ivating' character of renin inhibitors is probably a class effect (see 
chapter 2.1), using the R- and PR-IRMA allows to dissect meticulously what happens to 
renin and prorenin levels during renin inhibitor therapy. 
Finally, we want to emphasize that this study is not concerned with superiority of the 
renin assay over the plasma renin activity assay. In our view and that of others,!' the PRA 
can be considered as 'a poor man's' angiotensin II assay. It is much easier to perform than 
angiotensin II measurements and yet a good measure of the activity of the renin-
angiotensin system. Nevertheless, theIRMAs described in this paper have the considerable 
advantage that they will enable interlaboratory comparison and may be used to establish 
reference values. It is our conviction that direct assays for the components of the renin-
angiotensin system will be of great help in the elucidation ofthe physiology of angiotensin 
generation. \Vhat is needed now is to further develop a new renin/prorenin standard, 
for which we propose the remikiren~treated recombinant prorenin preparation, and a 
multi-center testing of these assays. 
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CHAPTER 4 PRORENIN REGULATION IN DIABETES MELLITUS 

4.1 INCREASE IN SERUM PRORENIN PRECEDES ONSET OF 
MICROALBUMINURIA IN PATIENTS WITH INSULIN-DEPENDENT 
DIABETES MELLITUS 
Summary 
The renin-angiotensin system is possibly involved in the pathogenesis of diabetic 
nephropathy_ The most striking change in renin-angiotensin system components in blood 
of patients with diabetic nephropathy is an increased prorenin concentration. We 
investigated prospectively serum concentrations of renin-angiotensin system components 
and the time course of prorenin increase in normoalbuminuric diabetics developing 
rnicroalbuminuria. Patients (n ~ 199) with Type I diabetes mellitus and normoalburninuria 
at baseline were prospectively followed for 10 years. The prorenin concentration and 
other variables possibly associated with the occurrence of microalbuminuria, were 
investigated by Cox-regression analysis. Of the patients 29 developed microalbuminuria. 
Glycated hemoglobin concentrations were higher at baseline in these patients. Serum 
prorenin was similar at baseline, but rose in the 29 patients before the development of 
microalbuminuria and was stable in patients with stable albumin excretion. Renin, 
angiotensinogen and angiotensin converting enzyme serum concentrations were stable 
in both groups. Prorenin and glycated hemoglobin were independent prognostic factors 
for the development of microalbuminuria. A prognostic index, based on these variables, 
was constructed to estimate the relative risk of developing microalbuminuria. 
Increase in serum pro renin precedes onset of microalbuminuria in normotensive 
patients with insulin-dependent diabetes mellitus. High concentrations of pro renin in 
combination with high values of glycated hemoglobin may be used as a predictor of 
development of microalbuminuria. 
Introduction 
Progression of microalbuminuria (defined as urinary albumin excretion rate (AER) of 
30 -300 mg/24hl) to overt diabetic nephropathy in patients with type I (insulin-
dependent) diabetes mellitus is retarded by treatment with inhibitors of angiotensin 
converting enzyme (ACE). Even at the microalbuminuric stage, pathologic changes are 
already present in the kidney' together with widespread endothelial dysfunction. 3.4 
Microalbuminuria is associated with excess cardiac morbidity. sit may therefore be 
worthwile to identify diabetic patients at risk before the stage of microalbuminuria, to 
start preventive treatment. Several risk factors for progression to microalbuminuria have 
been proposed'" 7 such as poor metabolic control, hypertension and high-normal AER. 
The most attractive factors for identifying risk are those involved in the pathogenesis 
of the disease. The favorable response to ACE inhibitors" 9 suggests that the renin 
angiotensin system is one which is supported by experimental evidence indicating that 
angiotensin II (Angll) is an important factor in the pathogenesis of diabetic nephropathy. 10 
The major change detected in this system in diabetic patients with microalbuminuria or 
the ensuing stage of diabetic nephropathy is an increased plasma concentration of 
prorenin. 11,12 Prorenin is the inactive precursor of the aspartic protease renin, which is 
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produced by the kidney. Renin is essential in the proteolytic cascade leading to production 
of AngII, a key hormone in blood pressure regulation and fluid and electrolyte 
homeostasis. Data on the change in prorenin concentration over time, in relation to the 
onset of nephropathy are scarce. In a retrospective longitudinal surveyl3 total renin (i.e. 
prorenin + renin) increases before the onset of microalbuminuria. Here we report on a 
10ngitudinallO-year follow-up study in 199 patients with Type I diabetes mellitus who 
were normoalbuminuric at the outset. Microalbuminuria developed in 29 patients during 
follow-up. The aim of this study was to investigate whether the increase in prorenin that 
has been observed in type I diabetes mellitus, precedes the development of 
microalburninuria. 
Subjects and Methods 
Patients 
Patients (n ~ 209) with Type I diabetes mellitus from the outpatient clinic at the Steno 
Diabetes Centre (Copenhagen, Denmark) were included between October 1982 and 
January 1983. Characteristics of the cohort have been reported in detail.' All patients 
fulfilled the following criteria: age between 18 and 50 years, onset of diabetes before the 
age of 30 years, duration of diabetes 10 to 30 years, diastolic blood pressure < 100 
mmHg and AER less than 30 mgper 24 hour in one urine sample collected at home, and 
Table 1. Clinical dala of patients at entry of study 
Group with persistent Group developing 
normoalbuminuria microalbuminuria 
n=170 n=29 
Sex (flm) 74196 13116 
Age (years) 34±8 34±8 
Duration of diabetes(years) 17±5 17±5 
AER (mgI24h) 12 (3-29) 17 (3-29» 
HbA,o(%) 8.4±1.4 9.3.±.1.6t 
Retinopathy 
None 85 10 
Background 80 18 
Proliferative 5 
Systolic blood pressure (mm Hg) 125±16 128±13 
Diastolic blood pressure (mm Hg) 78±11 81±7 
Renin (mUll) 26.0 (23.6·28.7) 29.1 (25.0-33.9) 
Prorenln (mUll) 270 (250-291) 313 (254-386) 
Creatinine (~M) 82±11 80±10 
AER; albumin excretion rate; values are means.±. S.D. or geometric mean (95% C.I.);~ p<O.05 
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remaining normal in at least 2 out of 3 samples during the first year of observation. 
None ofthe patients received medication, including oral contraceptives, other than insulin. 
Patients were followedforten years. Every four months albumin excretion was determined 
in a 24 h urine collection. The patients were classified as having microalbuminuria when 
AER was 30-300 mg/24 h in two out of three urine samples in two consecutive years. 
Blood pressure was measured and ophthtalmoscopy was carried out annually. Blood 
samples for the measurement of glycated hemoglobin (HbA,J was also collected annually. 
Serum obtained annually was kept at -20"C for later measurement of prorenin, renin, 
angiotensinogen and angiotensin converting enzyme. Four patients were lost during 
follow-up and five patients were excluded due to severe diseases (AIDS, cancer, connective 
tissue disease, hyperthyroidism and chronic pyelonephritis). One patient could not be 
evaluated because of missing serum samples. Finally 199 patients were evaluated. 
During follow-up twelve patients became pregnant. Serum concentrations of prorenin 
and renin during pregnancy were excluded from analysis because prorenin is elevated 
during pregnancy. IS Of the patients, 13 developing microalbuminuria, developed 
hypertension (defined as a blood pressure exceeding 140/95 mm Hg), 5 before and 8 
after the onset of microalbuminuria. Antihypertensive treatment was initiated in only 15 
patients of the control group. The antihypertensive drugs that were used were mainly 
diuretics and calcium channel blockers. Because antihypertensive drugs might influence 
the serum concentrations of renin and prorenin, only data obtained from patients while 
not on antihypertensive therapy were included in risk analysis. 
Methods 
Blood pressure was measured with a standard sphygmomanometer after a 10-min rest in 
the sitting position. The disappearance of Korotkoff sounds (phase V) was used to 
determine diastolic blood pressure. Blood for measurement of pro renin, renin, 
angiotensinogen and angiotensin converting enzyme, was taken after a short rest in the 
sitting position. Serum was stored at -20 'C. Retinopathy was assessed by direct 
ophthalmoscopy by an ophthalmologist. Retinal lesions were categorized as either absent 
or present] combining background or proliferative retinopathy. 
AER was measured until May 1985 by a radial immunodiffusion technique." 
Thereafter an enzyme-linked immunoassay was used." HbA" (normal range 4.1-6.4%) 
was measured by HPLC (Biorad, Diamat, Richmond, CA, USA). Serum creatinine was 
measured by autoanalyser. 
Assays of Renin and Pro renin. Serum renin and prorenin were measured with a 
commercial kit (Nichols Diagnostics, San Juan Capistrano, CA, USA), based on an 
immunoradiometric assay ~RMA). In this assay renin is measured directly. Total renin, 
i.e. renin plus prorenin, is measured after enhancement of immunoreactivity of prorenin 
by preincubation with the renin inhibitor remikiren as described in ref. 18.Thedifference 
between total renin and renin is prorenin. The 95% reference limits are 7.7 - 54.8 mUlL 
for renin and 88.1 -390 mUlL for prorenin. 
Assays of Angiotensin Converting Enzyme and Angiotensinogen Assays. These 
assays were performed in the 29 patients developing microalbuminuria and in a group 
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of 29 patients remaining normoalbuminuric, matched for age, sex and duration of 
diabetes. Serum ACE activity was determined with a colorimetric kit (ACEcolor, Fujirebio 
Inc, Tokyo, Japan), using Gly-His-His as substrate. The concentration of angiotensinogen 
in serum was determined as the quantity of AngI that is generated after complete 
hydrolysis of angiotensinogen by recombinant human renin at pH 7.4 and 37 'C in the 
presence of inhibitors of AngI degrading enzymes." AngI was measured by 
radioimmunoassay. 14 Results are expressed as nmollL. 
Statistical Analysis 
Continuousdata were compared using the t-test. Serum renin, serum prorenin and urinary 
albumin excretion were log-transformed before statistical analysis and presented as 
geometric mean. The relation of various time-dependent clinical characteristics with the 
occurrence of micro albuminuria was investigated using Cox-regression analysis. 18 
Parameters with significant predictive value in univariate analysis were multivariately 
analysed. Backward elimination was used to determine which factors were independently 
associated with the occurrence of microalbuminuria. Statistical software used in the 
analyses was SPSS 7.0 (SPSS Inc. Chicago, IL). 
Results 
Clinical Data at Entry and during the Course of the Study 
Twenty nrne patients progressed to microalhuminuria during the ten years of observation 
and 170 continued with a normal AER. Eight of the 29 patients that developed 
microalbuminuria, progressed to overt diabetic nephropathy, i.e. an AER exceeding 
300 mg/24 h. Clinical characteristics of the patients are given in Table 1. In the patients 
who later developed microalbuminuria, AER values and HbA" were higher at outset. 
Serum prorenin and renin were not significantly different at the time of inclusion. During 
the 10 year follow·up serum prorenin and renin did not correlate with senlm creatinine) 
glycosylated HbA", diastolic or systolic blood pressure. At baseline the concentrations 
of prorenin were not different in patients with background or proliferative retinopathy, 
compared to patients without retinopathy (not shown). 
Fig. 1 shows the concentrations of prorenin, renin, angiotensinogen and ACE during 
follow-up. The year of first occurrence of microalbuminuria was designated as year zero. 
For patients who remained normoalbuminuric throughout follow-up year zero was chosen 
to be 1987, since this was the average year of onset of microalbuminuria in the other 
group. Data for angiotensinogen and ACE demonstrate stable concentrations during 
follow-up. Data in the upper two panels of Fig. 1 suggest that serum prorenin and possibly 
renin increase before microalbuminuria sets in. Univariate Cox.regression analysis of 
occurrence of microalbuminuriashowed significant relations with the concentrations of 
serum prorenin, HbA", and systolic and diastolic blood pressure, and with retinal status. 
Table 2 summarizes the size of the effect of these variables. No univariate significant 
relations were found for the duration of diabetes, and the serum concentrations of renin 
and creatinine. Subjecting the factors prorenin, HbA", diastolic and systolic blood 
pressure, and the existence of retinopathy to multivariate analysis, we found that the 
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Figure 1. Serum prorenln, renin, 
anglotenslnogen and ACE In patients 
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serum concentrations of prorenin and HbA1c were the most important factors predictive 
of microalbuminuria. No additional prognostic value was found for diastolic and systolic 
blood pressure, and for retinal status. Furthermore, we observed that the effect of 
pro renin was significantly affected by the duration of diabetes. Prorenin, but not HbA", 
lost its significance as a prognostic factor when the duration of diabetes exceeded 25 
years. Table 3 gives the results ofthe multivariate analysis separately for the duration of 
diabetes up to 25 years and thereafter. With DM present for less than 25 years the risk of 
developing microalbuminuria increases 4.7-fold when prorenin concentrations double. 
The relative risk associated with a 1% increase in HbA1c is 2.0. 
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Table 2. Results of univariate Cox-regression analysis for the 
occurrence of microalbuminuria in 199 patients with type I diabetes 
mellitus. 
Variable Relative Risk# p coefficient 
Prorenln 2.6a 0.001 
HbAI~ 2.3b <0.001 
Systolic BP (mmHg) 1.3c 0.019 
Diastolic BP (mmHg) 1.6c 0.019 
RelJnopalhy 2.7d 0.043 
J As compared to: 2-fold tower value (a), 1% lower value (b), 10 mm Hg 
lower value (e), no abnormalities (i.e. no relinopalhy){d). BP=blood 
pressure 
The results allow to construct a prognostic index (PI) for the development of 
microalbuminuria when diabetes has been present for less than 25 years. This is given by 
the following formula: 
PI - 1.56"log, prorenin + 0.68 HbA" 
In Fig. 2, the relative risk of developing microalbuminuria is graphed, according to the 
PI-value. A PI-value of 18, corresponding to a prorenin concentration of 400 mUlL 
and a HbA" of 8.9%, was arbitrarily chosen as a reference. If a patient in the present 
study group had a PI that was continuously below 19, corresponding to, for instance, a 
prorenin concentration of 500 mUlL with a HbA1c concentration of 9.7%, the chance 
of developing microalbuminuria was very small. However, patients scoring a PI exceeding 
19, had about 30% chance to develop microalbuminuria in the next 5 years (data not 
shown). 
Discussion 
This longitudinal, 10-years follow-up study on 199 patients with type I diabetes mellitus 
confirms and extends earlier data13 that indicate that an increase in serum prorenin 
Table 3. Relative risk of development of persistent mlcroalbumlnuria, determined by prorenin 
and glycated hemoglobin levels 
Duration of diabetes mellitus 
< 25 years >25 years 
Variable Regression RR 95% p-value Regression RR 95% p-value 
coefficient C.1. coefficient C.1. 
Log,(PR) 1.56 4.7 2.3-9.9 <0.001 -1.41 0.2 0.1-1.2 0.085 
HbA,c(%) 0.66 2.0 1.4-2.6 <0.001 1.05 2.9 1.1-7.7 0.036 
PR=serum prorenln; RR=refative risk, per doubling of value for prorenin or per percent 
increase for HbA 1e , 95% CI=95% confidence Interval 
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Figure 2. Relative risk of microalbuminuria In relation to the derived prognostic Index PI. 
The risks are expressed relative to the risk at PI=18 
precedes development of persistent micro albuminuria, the earliest phase in the 
development of diabetic nephropathy that can be recognized clinically. 
The cause of the early rise of prorenin in patients with type I diabetes mellitus 
developing nephropathy is not known. Normally, and also under pathological conditions, 
an increase in pro renin is associated with an increase in renin, the latter being 
proportionally larger than the fonner." In the patients with type I diabetes mellitus the 
increase in prorenin was not accompanied by an increase in renin, which suggests a 
derangement of the regulation ofthe renin-angiotensin system. Whether this derangement 
plays a causative role in the development of micro albuminuria and nephropathy or is 
merely a marker of early renal damage, more sensitive than others like albuminuria, is a 
matter of speculation. 
To view our results in a clinical perspective we derived from them a prognostic index 
(PI), based on HbA, and serum prorenin. This PI indicates the risk of future 
microalbuminuria and hence, of diabetic nephropathy. It underlines once again the 
importance of good metabolic control. The PI fulftlls the following criteria: it has strong 
predictive power, it is easily determined and it may have pathophysiological relevance in 
view of the involvement of hyperglycemia and, with regard to the favorable response to 
ACE inhibition, of the renin-angiotensin system in the development of diabetic 
nephropathy. Its use must be restricted, however, to normotensive diabetic patients. 
Moreover, use of drugs, in particular of contraceptive hormones, that considerably affect 
pro renin concentrations, precludes application of this PI. 
A threshold value for PI could be agreed upon above which additional treatment is 
considered besides optimal therapy for restoring glucose to normal. An obvious choice 
would be ACE inhibition. The EUCLID-study showed that ACE inhibition in 
normotensive, normoalbuminuric patients had little effect on AER.'o Use of the 
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proposed PI might have identified a subset of these patients that would have benefited 
from ACE-inhibition_ Obviously, a PI like the one proposed, needs to be validated in 
other longitudinal studies and work remains to be done to establish international 
standardization of glycated hemoglobin and prorenin assays.21 Moreover, whether 
treatment based on this index improves prognosis on a cost-effective basis needs to be 
determined. Finally, we would like to stress that a reassuring level of the PI value would 
not be an excuse for inadequate metabolic or blood pressure control. 
The model that predicts microalbuminuria included an interaction term for prorenin 
and duration of diabetes. It is not sure if this statistically obtained variable has a biologic 
meaning. It could mean that microalbuminuria occurring before a duration of 25 years, 
has a different pathogenesis, with involvement of the renin-angiotensin system, from 
microalbuminuria that occurs very late in the course of type I diabetes mellitus. This is 
possibly compatible with reports that the incidence of diabetic nephropathy decreases 
after 16 years duration of diabetes but has a second smaller peak at about 32 years 
duration.22 
In conclusion, an increased prorenin concentration in the blood is a herald of 
micro albuminuria and diabetic nephropathy. Serum prorenin together with glycated 
hemoglobin can be used to calculate a prognostic index that may be used as a predictor 
of clinically manifest renal disease in normotensive patients with type 1 diabetes mellitus. 
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4.2 PLASMA RENIN AND PRORENIN AND RENIN GENE V ARIATJON IN 
PATIENTS WITH INSULIN-DEPENDENT DIABETES MELLITUS AND 
NEPHROPATHY 
Summary 
The most striking abnormality in the renin·angiotensin system in diabetic nephropathy 
(ON) is increased plasma prorenin. Renin is thought to be low or normal in DN. In spite 
of altered (pro)renin regulation the renin gene has not been studied for contribution to 
the development of DN. 
We studied plasma renin, prorenin and four polymorphic markers of the renin gene 
in 199 patients with IDDM and DN, and in 192 normoalbuminuricIDDM controls 
matched for age, sex and duration of diabetes. Plasma renin and total renin were measured 
by immunoradiometric assays. Genotypingwas PCR·based. 
Plasma renin was increased in patients with nephropathy (median (range), 26.3 (5.2-
243.3) vs. 18.3 (4.2-373.5)!'U/ ml in the normoalbuminuric group, p < 0.0001). Prorenin 
levels were elevated out of proportion to renin levels in nephropathic patients (789 (88-
5481) vs. 302 (36.2226) !,U/ml, p <0.0001). Proliferative retinopathy had an additive 
effect on plasma prorenin, but not on renin. DN was associated with aBgl I RFLP in the 
first intron of the renin gene (bb-genotype: n -106 vs. 82 in DN and normoalbuminuric 
patients resp., p-0.037), but not with three other polymorphisms in the renin gene. A 
trend for association of higher prorenin levels with the DN-associated allele of this 
renin polymorphism was observed in a subgroup of patients with DN (bb vs. Bb + BB 
p-O.07). 
The results indicate that in DN there is an increase in both renin and prorenin levels. 
A renin gene polymorphism may contribute weakly to DN. Although speculative, one 
of the renin gene alleles could lead to increased renin gene expression, leading to higher 
renin and pro renin levels. These may playa role in the pathogenesis ofDN. 
Introduction 
A major cause of morbidity and death in insulin dependent diabetes mellitus (IDDM) is 
diabetic nephropathy (ON), characterized by proteinuria, steady decline of kidney 
function, hypertension and cardiovascular disease.' Although poor metabolic control 
plays a role in the development ofDN, it appears that 60 to 70 percent ofthe diabetic 
population is protected from nephropathy despite inadequate metabolic controL2 It has 
therefore been suggested that susceptibility to DN is innate and determined by genetic 
factors. This hypothesis is supported by reports on familial clustering of DN' and by 
studies demonstrating association with familial predisposition to hypertension.4 
The favorable effect of ACE inhibition on the development' and progression6 of 
DN is suggestive evidence that the renin-angiotensin system (RAS) is involved in the 
pathogenesis ofDN and that variation at RAS gene loci might determine susceptibility 
to DN. In many studies, however, plasma renin and angiotensin II are normal or suppressed 
in diabetics (for review see 7 and 8) and reports on association between DN and 
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polymorphic markers have been equivocal for the angiotensinogen gene (ref. 9·11 positive 
and 12 negative) and negative for the AT1-receptor gene."· 14 Three meta-analyses of 
the numerous studies on association of the ACE liD polymorphism with ON show that 
the D-allele may confer an increased risk of ON. 1S·17 Interaction between the ACE I/O 
polymorphism and an angiotensinogen allele may also present elevated risk of ON. IS 
Similarly. poor metabolic control may interact with the A Tl-receptor polymorphism to 
augment risk of ON. I. The renin gene that codes for prorenin and renin, has not yet been 
investigated in ON in large study groups. Prorenin is the enzymatically inactive biosynthetic 
precursor of renin, the rate-determining enzyme in the proteolytic cascade leading to 
formation of angiotensin II, the effector of the RAS. Several reports have described 
increased plasma prorenin levels when diabetes is complicated by microvascular disease 
like ON and retinopathy. 19·22 In the present case· control study we measured plasma 
levels of renin and prorenin and determined genotypes of the renin gene in patients with 
IDDM complicated by ON and in matched normoalbuminuric controls. 
Subjects and Methods 
Subjects 
In 1993 242 IDDM patients with ON had their glomerular filtration rate measured at the 
Steno Diabetes Centre (Copenhagen. Denmark). Plasma and DNA samples were 
obtained from 199 patients of this cohort. Nephropathy in this study was defined as the 
presence of a urinary albumin excretion rate> 300 mg/24 h in at least two out of three 
consecutive urine samples, combined with the presence of retinopathy, while clinical or 
laboratory evidence of urinary tract disease other than diabetic glomerular sclerosis was 
absent. A group of 192 IDDM patients with persistent normal urinary albumin excretion 
rate ( < 30 mg/24 h) and matched for sex, age and duration of diabetes, served as controls. 
A detailed description of the subjects with and without diabetic nephropathy can be 
found in references 23 and 24 . 
Methods 
Blood pressure was measured with a Hawksley random zero standard sphygmo-
manometer after a ten minutes rest in the sitting position. The disappearance ofKorotkoff 
sounds (phase V) was used to determine diastolic blood pressure. Retinopathy was assessed 
by fundus photography after pupillary dilatation. Retinal lesions were categorized as 
either no, background or proliferative retinopathy. EDT A-anticoagulated blood for 
measurement of plasma prorenin and renin was collected in the morning after an overnight 
fast from an indwelling catheter in a forearm vein after the patient had been in the supine 
position for at least fifteen minutes. The blood was centrifuged at 3000 g at room 
temperature and plasma was stored at -80°C. Sixry nine patients with nephropathy and 9 
with normoalbuminuriadid not want to stop their antihypertensive drugs at least 8 days 
before the day investigations were performed. 
Laboratory procedures. All measurements were done by technicians who were unaware 
of the status of the patients. Urinary albumin excretion rate (AER) was measured from 
24 hour·collections by an enzyme-linked immunoassay.'s Hemoglobin A" (HbAld was 
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measured by high performance liquid chromatography (HPLC, Biorad, Diamat, 
Richmond, CA, USA). The normal range is 4.1-6.4 %. Serum creatinine was measured 
byautoanalyser. 
PlasmaProrenin and Renin Detennination. Renin and total renin (I.e. renin + prorenin) 
were measured by an immunoradiometric assay (IRMA), purchased as a kit from Nichols 
Institute, Wijchen, The Netherlands." In this assay renin is sandwiched between a 
biotinylated monoclonal antibody (mAb) R3-36-16 against human renin, immobilized 
on an avidin-coated polystyrene bead, and a 12SI-Iabeled mAb RI-20-5 against a renin-
specific epitope not expressed on prorenin. Therefore, the radiolabeled mAb does not 
recognize native prorenin. Yet, prorenin can be measured with this assay, after 
preincubation with the active-site directed renin inhibitor remikiren, which causes exposure 
of the renin-specific epitope recognized by mAb R 1_20-5.26 The difference between the 
results with and without remikiren, i.e. the difference between total renin and renin, is a 
measure of the prorenin concentration. The assay was modified by shortening incubation 
to 6 hours and performing the assay at 37 'C. These modifications prevent inadvertent 
activation of prorenin and therefore exposure of the renin-specific epitope during the 
assay. Intra- and interassayvariation forprorenin (320 mV/ml) is4 and 13% respectively 
and for renin (22.2 mV/mI) 8 and 15%. Renin and prorenin of each patient were always 
measured in the same assay. Results of the renin and prorenin measurements are expressed 
as mV/ m!. Standards in the assay were dilutions olthe international reference preparation 
of human kidney renin 68/356 of the National Institute for Biological Standards and 
Control (potters Bar, Hertfordshire, UK). The geometric mean and 95 % reference limits 
for 100 normal subjects (50 women) with an age range of 19-62 years was 22.0 (7.7-54.8) 
m V/ mI for renin and 199 (88.1-390) mV/ mlfor prorenin. 
DNA Extraction. Genomic DNA was extracted from peripheral leukocytes by a standard 
technique. It was aliquoted and stored at -80 'C until use. 
Genotyping. Four polymorphisms were studied at the REN locus (Fig. I). They consist 
of two restriction fragment length polymorphisms (RFLps}27. 28 and two 
microsatellites.29• 30 The Taq I RFLP is located 4063 bases upstream of the start codon 
and consists of a CoT mutation. The BgI I RFLP is a CoT mutation located at base 1161 
of intron A. The (ACAG) microsatellite is located in intron G. The CA-repeat is located 
downstream of the REN10cus. Genotyping was PCR-based. Primers were obtained 
from Eurogentec (Seraing, Belgium), as were Goldstar Taqpolymerase and the restriction 
Taq I 9gl1 (ACAG)n 
Figure 1. Schematic representation of the hUman renin gene. Shown are the exons (boxes) 
and the sites of the four polymorphic markers that were studied (see text). Length from Taq 
I marker to final exon is about 16 Kb. 
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Table 1. Primer sequences and peR conditions for genotyping of renIn gene polymorphisms 
polymorphism Primers Product Size PCR 
(bp) 
Bgll·RFlP 5'·GGGGAAGCAGCTIGATATCGTGG 772 3' 95 ~C, 30 x (30" 92 'e, 30" 
5'·CTAGGCTGGAGCTCMGCGATC (5151257)· 60 "c, l' 72 "c), 4' 72 "c 
Taq I·RFlP 5'·GCTGTCTTCTGGTGGTACTGCC 964 5' 95 "c, 30 x (45" 95 "c, 30~ 
5'·TGCTGGCCATGAACTGGTTCTAGC (394/570* 60 "c, 1'30" 72"G), 6' 72 "c 
Taq ltBgll haplotype 5'·GCTGTCTTCTGGTGGTACTGCC 6079 2' 94 "c, 10 x (10" 94 "C. 30" 
5'·CTAGGCTGGAGCTCMGCGATC (5324156871 65 "C, S' sa'C), 15x ( 10~94 
571d "c, 30" 65 'e, 5' plus 
20n/cycle 68 ee), 7"C 
letranuc!eotlde 5'·AGAGTACCTTCCCTCCTCTACTCA' 255,263, 5'95°C. 15x(1'92"C, 1'59 
repeal 5'·CTCTATGGAGCTGGTAGAACCTGA 267,271 "c, 2' 72 °Cf), l5x (1' 92 'C, 
l' 59 QC, l' 72 °C), 
dinucleotJde 5'·GCGGGATATTIGAGTIGTGT 126·144 5' 72 °C 
repeal 5'·GAACTGTICAACTGGAGCCT' (10 a\!eies) 
• size of bands after digestion if restriction site Is present 
§ size of major bands If both 8gl1 and Taq I, only Taq I or only 8g11 restriction sites are present 
respectively 
enzymes. Except for haplotyping the Bgl I and Taq I loci (see below), PCR volume was 
25 I'L, consisting of 200 ng of DNA, 75 mM Tris-HC1, 20 mM (NB,),SO" 0.01% 
Tween 20, 0.5 I'M of each primer, dNTP concentrations of 10 I'M each and a polymerase 
activity of lu/25 1'1 PCR volume. Primer sequences and cycling conditions are 
summarized in Table 1. 
Genotyping of the RFLPs was performed by PCR of the chromosomal region around 
the marker locus, followed by digestion by the restriction enzyme. Alleles were called B 
and T or band t, indicating respectively digestion by Bgl I and Taq I or not. Controls 
with different genotypes, verified by direct sequencing, were run in each assay. Baplotyping 
of the Bgl I and Taq I loci in double heterozygotes was performed by a PCR on genomic 
DNA, using the Expand Long Template PCR System according to instructions by the 
manufacturer (Boehringer Mannheim, Germany). PCR volume was 50 1'1 and primer 
and DNA concentrations were the same as above, Primer sequences and cycling 
conditions are given in Table 1. PCR products were resolved on a 0.5 % agarose gel. 
Sequencing of the RFLP-loci was performed with PCR products as templates and a 
dye-Terminator technique (perkin-Elmer, Applied Biosystems Division, Foster City, CAl 
using a nested primer. Electrophoresis was on the ABIMPrism 377 automatic sequencer, 
Results were analyzed with ABI Sequencing software. 
Microsatellite loci were amplified in a duplex PCR, with one of each primer pair 
labeled with the fluorochrome FAM. Labeled PCR products were separated by 
electrophoresis on a denaturing 5% polyacrylamide gel, with fluorescence detection by 
an ABI Prism 377 automatic sequencer (Perkin Elmer, Applied Biosystems Division, 
Foster City, CAl. In each lane a TAMRA-labeled calibration ladder was run. Allele lengths 
were calculated by Genescan software and checked by eye by two independent observers. 
Statistical Analysis. Continuous normally distributed data were expressed as mean 
(standard deviation). AER, creatinine, plasma renin and prorenin were log transformed 
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before statistical analysis in order to obtain normal distribution. They are presented as 
median (range). Comparisons between groups were performed by a Student t-test 01' 
ANOVA. Chi square analysis was used to compare the distribution of genotypes and 
alleles and for comparison between groups for non-continuous variables. Two-sided P-
values'; 0.05 were considered significant. All aforementioned analyses were performed 
using the statistics package Statgraphics (Manugistics, Princeton NJ). Multi-allelic 
polymorphisms were tested using the CLUMP program. CLUMP employs Monte Carlo 
simulation and has been developed for use in genetic case-control studies. A description 
of the program can be found in reference." 
Results 
Patient Characteristics. Table 2 describes the features ofthe patients that were enrolled 
in the study. Patients with nephropathy and those with normoalbuminuria were well 
matched with regard to sex, age and duration of diabetes. In the nephropathic group 
systolic and diastolic blood pressure were higher and serum creatinine was increased 
compared to the normoalbuminuric group. Furthermore, HbA,)evels were higher in 
nephropathic patients. 
Renin and Prorenin are Increased in Diabetic Nephropathy. When plasma levels 
were evaluated according to the use of antihypertensive medication (aHT) at the time of 
blood sampling, both renin and prorenin levels in the 69 patients with nephropathy on 
aHT were higher than those in the patients not on aHT at the time of blood sampling. 
Normoalbuminuric patients showed no difference in renin or prorenin levels between 
patients with or without aHT at the time of blood sampling (Table 3). In the 130 patients 
with DN and the 183 normoalbuminuric patients that either used no drugs or had stopped 
aHT for at least 8 days, renin and prorenin levels were elevated in nephropathic patients 
(26.3 (5.2-243.3) and 789 (88·5481) mU/ml resp. VS. 18.3 (4.2-373.5) and 302 (36·2226) 
mU/ml in normoalbuminuric patients, p<O.OOOl both for renin and prorenin). If 
nephropathic patients that had never used antihypertensive drugs (n -48) were compared 
to 48 normoalbuminuric patients, matched for age, sex and diabetes duration, prorenin 
levels were 527 (110-1653) vs. 296 (80-1812) mU/ml and renin levels were 23.3 (5.8-
114.8) vs. 19.4 (4.2·81.6) mU/ml (p <0.001 and p-0.059 resp.). The increase in renin in 
nephropathic patients was not due to lower sodium intake as assessed by 24 hour urinary 
excretion of sodium chloride. Sodium excretion was the same in both groups (150±84 
vs.151±66 mmol/24 hour, NS). Sodium excretion was also identical in nephropathic 
patients usingaHT at the time of blood sampling, nephropathic patients that had stopped 
aHT and patients not on aHT medication. Log[ renin) and log[ creatinine) as well as 
log[prorenin) and log[creatinine) were correlated in the nephropathic group (R resp. 
0.31 and 0.41,p-0.0003 and p < 0.0001 respectively). 
Influence of Retinopathy on Renin and Prorenin Levels. Proliferative retinopathy 
appears to have an effect on prorenin that is independent of the presence of nephropathy 
(Table 4). The effect on renin levels is at most modest and equivocal, depending on the 
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Table 2. Clinical characteristics of the case-control study group, consisting of 199 patients 
with diabetic nephropathy and 192 diabetic patients with normoalbuminuria 
Nephropalhy Normoalbuminuria 
n 199 192 
sex (ml0 122177 118174 
age (years) 40.9:,:9.6 42.7:,:10.2 
duration of diabetes (years) 27.7:,:7.9 26.8:,:8.5 
BMI (kglm') 24.0±3.3 23.6:,:2.5 
HbA1t(%) 9.6:,:1.5 8.5±1.1' 
UAER (mg/24 h) 796 8 
(16·14.545) (1·30) 
serum creatinine (~M) 103 76' 
(54·684) (40·116) 
syslollc BP (mm Hg) 151:,:23 132:,:18' 
Olaslollc BP (mm Hg) 86:,:13 76±10' 
Antihypertensive Irealmenl (n) 150 23' 
ACE·inhibilor 106 9 
Beta-blocker 28 3 
Calcium-entry blocker 44 6 
Olurellc 129 15 
Retinopalhy (n) 
Nil 0 68 
Simplex 62 105 
Proliferative 137 19 
Data are means .±.SD, median (range). or n(%). * p<O.OO1 
test used. The results of the statistical analysis by two-way ANOVAshould be considered 
with caution, because groups are unbalanced. 
Relationship between Diabetic Nephropathy and Renin Gene Polymorphisms 
Table 5 gives the frequencies of genotypes or alleles of the renin gene polymorphisms in 
the two groups. Frequencies ofTaq I andBgI I polymorphisms and of the microsatellites 
are in accordance with frequencies found in other Caucasian populations.27•3o Genotypes 
of the RFLPs were in Hardy·Weinberg equilibrium. The power of detecting a 20% 
increase in frequency of allele b of the BgI I polymorphism is 98%, and 60 % for a 10% 
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Table 3. Plasma renin and prorenln levels in patients with diabetes mellitus with or 
without diabetic nephropathy 
nephropathy normoalbuminuria 
26.3' 18.3 
no anti·HT (5.2-243.3) (4.2-373.5) 
n=130 n=183 
renin (~/ml) 
55.2t 26.8 
+anti·HT (10.9-506.3) (6.6-78.5) 
N=69 n=9 
789' 302 
no anti»HT (88-5481 ) (36-2226) 
n=130 n=183 
prorenln (~U/ml) 
1085t 288 
+anti·HT (178-10740) (173-686) 
n=69 n=9 
Data are median(range). "p<O.0001 compared to levels In normoalbumlnuric 
patients :tp<O.01 compared to levels in patients with same renal status but without 
antihypertensive medication. anti·HT= antihypertensive therapy 
increase. Similarly, the power to detect a 20 % increase in frequency ofthe t-allele of the 
Taq I polymorphism is 99% and 72% for a 10 % increase. There were no significant 
differences in allele frequencies of the Bgl I and Taq I polymorphism in the two groups. 
However, genotype frequency distribution appeared to differ. Chi square analysis ofBB 
vs. Bb vs. bb in the two groups yielded a p-value of 0.056. GroupingofBgl I genotypes 
based on the presence of either at least one B-allele (BB + Bb vs. bb) or at least one b-
allele (bb+ Bb vs. BB) gave p-values of 0.037 and 0.87. This suggests an overrepresentation 
of bb-genotypes in the nephropathic group. The unadjusted odds ratio for nephropathy 
for subjects with a bb-genotype is 1.56 (95% C.r. 1.05-2.33). The odds ratio for 
nephropathy, as determined by multiple logistic regression analysis, and adjusted for 
sex, age, duration of diabetes, glycated hemoglobin level and systolic blood pressure, 
was 1.70 for the bb-genotype (p-0.03). Haplotypingof the Bgl I and Taq I loci revealed 
the absence of bt alleles. Therefore only 6 different genotypes were observed. We studied 
with the Clump-package the distribution of two microsatellites at the renin gene locus 
and the genotypes of the Bgi I1Taq I haplotypes, arranged in 2xN tables as shown in 
Table 5. Estimated 'p-values' for the least conservative of the four available tests was 
0.188 forthe Bgi I/Taq I haplotypes, 0.81 forthe tetranucleotide repeat and 0.088 for 
the dinucleotide repeat (each value calculated after 1000 simulations), arguing against 
association between nephropathy and these polymorphic markers. 
Although a trend towards higher prorenin levels exists in bb homozygotes (bb vs. 
BB + Bb, p - 0.07) (I' able 6), we did not find significant differences in plasma levels between 
the other renin genotypes, neither in the nephropath.ic nor in the normoalbuminuric group 
(results not shown). 
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Table 4. Renin and prorenln plasma levels In paUenls with or without diabetic nephropathy, 
according to the presence or absence of retinopathy 
retinopathy 
no 
background 
proliferative 
nephropathy normoalbuminuria 
renin 
(~U/ml) 
26.5 
(5.2·82.4) 
26.1 
(7.7-243.3) 
n" 43 
prorenln* 
(~U/ml) 
553 
(88·2301) 
869 
(167-5481) 
renin 
(~U/ml) 
17.5 
(4.2·66.8) 
18.1 
(5.3·373.5) 
19.4 
(10.5-81.6) 
n" 65 
prorenin:t: 
(~U/ml) 
267 
(36-711) 
321 
(45-1124) 
n" 100 
414 
(224-2226) 
n" 87 n" 18 
<0.001 proliferative vs. background. t ANOVA: P"0.0004, proliferative vS.background: 
p"0.001, Proliferative + background Shown are median (range). Patients taking 
antihypertensive medication are not included. 
* p VS. nul: p=O.04. Renin levels are not significantly different In different stages of retinopathy 
by this analysis. A two-way ANOVA of log-transformed renin and profenin levels In a collapsed 
table (proliferative retinopathy YES/NO and nephropathy YES/NO) demonstrates a significant 
effect of the presence of nephropathy and proliferative retinopathy on profenln levels 
(p<0.0001). In contrast with the results of ANOVA on the table above a Wio-way ANOVA on a 
collapsed table demonstrates an effect of retinopathy on renin levels (p 0.02). The effects of 
retinopathy and nephropathy on renin and profenin levels are independent (p=0.30 and 0.91 
resp, Wio-way ANOVA). 
Finally, we analysed the data for association of renin gene polymorphisms with coronary 
heart disease, hypertension and retinal status. No statistically significant differences were 
revealed (data not shown). 
In multiple logistic regression analysis, with presence or absence of nephropathy as 
dependent variable and the renin Bgl I and Taq I polymorphisms, ACE IID 
polymorphism, angiotensinogen M235T and T174M polymorphisms and the angiotensin 
receptor type 1 AlC polymorphism at position 1166 as independent variables, only the 
renin bb-genotype, not surprisingly, remained in the final model (p - 0.037), but more 
importantly, no interactions were observed between the bb-genotype and the 
polymorphisms in the angiotensinogen, ACE and ATIR genes. 
Discussion 
In this report we confirm previous findings that in IDDM patients plasma prorenin levels 
are increased by 150% when DN is present. We also found plasma renin to be 50% 
higher in nephropathic than in normoalbuminuric patients with IDDM. Furthermore, 
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Table 5. Renin gene polymorphisms In pallenls wilh Insulln-dependenl diabeles melillus 
Genolypel nephropathy normoalbumlnurla 
alleles n n 
IT 158 140 
Tt 36 48 
It 5 4 
BB 21 19 
Bb 71 91 
bb 107 82 
haplolype genolypes 
BT/BT 7 7 
BVBt 5 4 
bTIbT 107 82 
BTlBt 9 8 
BTIbT 44 51 
BVbT 27 40 
tetranucleotide repeat (Ienglh in base pairs) 
255 314 309 
259 0 0 
263 38 32 
267 43 41 
271 3 2 
dlnucleollde repeat (length in basepalrs) 
126 0 4 
128 37 32 
130 165 149 
132 19 20 
134 52 53 
136 68 80 
138 30 34 
140 22 12 
142 4 0 
144 1 0 
the presence of diabetic nephropathy is weakly associated with one of the genotypes of 
a Bgl I polymorphism in the first intron of the renin gene. 
Although there are other reports of increased renin levels in DN,8, 20, J2 general 
impression has always been that renin levels are low in DN (for a list of references see 
ref. 7). The apparent discrepancy with our finding of increased renin levels could be due 
to various factors. The first may be the poorly developed measurement methodology 
for renin.JJ Most studies date from the seventies and early eighties and employed variants 
of an enzyme-kinetic, plasma renin activity (PRA) assay, which measures angiotensin I 
production by renin from endogenous angiotensinogen. The PRA assay depends on 
both renin and angiotensinogen concentration. Kinetics of the enzymatic reaction of 
renin with angiotensinogen, often performed at non-physiologic pH in PRA assays, may 
differ in diabetic plasmas, including altered renin reactivity and non-linear angiotensin I 
generation, but no reports exist that address this problem. The immunologic, direct 
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assay we employed, measures molecules and is unlikely to be affected by the diabetic 
state. Another recent study that measured renin by IRMA, also found a trend to higher 
renin levels in diabetic subjects with microalbuminuria-the early phase ofDN- compared 
to normoalbuminuric diabetics.2I This suggests again that the cause of the discrepancy 
may be assay~related. Renin IRMAs may have a problem in co-measurement of prorenin 
as renin. Our IRMA employs a monoclonal antibody specific for renin. Prorenin may 
also assume a renin-like conformation by so-called cryoactivatioll, even at room 
temperature, which is the temperature of the assay incubation.34 Although this activation 
amounts to not more than 1 to 2 %, renin levels may be overestimated, especially if 
pro renin levels are high. In our assay co-measurement of pro renin as renin is eliminated 
by performing the assay for 6 hours at 37 "C. We are therefore confident that our results 
on plasma renin in DN are valid. Another explanation for the discrepancy of previous 
reports with our observation of increased renin may be that study groups were often not 
homogeneous. Data for NIDDM and IDDM patients were often pooled in earlier studies 
and it is not known whether this is justified. Moreover, the various stages ofDN were 
not always separated, partly because at the time these stages were not yet discerned. A 
final possible explanation for our high renin levels is that these are due to previous 
antihypertensive use. High renin levels may be observed with ACE-inhibitors and diuretic 
use (AT1-receptor antagonists were not yet being prescribed to these patients). Patients 
had stopped antihypertensive medication at least 8 days before blood-sampling. This is 
usually sufficient for any effect of ACE-inhibition to wear off.35 After cessation of diuretic 
use secondary hyperaldosteronism may persist for longer periods than 8 days. However, 
this, together with a higher blood pressure, is expected to cause decreased renin levels, 
rather than the increased levels we found. Unfortunately, data on aldosterone that may 
clarify the issue somewhat, are not available. Finally, nephropathic patients virgin to 
antihypertensives have somewhat less increase in plasma renin and prorenin levels. This 
might argue in favor of a carry-over effect of antihypertensives on prorenin and renin 
levels in the hypertensive subgroup. On the other hand, this normotensive subgroup too 
does not show suppressed renin levels as is expected from older literature/ but rather 
increased levels. 
Increased plasma renin and prorenin levels in DN support the hypothesis that the 
RAS is overactive and possibly even pathogenetic in the development or progression of 
DN, especially since increase in total renin occurs early.22 A possible mechanism could 
be higher intra-glomerular pressure, through angiotensin II-mediated constriction of 
the efferent arteriole, with resulting proteinuria, but this remains speculative. The origin 
of elevated renin is most probably the kidney, since no other source of renin has been 
described.36 Whether an excess prorenin also originates from the kidney is not known. 
Franken et aI. did not observe an increase in renal vein-to-artery ratio for prorenin in 
patients with near end-stage diabetic nephropathy and high prorenin, suggesting that 
there is no markedly increased production of prorenin in the kidney.'o Prorenin may 
also originate from extra-renal sites like ovaries, testes and adrenals.36 Whether pro renin 
itself acquires enzymatic activity in DN is an unsolved question. Several mechanisms of 
pro renin activation have been described.36 37 
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Some controversy exists concerning the relation between retinopathy and plasma 
prorenin. We observed increased prorenin levels with proliferative retinopathy. This is 
in agreement with Franken et al., who found an increase of plasma prorenin with increasing 
severity of retinopathy.20 However, contraty to their findings, we did not find a difference 
between patients without and those with background retinopathy in the normo~ 
albuminuric group. This is similar to the result obtained by Allen et al., who did not 
observe·in a longitudinal survey- an increase in plasma prorenin when patients progressed 
from no to background retinopathy" Thus, apparently retinopathy and nephropathy 
have an additive effect on plasma pro renin levels, suggesting that the increase in plasma 
prorenin is an aspecific marker for microvascular disease as proposed previously,19 Yet, 
probably only the advanced, proliferative stage of retinopathy influences plasma prorenin. 
This is in contrast with DN, where plasma prorenin increases very early in the course of 
the disease." 
The derangement in renin and prorenin in DN could be connected to a polymorphism 
in the renin gene, if this polymorphism is associated with DN. DN is weakly associated 
with the bb-genotype of aBgl I RFLP in the first intron of the renin gene. This suggests 
a deleterious recessive effect of the b-allele. The first intron is involved in renin gene 
transcription regulation)8 and the Bgl I polymorphism may be linked to this regulatory 
sequence. This may provide a mechanism that explains the association of DN with this 
marker. It could also explain the findings of Daneman et al. who described a genetic 
influence on plasma prorenin levels in diabetic patients with microalbuminuria,21 although 
no genotyping of the renin gene was performed in this study. From this observation we 
anticipated a relation between Bgl I renin genotype and plasma renin or prorenin level. 
However, we could not demonstrate such an association, although a trend towards higher 
prorenin levels was observed in bb homozygotes. This trend may have failed to reach 
significance because only prorenin levels in the subgroup of patients not on 
antihypertensives were included in our analysis. 
There was no interaction of the Bgl I marker with variants of other genes of the RAS, 
although the power of the study was not sufficient to detect any interactions but very 
strong ones. Three other markers in the renin gene were not associated with nephropathy. 
There is only one report about polymorphic markers in the renin gene in diabetic patients 
with nephropathy and their controls.)' This report did not show an association of renin 
gene polymorphisms with diabetic nephropathy. However, the report was based on a 
small group (40 patients) and diabetes duration was shorter (11 years), so that future 
nephropathic patients may have been present among control subjects. 
The polymorphic marker that was first studied in the present study group, the ACE 
gene IID polymorphism, was not in Hardy-Weinberg equilibrium in the control group,2) 
which might cast doubt on any conclusion on the genetics of DN in this study group. 
However, polymorphic markers in the renin, angiotensinogenlO and AT1-receptortJ genes 
were in Hardy-Weinbergequilibrium in the control group, which makes selection bias of 
controls unlikely. The absence of Hardy-Weinberg equilibrium in the ACE gene may be 
caused by misclassification of alleles, 40 or may be incidental, the ACE-gene not being 
linked to the other RAS-genes. 
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Our control group turned out to have better metabolic control. Individuals with the 
bb-genotype of the renin gene may have been protected from DN if this better metabolic 
control has been long-term. Whether this may have weakened the association between 
DN and a renin gene polymorphic marker, we do not know. In subgroup analyses 
according to glycated hemoglobin levels either matching was lost or groups became 
very small. 
Our study group is unique in that now the renin, angiotensinogen, ACE and A TIR 
genes have been studied for association with DN. We can conclude that in this group of 
all RAS-components'o, B. 23 plasma renin and prorenin and possibly the renin gene Bgl I 
polymorphism are associated with DN. Plasma ACE has also been found to be increased 
in DN in this study group,23 but the ACE gene liD polymorphism was not associated 
with DN in these patients. Recent meta·analyses, however, showed that the ACE gene D· 
allele may confer an increased risk for DN (excess risk up to 56% depending on ethnic 
background and reliability of genotyping method). 15·17 
Since the effect of the ACE liD polymorphism and, in our group, the renin Bgl I 
polymorphism is small and since there is no major interaction between the RAS·gene 
variants we must assume that the main part of the genetically determined susceptibility 
to DN lies outside the genes that code for RAS·components. Still, in view of our results 
on plasma renin and prorenin measurements and in view of the favorable reaction to 
ACE inhibitors, a pathogenetic mechanism ofDN in which the RAS, in particular renin 
and prorenin) is involved, remains likely. 
In conclusion, a direct, validated assay showed that both pro renin and renin are 
increased in plasma ofIDDM patients with diabetic nephropathy. In the present patient 
group a renin gene variant is the sole genetic factor within the RAS that may contribute, 
albeit weakly, to the genetic susceptibility to diabetic nephropathy. Renin and prorenin 
could well playa direct pathogenetic role in DN. 
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CHAPTER 5 TISSUE PRORENIN: THE EYE 

5.1 RENIN, PRO RENIN AND IMMUNOREACTIVE RENIN IN VITREOUS 
FLUID FROM EVES WITH AND WITHOUT DIABETIC RETINOPATHV 
Sununary 
Renin, prarenin and immunoreactive renin were present in vitreous and subretinal 
fluid of eyes from subjects with and without diabetic retinopathy. Renin substrate, 
albumin, transferrin and immunoglobulin G were also found in these ocular fluids. 
In many samples renin levels were close to the detection limit of the assay. The levels 
of renin substrate, albumin, transferrin and immunoglobulin G varied widely among 
ocular fluid samples, but in each individual sample the levels were, relative to each 
other, similar to those in plasma. In contrast, the prorenin level in ocular fluid was 
up to 100 times higher than expected on the basis of the plasma protein content of 
ocular fluid. Moreover, there was little difference in pro renin concentrations between 
samples with a low and a high plasma protein content. Prorenin, relative to albumin 
and other plasma proteins, was higher in vitreous fluid from eyes with proliferative 
diabetic retinopathy complicated by traction retinal detachment than in eyes of non-
diabetic subjects with spontaneous retinal detachment. It appears that pro renin (and 
possibly renin) in ocular fluid is controlled by an active and specific process, possibly 
local synthesis within the eye. In view of the vascular actions of angiotensin IT, an 
intraocular renin-angiotensin system may playa role in diabetic retinopathy. 
Introduction 
The kidney secretes both renin and prorenin, an inactive precursor of renin, into the 
circulation. Plasma of nephrectomized patients contains little or no renin but it does 
contain prorenin, 1,2 in concentrations sometimes as high as those in normal individuals. 
It thus appears that extrarenal production can make a major contribution to the level of 
prorenin in plasma, whereas most, if not all, renin in plasma is secreted by the kidneys. 
Synthesis of renin or prorenin and other components of the renin-angiotensin system is 
known to occur at various extrarenal sites, for instance adrenal/' 4 pituitary,J·4 testis/. 4 
brain,5 and ovary.6, 7.' Cultured human chorionic cells' and ovarian thecal cells' release 
pro renin into the medium and there is good evidence that in women with hyperstimulated 
cycles and during pregnancy, the ovary, probably the corpus luteum, releases prorenin 
into plasma." 10 
A common feature of the organs in which synthesis of renin or prorenin occurs is 
their extensive vascularization. II The eye, particularly the retina and uveal tract, is such a 
highly vascularized organ. Angiotensin II-binding sites have been found in retinal blood 
vessels, 12 and transvitreal infusion of angiotensin I and II produces constriction of the 
retinal arteries.13 The retina contains angiotensin converting enzyme activity14 and this 
enzyme is also found in aqueous fluid. 15Here we report measurements of renin, prorenin, 
immunoreactive renin, renin substrate and various plasma proteins in aqueous, vitreous 
and subretinal fluid. The ocular fluid samples were obtained at the time of cataract 
extraction or vitrectomy and the protein concentrations in these samples were compared 
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with those in simultaneously obtained plasma. Our study included eyes affected by 
proliferative diabetic retinopathy because the renin·angiotensin system has been implicated 
in neovascularization. 16 
Subjects and Methods 
Non-diabetic Subjects 
Aqueous fluid was collected at the time of cataract extraction from 21 subjects (15 women 
and 6 men; mean age, 68 yr; range, 26-86 yr). Four subjects wefe receiving a diuretic and 
six a p-adrenergic antagonist. 
Vitreous fluid aspirates were obtained from 16 subjects (8 women and 8 men; 
mean age, 52 yr; range, 20-82 yr). The samples were collected at the time of pars 
plana vitrectomy, which was performed because of recurrent retinal detachment due 
to proliferative vitreoretinopathy. Four subjects were receiving a diuretic, in 3 of 
them combined with a b-adrenergic antagonist. 
Subretinal fluid was obtained from 18 subjects (8 women and 10 men; mean age, 
59 yr; range, 8·76 yr), with rhegmatogenous retinal detachment, which is a type of 
retinal separation precipitated by a hole or a tear in the retina. In this type of 
detachment fluid accumulates between the retinal pigment epithelial layer and the 
neural retina. The retinal detachments had occurred between 1 day and 3 months 
(median, one week) before subretinal fluid collection. Three subjects were receiving 
a diuretic, in 2 of them combined with a b-adrenergic antagonist. 
Diabetic Subjects 
Vitreous fluid was obtained from 15 diabetic subjects with proliferative diabetic 
retinopathy (8 women and 7 men; mean age, 51 yr; range, 28·71 yr). Vitrectomy was 
performed because of traction retinal detachment. The duration of diabetes ranged 
from 6-32 yr. Twelve subjects were receiving insulin, 5 were receiving a diuretic and 1 
was receiving a b-adrenergic antagonist. 
Aqueous fluid can only be collected at the time of cataract extraction. In diabetic 
subjects, however, this procedure may stimulate proliferative retinopathy. Cataract 
extraction is therefore not performed in eyes affected by proliferative diabetic 
retinopathy. Consequently, aqueous fluid could not be collected from such eyes. We 
also were unable to collect subretinal fluid from diabetic subjects with traction retinal 
detachment because drainage of subretinal fluid is rarely performed in these subjects 
and, if it is performed, the approach is via the transvitreal route, so that the sample is 
heavily contaminated with material from the vitreous. In subjects with a 
rhegmatogenous retinal detachment, subretinal fluid is removed via the transscleral 
route, where no such contamination occurs. 
Collection of Ocular Fluid Samples 
Approximately 0.1 mL aqueous fluid was collected with a tuberculin syringe and a 25-
gauge needle. The needle was introduced at the limbus of the cornea through the groove 
of the cataract incision. A 0.3-1.0 mL sample of vitreous fluid was aspirated before 
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substitution fluid was infused into thevitreolls. Subretinal fluid was aspirated transsclerally, 
after local diathermic coagulation of the choroid. 
The ocular fluid samples were free of macroscopically visible blood and were frozen 
at -70 °C immediately after collection. A peripheral venolls blood sample was drawn 
simultaneously with the collection of ocular fluid. Blood for determination of renin, 
prorenln, immunoreactive renin, renin substrate, albumin, transferrin and immunoglobulin 
G (IgG) was collected in tllbes containing 0.1 volume of 0.13 mollL trisodium citrate. 
The blood was immediately centrifuged at 3000 x gfor 10 minutes at room temperature, 
and l-mL aliquots of plasma were stored at -70 0c. Blood for determination of 
angiotensin II was collected in prechilled tubes containing 0.1 volume of 0.06 mmollL 
pepstatin-A, 0.125 mollL disodium EDT A and 0.025 mollL phenantroline in order to 
block renin, angiotensin converting enzyme and angiotensinases, respectively. The blood 
samples were immediately centrifuged at 3000 g for 10 minutes at 4 °C, and 2-mL 
aliquots of plasma were stored at -70 °C. 
Analytical Methods 
Renin was measured in duplicate by enzyme-kinetic assay, in which the samples were 
incubated at 37 °C and pH 7.5 with saturating amounts of sheep renin substrate in the 
presence of inhibitors of angiotensinases and angiotensin converting enzyme. The 
generated angiotensin I was quantitated by RIA. 17 For measuring prorenin in plasma, 
prorenin was converted into renin by incubation with Sepharose-bound trypsin (0.25 
mgl mL) for 48 hOllrs at 4 0c. Previous studies, including measurements of total 
immunoreactive renin (renin plus prorenin), indicated that the prorenin to renin conversion 
in plasma is complete after incubation with the immobilized trypsin under these 
circumstances and that destruction of renin or prorenin does not occur. 18 Experiments 
in which known quantities of purified human kidney renin were added to ocular fluid 
demonstrated that in some samples destruction of renin did occur with this method. 
This destruction might be due to the low content of serine protease inhibitors in ocular 
fluids as compared to plasma. Therefore) in ocular fluid we chose to use plasmin to 
convert prorenin into renin. 17. 19Por this purpose the sample was incubated with plasmin 
at a final concentration of O.5l'mollL for 48 hours at 4 °C before the assay. 
Comparison of the results of the enzyme-kinetic assay in plasmin-activated ocular 
fluid samples with the results of the assay of total immunoreactive renin in non-
activated samples demonstrated that the conversion by plasmin was complete without 
any loss of pro renin or renin; the specific enzymatic activity of plasmin-activated 
prorenin in ocular fluid samples was not different from the specific activity of purified 
kidney renin and plasma renin (see Reslllts). Plasmin at the concentration mentioned 
above cannot be used to activate prorenin in native whole plasma because of its high 
content of plasmin inhibitors. 
The concentrations of renin and prorenin measured by the enzyme-kinetic assay were 
expressed as milliunits per L using the WHO human kidney renin standard 68/356 (WHO 
International Laboratory for Biological Standards, London, United Kingdom) as reference 
standard. The lower limit of detection was 0.5 mUlL and the interassayvariability at 
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low concentrations of renin or prorenin (2-5 mUlL) was 11 % for both renin and prorenin. 
Immunoreactive renin was measured in duplicate with a sandwich assayl8, 20 using the 
monoclonal antibodies R 3-27-6 and R 3-36-16 (Ciba-Geigy, Basel, Switzerland). The 
two monoclonal antibodies recognize different <pitopes of the renin molecule and react 
equally well with human kidney renin and chorionic cell culture prorenin. The assay was 
carried out in polystyrene tubes (Star Tubes, code 4-70319; Nunc, Roskilde, Denmark). 
The inner surface of these tubes was coated with antibody R 3-27-621 . Immunoreactive 
renin in the assay sample is quantitatively bound to this antibody. The amount of solid 
phase-bound immunoreactive renin was measured with antibody R 3-36-16, which had 
been radio labeled with 125r. The results of this assay were expressed as nanograms per L 
using highly purified human kidney renin (Ciba-Geigy) as a standard. One milliunit of 
the WHO human kidney renin standard corresponded to 1.41 ng of the Ciba-Geigy 
standard. The lower limit of detection was 5 nglL, and the interassay variability was 8 
%. 
The concentration of renin substrate was determined as the maximum quantity of 
AngI that was generated during incubation at 37°C and pH 7.5 with an excess of purified 
active human kidney renin in the presence of inhibitors of angiotensinases and angiotensin 
converting enzyme. 18 The lower limit of detection was 1 nmollL and the interassay 
variability was 10 %. 
Immunoreactive AngII was measured by radioimmunoassay after SepPak (\'V'aters, 
Milford, MA, USA) extraction of the sample." The lower limit of detection was 2 pmol! 
L and the interassay variability was 15%. 
Albumin, transferrin and IgG were measured by single radial immunodiffusion 
(LC and NOR-Partigen plates, Behringwerke, Marburg, Germany) according to the 
method of Mancini et al. 2l 
Data Analysis 
Plasma proteins enter the vitreous mainly by diffusion. One of the reasons why the 
concentrations of these proteins are low in vitreous fluid is that they have to cross a 
relatively impermeable barrier. Breakdown of this so-called blood-retinal barrier leads 
to increased diffusion of plasma proteins into the eye. The rate of diffusion of a given 
protein is related to its molecular size and plasma concentration. In accordance with 
this is the fact that the concentrations of the different proteins relative to each other 
are similar in plasma and vitreous fluid. 24, 25 
Thus, unless certain specific uptake processes exist, for which in the eye no evidence 
is available with regard to any of the proteins mentioned in this paper, one would 
expect a relatively high intraocular albumin concentration (due to partial breakdown 
of the blood-retinal barrier) to be accompanied by a proportionally high concentration 
of plasma proteins of comparable size. Therefore, we chose to take the vitreous fluid! 
plasma concentration ratio of albumin as an index of the integrity of the blood-
retinal barrier, an abnormally high ratio being an indication of breakdown of this 
barrier. By multiplying this ratio with the level of a given protein in plasma, the level of 
this protein in ocular fluid can be estimated, assuming that, as mentioned above, this 
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protein is transferred from the blood into the vitreous and vice versa by mechanisms that 
are qualitatively and quantitatively the same as those for the transfer of albumin. For 
example, for renin substrate the calculation would be as follows: 
[RS ] ~ [RS l]x[ALB ]/[ALB I]' 
oc p oc p 
in which RS is renin substrate, ALB is albumin, oc is ocular fluid, pI is plasma, and 
brackets denote the concentration. 
If our assumptions are correct, the calculated concentrations should be equal or 
at least closely correlated to the actually measured concentrations. Therefore, the 
two sets of data were analyzed by linear regression. 
For analyzing differences between diabetic and nondiabetic subjects unpaired t-
tests were performed after logarithmic transformation of the data. Values were 
considered significant if p <: 0.05. 
Results 
Non·diabetic Subjects 
The levels of renin in many vitreous and aqueous fluid samples were at or below the 
detection limit of the assay (0.5 mUlL), which is less than 5 % of the level in plasma. 
In subretinal fluid the renin level was about 20 % of that in plasma (Table 1). Prorenin 
was detectable in all samples of vitreous and aqueous fluid; its level in vitreous fluid 
was about 20 % and in aqueous fluid about 5 % of that in plasma. In subretinal fluid the 
prorenin level was as high as in plasma. Renin and pro renin concentrations in the fluid 
compartments of the eye were in the order: subretinal fluid> vitreous fluid> aqueous 
fluid. The levels of renin substrate in subretinal, vitreous and aqueous fluid were 10, 5 
and 0.5 % of those in plasma, respectively. Thus, they too were in the order: subretinal 
Table 1. Levels of prorenin, renin, and renin substrate In ocular fluids. 
Prorenin Renin Renin substrate 
(mUll) (mUll) (nmolll) 
n eye plasma eye plasma eye plasma 
~on-diabetic subiects 
Aqueous v5.plasma 21 4.4 163 <0.5 9.8 5.1 1080 
2.0-8.7 36.7-453 NO-0.5 1.5-62.9 1.6-15.4 898-1430 
Vitreous vs. plasma 16 34.5 174 <1.0 17.3 54.5 1120 
17.4-61.9 67.0-396 NO-2.8 3.7-51.0 3.0-630 791-3030 
Subretinal vs. olasma 18 132 128 2.4 14.3 107 1230 
36.8-305 65.1-251 0.9-6.4 4.3-105 10-1430 841-2250 
Diabetic subjects 
Vitreous vs. plasma 15 61.0 357 <2.0 17.7 61.0 1030 
19.0-172 121-679 NO-3.5 4.4-127 7.0·1000 628-2040 
Shown are the geometric mean and range. NO, Not detectable. In vitreous fluId and plasma the 
levels of prorenin, but not those of renIn substrate, were higher In diabetic than in non·diabetlc 
subjecls (p < 0.01). 
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Table 2. Levels of albumin, IgG, and transferrin in ocular fluids. 
Albumin (giL) IgG (giL) Transferrin (giL) 
n eye plasma eye plasma eye plasma 
Non-diabetic subjects 
Aqueous 21 0.19 33.1 NO NO NO NO 
vs.plasma 
0.06-0.45 28.3-39.4 
Vitreous vs. 16 1.55 33.0 0.19 11.0 0.18 2.44 
plasma 
0.11-20.2 22.9-42.5 0.03-0.70 6.61-14.4 0.02-1.74 1.60-2.99 
SUbretinal 18 3.03 35.4 0.48 11.2 0.45 2.57 
V$. plasma 
0.39-28.5 29.2-41.9 0.07-5.10 7.0-18.2 0.06-3.97 2.08-3.44 
Diabetic subjects 
Vitreous vs. 15 1.51 29.2 0.19 9.2 0.14 2.06 
plasma 
0.32-17.1 21.7-36.8 0.04-0.96 3.88-16.7 0.06·0.37 1.50-2.70 
Shown are the geometric mean and range. The levels of albumin, IgG, and transferrin in 
both vitreous and plasma did not differ between diabetic and non·dlabetic subjects. NO, 
Not done. 
fluid> vitreous fluid> aqueous fluid. This was also true for the levels of albumin, 
transferrin and IgG (fable 2). There was no correlation between the levels in ocular fluid 
and those in plasma for any of the proteins. 
As described under Data analysis above, a theoretical concentration in ocular 
fluid for each protein was predicted based on the albumin content of the sample. For 
renin substrate, transferrin and IgG the calculated and measured values were linearly 
correlated in both vitreous and subretinal fluid, and the slopes of these correlation 
lines were not significantly different from 1.0 (fables 3 and 4). Renin substrate and 
transferrin concentrations in ocular fluid could, in fact, be accurately predicted by 
these calculations. The IgG level measured was systematically about 2 times lower 
than that calculated, which may be due, at least in part, to its larger molecular size as 
compared to that of albumin and the other proteins. 
For prorenin the findings were different. The prorenin levels in both vitreous and 
subretinal fluid varied much less than the levels of the other proteins (fables 1 and 
2). Furthermore, calculating prorenin concentrations on the basis of the albumin 
content of the sample yielded much lower (down to 1/100th) values than those actually 
measured, particularly in samples with a low plasma protein content (intact blood-
retinal barrier). The pro renin level in subretinal fluid was higher than that in vitreous 
fluid, even when corrections were made for the higher plasma protein content in subretinal 
fluid samples (Fig. 1). In both vitreous and subretinal fluid the slopes of the regression 
lines describing the correlation between the measured and calculated prorenin 
concentrations were significantly different from 1.0, thereby indicating the different 
behavior of prorenin as compared to albumin and other plasma proteins. 
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Table 3. Correlations between the measured and calculated 
concentrations of proteins In vitreous fluid, 
Protein Regression Line P 
Profenln 
Non·diabetlc y=0.015'x+1.523 0.05 NS 
subjects 
Diabetic subjects y=0.328'x+1,370 0,64 <0,05 
Renin substrate y=1.024x·0,028 0,97 <0,0001 
IgG y=1.063x·O,344 0,91 <0,0001 
Transferrin y=0,899x+O,066 0,89 <0,0001 
Y Is the log (measured concentration); x Is the log(calculated 
concentration). For renin substrate, IgG, and transferrin, data from diabetic 
and non·diabetic subjects were combined because no differences were 
found for these proteins between the two groups (Tables 1 and 2).' Slope 
different from 1,0, p<0,0001 
Table 4. Correlations beween the measured and calculated concnetrations 
of proteins In subretinal fluid. 
Protein Regression Line p 
Prorenln y=0,027'x+1.839 0,61 <0,01 
Renin substrate y=0,975x+0,064 0,98 <0,0001 
IgG y=0,941x·0,302 0,99 <0,0001 
Transferrin y=0,934x+0,262 0,94 <0,0001 
Y Is the log (measured concentration); x is the log (calculated concentration),a 
Slope different from 1.0, p<0,0001 
The data on prorenin shown in Tables 1, 3 and 4 and Figs. 1·3 were obtained by the 
enzyme-kinetic assay. That prorenin measured by this assay is, in fact, prorenin is supported 
by the excellent agreement with the measurements of immunoreactive renin (Fig. 4). 
The mean specific enzymatic activity of in vitro activated prorenin was 0.7 ± 0,2 (± SD) 
mU/ng (n-9) in vitreous fluid and 0,6 ± 0.2 mU/ng (n~ 10) in subretinal fluid, These 
values are not different from the specific activity of renin from plasma and kidney, 18 
Immunoreactive AnglI was 11.1 ± 1.8 pmollL in vitreous fluid (n -12) compared to 
17.5 ± 1.3 pmollL in plasma, In subretinal fluid (n-lS) it was 14.8 ± 1.6 pmollL 
compared to 23,9 ± 2,0 pmollLin plasma, 
Diabetic Subjects 
The results of the renin substrate, albumin, transferrin, and IgG measurements in vitreous 
fluid and plasma of the diabetic subjects were similar to those in the non·diabetic subjects 
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rrLVg 
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=plasrra 
l2ZZZZl ocular fluid 
Figure 1. Mean (± SE) prorenlnlalbumin concentration ratio in ocular 
fluids and plasma of nondiabetic patients 
(Tables 1 and 2). The levels of renin and prorenin in vitreous fluid were higher in the 
diabetic than in the non·diabetic subjects. Pro renin was also higher when allowance was 
made for differences in plasma protein content of the samples. In the diabetic subjects 
the prorenin concentration of vitreous fluid correlated with the plasma pro renin 
concentration (r-0.78, n -15, p < 0.001). In the non·diabetic subjects there was no 
significant correlation between the levels of prorenin in vitreous fluid and plasma. 
As in the non·diabetic subjects, prorenin in vitreous samples with low plasma protein 
content was much higher (up to 25 times) than expected on the basis of the albumin 
content of the samples. 
Immunoreactive AngII was 9.0 ± 2.5 pmol/L in vitreous fluid (n -15) compared to 
9.9 ± 2.9 pmol/L in plasma. 
Discussion 
The levels of albumin (mol wt, 69 K), transferrin (mol wt, 90 K), IgG (mol wt, 150 K) 
and renin substrate (mol wt, 65 K) in vitreous fluid differed widely from sample to 
sample, but in each individual sample the levels were, relative to each other, comparable 
to those in plasma. The IgG level in vitreolts fluid, relative to that of albumin, was 
systematically somewhat lower than in plasma, probably due to its larger molecular 
size.25 These results are in agreement with earlier findings that most soluble protein in 
the vitreous is derived from plasma.'" 26 
The plasma protein content of normal vitreous fluid has been estimated to be 0.5-2 
% of that in plasma.25". In our study vitreous fluid from eyes with recurrent retinal 
detachment due to proliferative vitreoretinopathy contained higher levels of plasma 
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proteins. These higher values probably reflect partial breakdown of the blood·retinal 
barrier in such eyes.27 
The blood·retinal barrier is formed by the tight junctions between the endothelial 
cells of the retinal capillaries and the tight junctions between the retinal pigment epithelial 
cells, the latter restricting the transfer of plasma proteins escaping from the capillaries of 
the choroid.2s Proteins from plasma may enter the vitreous as a result of focal cellular 
necrosis, opening of the intercellular junctions, or vesicular transport and formation of 
transcellular channels. The rate of diffusion of proteins through such discontinuities in 
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Figure 2. Measured versus calculated concentrations of profenln (top panel) and renin 
substrate (bottom panel) in vitreous fluid. For an explanation of the calculation see text 
(Data analysis). The slopes and significance levels of the correlations are given In Table 
3. open symbols: diabetic, closed symbols: non-diabetic. 
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the blood-retinal barrier depends upon the concentration gradient across this barrier, 
the molecular size of the proteins and the number and area of discontinuities. Our results 
are in accordance with the contention that diffusion through these pores is the main 
mechanism of transfer of plasma proteins to the vitreous. 
This process, however, does not appear to hold true for pro renin (M, 47,000). The 
concentration of pro renin, relative to that of albumin, was much higher in vitreous fluid 
than in plasma, and the prorenin level in vitreous fluid also was little influenced by its 
plasma protein content. Thus, prorenin may enter the vitreous by a mechanism that is 
different from that of albumin and other plasma proteins. This mechanism is selective 
138 
Ftorenin 300 
rresured 
rrLVL 100 
30 
10 -
3 
0.3 
0.1 
0.1 
Renin 3000 
substrate 
rreasured 1000 
mmllL 
300 
100 
30 
10 
3 
• rI' eO 
eo • ..., 
• • 
• • 
• • 
0.3 3 10 30 100 300 
A'orenin calculated rrLVL 
• 
3 10 30 100 300 10003000 
Renin substrate rreasured nrroVL 
Figure 3. Measured versus calculated concentrations of prorenln (top panel) and 
renin substrate (bottom panel) In subretinal fluId. Foran explanation of the calculaUon 
see text (Data analysis). The slopes and significance levels of the correlations are 
given In Table 4. 
RENIN AND PRORENlN IN HUMAN EYES 
InmJnoreactive 3000 
renin 
ngiL 1000 e 
300 :I> 
100 
• 
30 • .. 
• 
10 .. 
3 
3 10 30 100 300 10003000 
Renin plus prorenin (enzyrre-kineUc assay) nt..vL 
Figure 4. Total renin (prorenln plus renin) measured by enzyme-kinetic assay versus 
Immunoreactive renin (r=0.97, p < 0.0001).0 plasma, III subrelinal fluid, ., vitreous 
nuld, A aqueous nuld, + WHO human kidney renin slandard. 
for prorenin and may involve an active process. Receptor-mediated transcellular transport 
is such a selective mechanism, but as yet there is no evidence for the existence of this 
mechanism, although pro renin-binding by cells has been described,29, 30 Our findings 
raise the possibility that not all the prorenin in the vitreous is derived from plasma but 
that some of it is produced in the eye, 
As described under Data alltllysis above, the vitreous level of prorenin that has crossed 
the blood-retinal barrier by passive diffusion in the same way as albumin can be estimated 
by multiplying the vitreous! plasma concentration ratio of albumin by the plasma prorenin 
level. By subtracting this calculated level of plasma-derived prorenin from the level actually 
measured, we estimated the level of pro renin that entered the vitreous by some process 
that is different from diffusion out of the circulation. In most samples of vitreous fluid 
the estimated level of prorenin that had entered the vitreous by such a diffusion-
independent process was more than 4 times higher than the estimated level of pro renin 
that had entered the vitreous by passive diffusion from blood. Thus, relative to the total 
amount of pro renin in vitreous fluid, the contribution of plasma-derived pro renin 
crossing the blood-retinal barrier merely by diffusion appears to be small. The implicit 
assumption underlying these calculations is that albumin and prorenin leave the vitreous 
in the same way, that is by free diffusion into the aqueous fluid,3! where the concentrations 
of these proteins were much lower than in the vitreous. 
The concentrations of albumin, transferrin, IgG and renin substrate were 2-3 times 
higher in subretinal fluid than in vitreous fluid. This was to be expected, since subretinal 
fluid from eyes with retinal detachment is more or less a concentrate of vitreous fluid.27 
Vitreous fluid enters the subretinal space through the hole(s) of the retina, and water is 
actively absorbed from the subretinal space by the retinal pigment epithelium, Again, 
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the findings for prorenin were different. The concentration of prorenin, relative to 
albumin, was much higher in subretinal fluid than in plasma, particularly in subretinal 
samples with low plasma protein concentrations. Moreover, relative to albumin and other 
plasma proteins, pro renin was 2 times higher in sub retinal than in vitreous fluid. If it is 
assumed, on the basis of the evidence discussed above, that most of the pro renin in the 
vitreous is not derived from plasma but is produced in the eye, the difference in prorenin 
content between subretinal and vitreous fluid may suggest that the sub retinal 
compartment is closer to the site of prorenin production. 
Not only were the prorenin concentrations of vitreous and subretinal fluid higher 
than expected, so too were the renin (Mr 48000) concentrations. The data on renin, 
however) are more difficult to interpret than those on prorenin because in many 
samples renin was at or below the detection limit of the assay and because some 
prorenin to renin conversion may have occurred during storage and handling of the 
samples. Even as little as 1 % conversion will result in a large percentage increase of 
renin in these samples. 
Immunoreactive Angll also was found in samples of vitreous fluid, in concentrations 
comparable to those in plasma. Further work is needed to answer the question of its 
ongm. 
That the levels of albumin andIgG in vitreous fluid from eyes affected by proliferative 
diabetic retinopathy were higher than the levels in normal eyes can be explained by the 
increased permeability of the blood·retinal barrier in this condition." The higher vitreous 
level of prorenin, relative to those of albumin and other plasma proteins, in the diabetic 
subjects as compared to non·diabetic subjects is more difficult to explain. The same 
arguments in favor of the hypothesis that, generally, diffusion from the blood contributes 
little to the total amount of prorenin in the vitreous, apply to both diabetic and non-
diabetic subjects. It seems, therefore, unlikely that the higher level of prorenin in vitreous 
fluid of the diabetic subjects (2 times that in non·diabetic subjects) was caused by the 
higher level in plasma (also 2 times that in non·diabetic subjects). It might be the other 
way around; increased release or leakage of prorenin from the eye affected by proliferative 
diabetic retinopathy may contribute to the increased prorenin level in plasma. 
This possibility is further supported by the finding that, in contrast with other proteins, 
the plasma concentration of pro renin in diabetic subjects correlated significantly with 
the concomitant vitreous pro renin concentration. Considering the fact that in some 
diabetic subjects the blood·retinal barrier for plasma proteins was still relatively intact 
Qowvitreous/plasma albumin concentration ratio), whereas in others it was extremely 
leaky, no such correlation was to be expected, if diffusion from plasma into the vitreous 
was the main mechanism of transfer of prorenin. 
An elevated plasma prorenin level in diabetic subjects has been found to be associated 
with microvascular complications, including retinopathy.33 Evidence is accumulating that 
neovascularization is initiated by diffusible chemical factors arising from ischemic areas 
of the retina.3! Renin and angiotensin have been found in cultured neuronal and glial 
cells from rat brain;35. 36 both cell types are abundantly present in the retina. AngII acts 
on vascular tone and has mitogenic and trophic actions on vascular smooth muscle and 
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other ceIls,37 In fact, it has been reported to promote neovascularization.16 An intraocular 
renin-angiotensin system may, therefore, playa role in proliferative diabetic retinopathy. 
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5.2 IDENTIFICATiON AND QUANTIFICATION OF RENIN AND PRO RENIN 
IN THE BOVINE EYE 
Sununary 
Angiotensin II, the most important biologically active product of the renin-angiotensin 
system, has been reported to playa role in neovascularization and prorenin has been 
found in the vitreous of human eyes, particularly in those affected by proliferative diabetic 
retinopathy, a disease characterized by neovascularization. Prorenin in these eyes was, 
relative to plasma albumin, higher than in eyes without neovascularization. These fmdings 
suggested that an intraocular renin-angiotensin system exists, which might be involved in 
the development of retinal neovascularization in diabetes mellitus. In this study angiotensin 
I generating activity was measured in bovine aqueous humor and vitreous and in extracts 
of bovine retina, pigment epithelium-choroid and anterior uveal tract, before and after 
subjecting these extracts to procedures known to convert prorenin to renin. The 
measurements were made by incubation at 37 °C with plasma from nephrectomized rats 
at pH's ranging form 5.0 to 8.5. 'True' renin in the ocular samples could be separated 
from non-renin acid protease by a·casein-Sepharose affinity column chromatography at 
pH 3.5; 'true} renin did not bind to the column, whereas acid protease did. 'True' renin 
was further identified by its relatively high pH optimum (6.5-7.0) for angiotensin I 
generation and by its complete inhibition with specific renin antiserum and its high affmity 
for specific renin inhibitors. More than 75 percent of angiotensin I generating activity of 
the ocular samples consisted of 'true' renin. Approximately 90 percent or more of 'total' 
renin (renin plus prorenin) in aqueous humor, vitreous and the ocular tissues could not 
be explained by trapped plasma. 'Total' renin in aqueous humor and renin in vitreous 
were near the detection limit of the assay of angiotensin I generating activity. In vitreous 
pro renin comprised 99 percent of 'total} renin, in retina 81 percent, and in pigment 
epithelium-choroid and anterior uveal tract less than 50 percent. Pro renin in ocular fluids 
showed a concentration gradient, posterior vitreous> anterior vitreous > aqueous humor, 
suggesting that the main source of extracellular prorenin was in the posterior eye. These 
data support the contention oflocal renin and! or prorenin synthesis in the eye and are in 
accordance with the observations in other tissues that extrarenal synthesis of renin is 
often associated with the release of mainly, or exclusively, prorenin into extracellular 
fluid. 
Introduction 
The aspartyl protease renin is the key enzyme in the formation of angiotensin IT, an 
octapeptide with well known functions in blood pressure regulation and fluid and 
electrolyte homeostasis. Classically, renin is considered a blood-borne enzyme synthesized 
and secreted by the kidney together with its inactive precursor, prorenin. Plasma from 
nephrectomized subjects predictably contains little or no renin but it does contain 
prorenin, in some cases in concentrations as high as in normal individuals. I Apparently 
most, if not all, renin in plasma originates from the kidney, whereas a large proportion 
of plasma prorenin is produced at extrarenal sites. 
143 
CHAPTER 5.2 
Synthesis of renin or prorenin and other components of the renin-angiotensin system 
(RAS) is known to occur in many organs besides the kidney, for instance adrenal,>' , 
pituitary,>·, testis/" brain4 and ovary.5 ••• 7 In the luteal phase of the menstrual cycle and 
during pregnancy the ovary, probably the corpus luteuffi, secretes pro renin into the 
circulation.5 Certain renal and extrarenal tumors secrete prorenin in large amounts,8 and 
in some patients carrying these tumors plasma renin is elevated as well. Finally, cultured 
smooth muscle cells,9 chorionic cells'o and ovarian follicular theca cells· have been shown 
to secrete pro renin into the medium. 
It has been postulated that a correlation exists between the degree of vascularization 
of tissues and their renin content l1 and there is evidence to suggest that angiotensin II has 
a role in angiogenesis. 12 Because neovascularization is a hallmark of progressed diabetic 
retinopathy, we wondered whether renin might also be synthesized in the eye. Previously 
we described the presence of prorenin in the human eye (see chapter 5.1). Levels of 
prorenin in vitreous and subretinal fluid obtained during eye surgery were, relative to 
albumin and other plasma proteins, up to 100 times higher than in plasma. These results 
lend support to the hypothesis that synthesis of prorenin may occur in the eye. Presumably 
synthesis takes place in one or more of the surrounding tissues of the vitreous since 
vitreous itself is virtually acellular. In the present study we attempted to identify and to 
measure renin and prorenin in extracts of different parts of freshly obtained bovine eyes 
and in simultaneously taken plasma. 
Materials and Methods 
Bnffers and Reagents 
Bovine serum albumin (BSA), 8.hydroxyquinoline (8-0HQ). bovine a-casein, bovine 
cathepsin D and bovine hemoglobin were obtained from Sigma (St. Louis, MO). 
Phenylmethylsulfonyl.fluoride (PMSF) and sodium azide (NaN) were purchased from 
Merck (Darmstadt,FRG). EDT A, glycin and polyvinylpyrrolidone (pVP) were purchased 
from Riedel de Haen (Seelze.FRG), trypsin from Serva (Heidelberg,FRG), N-
ethylmaleimide (NEM) from Aldrich (Milwaukee. WIS), sodium tetrathionate (NT!) from 
Fluka (Buchs. Switzerland), plasmin from Kabi Vitrum (Stockholm,Sweden) and CNBr-
activated Sepharose 4B from Pharmacia (Uppsala, Sweden). Aprotinin was purchased 
from Bayer (Leverkusen. FRG). Antiserum against BSA was obtained from Dakopatts 
(Glostrup, Denmark). The kit for total protein determination was obtained from 
Instruchemie (Hilversum, The Netherlands). Rabbit antiserum against bovine pituitary 
renin was a gift by dr. Murakami, University of Tsukuba, Japan (seeref. 13). The renin 
inhibitor remikiren was a gift from dr. van Brummelen (Hoffman-La Roche, Basle, 
Switzerland). The statin containing renin inhibitor CGP 29 287 was a gift from dr. 
Hofbauer (Ciba-Geigy, Basle. Switzerland). The World Health Organization (WHO) 
human kidney renin standard 68/356 was obtained from the WHO International 
Laboratory for Biological Standards (London, UK). For studying the optimal conditions 
for in vitro activation of prorenin the following buffers were used: buffer A of pH 3.3, 
consisting of 0.05 M glycin, 0.001 M EDT A and 0.095 M NaCI, and buffer B of pH 7.4, 
consisting of 0.1 M phosphate. 0.001 M EDT A and 0.075 M NaCI. Buffer C of pH 7.4 
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was used for washing tissues and for homogenization; it consisted of 0.01 M phosphate 
and 0.15 M NaCl. 
Collection of Blood and Ocular Tissues 
Blood was obtained from cows at the local slaughterhouse immediately after death. Blood 
was collected in tubes containing sodium citrate (13 mM, final concentration). At the 
same time both eyes were enucleated. Eyes and blood were kept on ice and were processed 
within 60 min. Blood was centrifuged at 4 °C for 10 min at 3000 g, and plasma was 
frozen at -20°C. Eyes were dissected as described below. Dissection and extraction 
procedures were performed at 4 °c. 
Aqueous humor was drawn using a tuberculin syringe with a fine needle. The eye was 
cut equatorially at the ora serrata and the anterior segment was lifted off. The vitreous 
body was isolated by gently shaking it out of the eye cup. Care was taken to remove all 
vitreous. The neural retina was cautiously teased away from the pigment epithelium with 
a thin glass rod and isolated by cutting it at the optic nerve. The choroid with adhering 
pigment epithelium layer was isolated by dissecting it from the sclera with a pair of fine 
scissors. The anterior uveal tract, consisting of iris and ciliary body, was isolated by 
removing the lens from the anterior eye cup, then gently pulling the anterior uveal tract 
loose from the sclera and blotting it on dry paper to remove any adhering vitreous. 
Cornea, lens and sclera were discarded. . 
For the chemical and immunological identification of renin and prorenin in the ocular 
tissue extracts and in plasma, either the retina, the pigment epithelium-choroid or the 
anterior uveal tract of 60 bovine eyes, the vitreous bodies of four eyes or 70 ml of 
bovine plasma were pooled. Tissues were minced with scissors into small pieces and 
washed three times in two volume weights of ice-cold buffer C, in order to remove as 
much plasma as possible. Tissues were homogenized in one volume weight of buffer C 
with aPolytron PTIO/35 (Kinematica,Luzern,Switzeriand) with 2xl5 sec. bursts, level 
10. The Polytron was also used to break the gel structure of the vitreous. Homogenates 
were rapidly frozen and thawed three times and then centrifuged at 4 °C for I hat 13000 
g. Supernatants were decanted and stored at -20°C. Pellets were discarded. Preliminary 
experiments had shown that there was no difference in renin content in extracts that had 
been made in buffer C alone and those made in buffer C containing the protease inhibitors 
PMSF (0.5 mM), EDT A (I mM) and NTT (0.25 mM) (final concentrations)." Apparently 
inadvertent activation of prorenin during the extraction procedures did not take place 
in these extracts. 
The extracts of retina, pigment epithelium-choroid and anterior uveal tract were 
divided into two portions. One portion of each extract was dialyzed against buffer A to 
pH 3.3 for 48 h and subsequently against buffer B to pH 7.4 for 48 h, both at 4°C, after 
which denatured protein was removed by centrifugation. The resulting supernatants were 
dialyzed for 6 h in distilled water, lyophilized and stored at -20°C. The acidification step 
removed effectively much of the angiotensinase activity, which in preliminary experiments 
was found to interfere with the renin assay in non-acidified lyophilized extracts despite 
the use of angiotensinase inhibitors. These Iyophilisates were used for the experiments 
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with renin antiserum or the renin inhibitor remikiren or for a-casein-Sepharose affinity 
chromatography, as described below. The other portion of each homogenate was dialyzed 
against buffer B, pH 7.4, only. The dialyzed homogenates were centrifuged and used to 
establish the optimal method for activatingprorenin. 
For quantification of renin and prorenin in eyes and simultaneously taken plasma, 
eyes from eight cows were studied. Isolated parts of one eye were pooled with the 
corresponding parts of the other eye of the same animal, aqueous and vitreous in equal 
volumes. No washing procedure to remove plasma was included in order not to lose 
tissue renin. Tissues were weighed and one volume weight of buffer C was added. 
Homogenization was performed in the same way as described above. 
To examine whether a concentration gradient exists in the vitreous for prorenin and 
total protein, the vitreous bodies of five eyes that had been snapfrozen in liquid nitrogen 
immediately after enucleation were divided into a posterior, central and anterior part, 
after the surrounding tissues had been peeled off. Aqueous of these eyes had been collected 
rapidly just before freezing. 
Bovine kidney was homogenized in one volume weight of buffer C and submitted to 
pH 3.3 dialysis against buffer A for 48 h; pH was restored to pH 7.4 by dialysis against 
buffer B for 48 h. Denatured protein was removed by centrifugation. The resulting 
supernatant contained renin at a concentration of about 20 mgAnr}.l rul per h) as assessed 
by incubation at pH 7.4 with plasma from nephrectomized rats as a source of renin 
substrate. In most experiments this extract was diluted 300-fold in 0.1 M phosphate 
buffer, pH 7.4. No acid protease activity was detectable at this dilution. 
Identification of Renin 
Affinity Chromatography on a-casein-Sepharose. Aspartyl proteases bind to a-casein 
at low pH. Renin, however, is an exception because of its relatively high pH optimum. 
This property of renin can be used for separating renin from other aspartyl proteases by 
affinity chromatography on a·casein-Sepharose. 15 AHa·casein was coupled to CNBr-
activated Sepharose 4B,15 and a column of 10x1cm was prepared. The column was 
equilibrated with 0.05 M HAc! Ac' buffer, pH 3.5, containingO.075 MNaCI. A lyophilized 
extract of pigment epithelium-choroid was dissolved in this buffer and 1 ml of this 
extract was applied to the column and left to stand for 5 h. Elution was started with 
adsorption buffer at a flow rate of approximately 10 ml/h. After a washout volume of 
90 ml, a 0.1 M Tris/HAc buffer, pH 8.6, containing1.0 M NaCl, was applied and elution 
was continued at a flow rate of 10 ml/h. Fractions of 3 ml were collected. All procedures 
were carried out at 4°C. All fractions were assayed for angiotensin I generating activity 
at pH 7.4 and for acid protease activity at pH 3.5. 
pH Optimum Study. Plasma from nephrectomized rats, which served as a source of 
renin substrate, and the samples to be tested for angiotensin I generating activity were 
brought to appropriate pH by overnight dialysis in separate dialysis bags at 4 °C in 0.1 
M phosphate buffers ranging from pH 5.0 to pH 8.5. Angiotensin I generating activity 
was assessed at these pH's, incubation conditions being the same as in the renin assay 
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described below except for pH. The pH of the incubation mixture did not change more 
than 0.05 pH unit during incubation. The following samples were tested: 1) pool of 
bovine plasma, which was treated with trypsin-Sepharose for activatingprorenin (vide 
infra), 2) dilute bovine kidney extract, 3) bovine vitreous fluid, which was treated with 
acid and plasmin for activating prorenin (vide infra), 4) renin from bovine pigment 
epithelium-choroid purified by a-casein-Sepharose chromatography (vide infra), and 5) 
purified bovine cathepsin D. 
Inhibition of Renin by Renin Antiserum or Renin Inbibitors. The rabbit antiserum 
against bovine pituitary renin at 1:320 dilution caused 50 % inhibition of the angiotensin 
I generating activity at pH 7.4 of a bovine kidney extract with a renin concentration of 
70 ngAngI·ml-l·h-l. 
A 1:40 dilution of antiserum was made in 0.1 M Tris/HCL, pH 7.4, containing 0.1% 
BSA and 0.02% NaN,. Equal volumes of test sample and dilute antiserum were mixed 
and left to stand for 20 h at 4°C. The following samples were tested: 1) bovine plasma, 
after treatment with trypsin-sepharose for activatingprorenin (vide infra}, 2) vitreous fluid, 
which was treated with acid and plasmin for activatingprorenin(vide infra}, 3) lyophilized 
extracts of retina, pigment epithelium·choroid and anterior uveal tract diluted in distilled 
water, 4) bovine kidney extract and 5) renin from pigment epithelium-choroid, purified 
by a-casein-Sepharose affinity chromatography (vide infra). 
To assess the specificity of the antiserum, inhibition experiments were also conducted 
with bovine cathepsin D. Renin assays that followed preincubation with the antiserum 
were performed not only at pH 7.4, but also at pH 5.5 because cathepsin D has little 
angiotensin I generating activity at neutral pH, whereas renin does have angiotensin I 
generating activity at neutral pH as well as at pH 5.5. Controls were samples incubated 
with preimmllne rabbit serum. Results were corrected for the presence of renin in the 
antiserum and preimmuneserum (approximately 3 ngAngI.ml-l.h-I). 
Inhibition of angiotensin I generating activity by two renin inhibitors was assessed by 
performing the renin assay in the presence of different inhibitor concentrations, ranging 
from W-II to W-' mol per liter (final concentration). One inhibitor was remikiren from 
Hoffman-La Roche, a substrate analogue, which is claimed to be enzyme-specific for 
renin. The concentration at which it causes 50 % inhibition (ICJ of human renin is 0.5 
x10-'M in the plasma renin activity assay, in which plasma renin is allowed to react with 
endogenous renin substrate at pH 7.4. TheICso0fthis inhibitor for bovine cathepsin D 
is 3.7xlO·' M, when assessed by proteolysis of denatured hemoglobin at pH 3.5 
(Information provided by the manufacturer). The other renin inhibitor was CGP 29 287 
from Ciba-Geigy, also a substrate analogue, which has been described in reference." CGP 
29287 is a potent inhibitor of human renin but appears to be less effective against dog 
or rat plasma renin, with an IC,oof 1xW-', 2xW-' and 3x10-'M respectively, in the 
plasma renin activity renin assay. 16 Its ICsofor bovine cathepsin D is 4xl0,sM, again 
assessed by proteolysis of denatured hemoglobin at pH 3.5.The samples tested with the 
renin inhibitors were the same as those used for the antiserum inhibition experiments, 
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except for renin purified from ocular tissues by ct-casein-Sepharose chromatography, 
which was only used in the antiserum experiments. 
In order to assess the specificity of the inhibitors for bovine renin, the effect of the 
inhibitors on angiotensin I generating activity of bovine kidney renin was compared with 
their effect on the angiotensin I generating activity of bovine cathepsin D. As in the 
antiserum inhibition experiments, this was done at pH 5.5. The effect of the inhibitors 
on the angiotensin I generating activity of human kidney renin in our renin assay was also 
tested and this was done both at pH 5.5 and 7.4. 
Assays of Renin and Activated Prorenin. Different procedures were attempted for 
activatingprorenin in bovine plasma, vitreous and extracts of retina, pigment epithelium-
choroid and anterior uveal tract. We used three methods that were proven to be successful 
in activating human prorenin. One can either make use of endogenous proteolytic 
activators of prorenin, such as factor xn/kallikrein, plasmin, or pepsin-like proteases, 
or one can add activators, for instance plasmin or trypsin. In two of our methods we 
used an acidification step. Acidification has several effects: 1) pro renin undergoes a 
reversible conformational change of the molecule by which it becomes more susceptible 
to limited proteolysis necessary for irreversible activation, 172) acidification destroys 
inhibitors of prot eases that activate prorenin at neutral pH, like kallikrein or plasmin, " 
and 3) pepsin.like acid proteases, capable of activating prorenin, may become active at 
low pH, like for example in human amniotic fluid." The first method of activation we 
tested in this study consisted of acidification followed by neutralization; no exogenous 
activator was added. Two ml of sample were dialyzed in buffer A for 48 h at 4 ·C. Then 
the dialysis buffer was changed to buffer B, which after 36 h was replaced by buffer B 
containing 6 % PVP to prevent dilution due to colloid·osmosis. Dialysis in the presence 
ofPVP proceeded for another 12 h after which the content of dialysis bags was collected 
by rinsing the interior with buffer B. Volumes were adjusted to 2 mI with the same buffer. 
The second method involved incubation at 4 °C with immobilized trypsin as previously 
described. "Trypsin had been coupled to CNBr-activated Sepharose 4B. The final 
concentration of trypsin was 4.4 xla' Na-Benzoyl·L-Arginine Ethyl Ester (BAEE) units 
per 500 1'1 sample. Activation of prorenin in plasma with this method does not require 
prior acidification. After 48 h incubation trypsin was removed by centrifugation. This 
method is similar to the often used trypsin-soy bean trypsin inhibitor (SBTI) 
combination) 14 with the advantage that destructive proteolysis of pro renin and renin is 
less likely to occur. The third method was an acidification step followed by incubation 
with plasmin at pH 7.4. After plasmin inhibitors have been removed at low pH, exogenous 
plasmin will cause activation of prorenin at neutral pH without destruction of pro renin 
or renin, a problem which is sometimes encountered with trypsin and acid proteases. 
After dialysis for 48 hat 4'C in buffer A, samples were rapidly adjusted to pH 7.4 with 
1 M NaOH. Then 0.1 volume of plasmin solution in 0.15 MNaCI was added to a final 
concentration of 1 Casein unit per mi. Incubation with plasmin was for 48 h at 4 'c. With 
each sample all three procedures were performed in duplicate. 
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Renin and activated prorenin were assayed in duplicate by measuring the rate of 
AngI generation at pH 7.4 and 37'C in the presence of the protease inhibitors PMSF 
(2.4 mM), EDT A (5 mM), 8·0HQ (3.4 mM), aprotinin (2.2 nM) and NEM (5 mM) {final 
concentrations). 14. IS The incubation mixture consisted of one volume of 0.1 M phosphate 
buffer, one volume sample, two volumes of renin substrate and 0.14 volume of inhibitor 
solution. Plasma from nephrectomized rats was the source of renin substrate. The renin 
activity ofthis plasma was less than 0.1 ngAngl.mI·l.h .1. The final substrate concentration 
in the incubate was 2.9 ngAngl equivalents per mI, which was about fourtimes Km' The 
mixtures were incubated for 1,2,3 and in some cases 6 h at 37°c' Angiotensin I was 
measured by radioimmunoassay. IS Only incubations in which angiotensin I generation 
was linear with time were used for renin assay. Recovery of angiotensin I added to the 
incubation mixture was 98 % after 6 h incubation, demonstrating effective inhibition of 
angiotensinase activity. 
Assays of Serum Albumin and Acid Protease. Albumin, as a measure of trapped 
plasma in the ocular tissue extracts, was determined with a single radial immunodiffusion 
technique, as described by Mancini et al." One ml of the BSA antiserum precipitated 
900 mg of BSA. Dilutions of samples were made in 0.07 M barbital, 0.003 M calcium 
lactate and 0.3% Tween 20, pH 8.6. Standard BSA solutions ranged from 5 to 100 mg! 
L. Diffusion into the agar gel plates was allowed to proceed for two days in humidified 
air at room temperature. The agar plates were then stained with coommassie blue. Recovery 
of added albumin ranged from 90·100% in the ocular tissue extracts. 
The acid protease assay was a modification of the method by Anson.20 Briefly, 200 /,1 
sample, which had been brought to pH35 with 1 M HCI, was added to 1 ml hemoglobin 
(I %) in 0.1 M glycine/HAc, pH 3.5, at 37°C, At t-O and t-20 min 500 /,1 of this 
mixture was mixed with 500 /,1 ice·cold 10% trichloroacetic acid (TCA). Denatured 
protein was removed by centrifugation and the absorption at 280 nm of the supernatant 
was read in an Uvikon 810 spectrophotometer (Kontron,Zurich,Switzerland). The 
difference in absorption at 280 nm between 20 and 0 min at 37°C was taken as a measure 
of acid protease activity. Acid protease activity is expressed in units; one unit is the 
proteolytic activity that causes a change in extinction of 1.000 per min at 280 nm by 
TCA·soluble products at pH 3.5 and a temperature of37 °C, with denatured hemoglobin 
as a substrate. 
Results 
Affinity Chromatography 
The protein concentration (absorption at 280 nm), the acid protease activity at pH 3.5 
and the angiotensin I generating activity at pH 7.4 of the eluted fractions from the a· 
casein·Sepharose column are depicted in Fig. 1. Renin·like activity was eluted later than 
the bulk of protein. Most angiotensin I generating activity was found in a broad peak 
eluted at pH 3.5 (peak I). A small amount of angiotensin I generating activity (peak II) 
was eluted after changing the pH to 8.6. Peak I contained renin activity but no acid 
protease activity. Peak II contained acid protease activity. Fractions 13·24 (peak I) were 
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Figure 1. Separation of renin from 
non-renin acid protease in extract 
of bovine pigment eplthellum-
chroid by affinity chromatography 
on a-caseln-Sepharose. Arrow 
indicates change of 0.05 M HAc-
Ac', containing 0.05M NaCt, pH 
3.5, to 0.1 M Tris-HAc buffer, 
containing 1 M NaCt, pH 8.6 
dialyzed against distilled water for 6 h and lyophilized. This preparation was used for 
determining the pH optimum of angiotensin I generation and for inhibition with renin 
antiserum. Peak II was not further evaluated because of its small volume and low renin-
like activity. 
Identification of Renin 
For preparing the extracts that were used for identification studies the tissues were washed 
in order to remove trapped plasma. Measurement of albumin in these extracts showed 
that washing with buffer C had removed 70·85 % of plasma, More than 90 % of the 
angiotensin I generating activity of these extracts could not be accounted for by 
contamination with plasma or by simple diffusion of renin from plasma, 
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Figure 2. pH optimum cuIVes for angiotensin l-generating activity of purified renin from 
bovine plgment-epithelium-choroid (0), activated prorenin from bovine vitreous (A.), 
acUvated prorenin from bovine plasma{O), bovine kidney extract ce) and bovine cathepsin 
D (T) 
The pH optimum curves of angiotensin I generating activity for kidney extract, 
activated prorenin of vitreous and plasma, and purified pigment epithelium-choroid 
renin (peak I of a·casein·Sepharose column) are shown in Fig. 2. During incubation pH 
did not shift more than 0.05 pH.unit. Results are expressed as a percentage of maximal 
Table 1. Angiotensin I-generating activity of various bovine specimens and its Inhibition by 
renin antiserum. 
Sample 
Plasma 
Vitreous 
Retina 
Pigment-epithelium-choroid 
Anterior uveal tract 
Kidney 
PUrified ocular tissue renin 
Cathepsin D 
Ang I generation (ng 
Angllmlh) 
pH 7.4 
5.8 
6.4 
23.4 
40.4 
76.7 
70.1 
10.6 
ND 
pH5.5 
20.1 
2.9 
3.8 
% Inhibition 
pH 7.4 
71 
70 
83 
83 
93 
97 
83 
pH 5.5 
94 
95 
3 
Plasma was treated with trypsin-Sepharose to activate prorenin. Vitreous was treated with 
plasmin after an acidification step In order to activate prorenln. Extracts of pools of bovine 
retina, pigment-epithelium-choroid and anterior uveal tract were dialyzed to pH 3.3 for 48 h 
and then to pH 7.4 for 48 h, before being lyophilized. Bovine kidney extract was treated In a 
similar manner as the eye tissue extracts, but was not lyophilized. PUrified ocular tissue renin 
was from plgment-epithelium-chorold (peak I of a-casein column). For details on preparation of 
samples, see text. Renin assays were perfonned at pH 7.4 or pH 5.5, with and without 
preincubation with antiserum at pH 7.4. Experiments were carried out in duplicate. ND, not 
detectable 
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Figure 3. Inhibition of angiotensIn I-generating activity of extract of bovine anterior uveal 
tract (III ando). bovine kidney extract (OandO) and bovine cathepsin D("fand \1) by the 
renin Inhibitors remikrien (closed symbols) and CGP 29.287 (open symbols). 
angiotensin I generating activity. Curves were similar, with a pH optimum of 6.5-7.0. 
Activated prorenin in plasma and in vitreous appears to have a shoulder in the curve at 
pH 8.0. pH optimum curves were clearly different from the curve of cathepsin D 
angiotensin I generating activity. Angiotensin I generating activity in kidney, retina, pigment 
epithelium-choroid and anterior uveal tract extracts and in vitreous as well as purified 
pigment epithelium-choroid renin was inhibited for. 97, 83, 93, 97, 70 and 82 % 
respectively by the antiserum against bovine pituitary renin (fable 1). No inhibition was 
observed when samples were incubated with preimmune rabbit serum. Cathepsin D was 
not inhibited by the antiserum at pH 5.5, whereas purified pigment epithelium-choroid 
renin was. This demonstrates that the inhibitory activity of the antiserum was retained at 
pH 5.5 and that the antiserum was specific for bovine renin. 
For the sake of clarity only the inhibition curves for kidney renin, anterior uveal tract 
extract and cathepsin D for each of the two renin inhibitors at pH 5.5 are depicted in 
Fig. 3. Samples of the other ocular tissues and vitreous showed identical curves. The 
Table 2. Renin in bovine plasma and various ocular tissue extracts after different procedures 
for activating prorenin. 
Renin activity (ng Ang IfmLh) 
Sample No pH 3.3-->7.4 Trypsln- PH3.3--> 7.4 
activation Sepharose + plasmIn 
plasma 1.6 3.0 5.9 4.1 
Vitreous 0.04 4.7 4.8 6.1 
Retina 0.3 1.6 1.2 2.1 
Pigment-eplthelium-chorold 3.0 3.1 3.2 4.4 
Anterior uveal tract 1.5 2.9 2.2 3.0 
For details on the activation procedures of prorenln, see text. Experiments were carried out In 
duplicate. 
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IClO of :emikiren for bovine renin was approximately 8.3 x 10'9~, where~ for b~vine 
cathepslll D the ICso appeared to be well over lO·'M. There was no difference Illlllhlbltory 
activity of remikiren on human kidney renin at pH 5.5 nor at pH 7.4, proving that in this 
range pH did not influence the inhibitory activity of remikiren. CGP 29 287 was clearly 
less potent th:m remikire?, with an IC~ of2.6 x 1O'7M, which isstill muc.h lower than :he 
IC,ofor bovllle cathepslll D {4 x 10' M}. Apparently, CGP 29 287 IS more specles-
specific than remikiren. 
Activation of Pro renin 
Acidification followed by rapid neutralization and subsequent plasmin treatment resulted 
in the highest renin activity in the ocular tissues and in vitreous (fable 2). Not so, however, 
in plasma, in which treatment with trypsin.Sepharose was the more effective to activate 
prorenin. Activation with trypsin-Sepharose at pH 7.4 {without prior acid treatment} 
and activation with plasmin at pH 7.4 {after acid-treatment} reached a plateau after 48 h 
at 4 °C in all samples tested {results not shown}. Hence for quantification of 'total' renin, 
i.e. renin plus prorenin, in the various compartments of the eye, we chose the acidification-
plasmin method for the eye tissue extracts and for plasma we used the trypsin·Sepharose 
method. From these maximal activation values a percentage of prorenin can be calculated. 
In vitreous prorenin comprised 99 % ofCtotal' renin, in retina 81 %, whereas in pigment 
epithelium-choroid and anterior uveal tract less than 50 % of 'total' renin was prorenin. 
Renin and Prorenin Levels in Different Parts of the Eye 
Table 3 shows the 'total' renin (renin plus prorenin) levels of plasma, aqueous humor, 
vitreous, retina) pigment epithelium-choroid and anterior uveal tract of eight cows, In 
none of the eye samples tested, renin could be accounted for by trapped plasma or by 
Table 3. Total renin (renIn plus prorenln) and serum albumin in bovine plasma and different 
parts of the bovine eye. 
Sample 
Plasma 
Aqueous 
Vitreous 
Rellna 
Pigment epithelium-choroid 
Anterior uveal tract 
Total renIn 
ng Ang I/g 
tissue"h 
6.3±0.5 
0.3±0.04 
5.7±0.4 
5.1±0.7 
14.5±0.8 
10.HO.7 
Tolal renin per Total renin, 
albumin attributable to 
plasma 
ng Ang IImg % 
albumlnh 
0.21±0.02 100 
2.36±0.39 11±2 
26.8±3.6 1±0.2 
16.3±2.0 HO.2 
2.26±0.19 10±1 
6.18±0.50 4±0.3 
The percentage of total renin attributable to contamination with or diffuslonfrom plasma was 
calculated as follows: (albussue/albplasma) x (reninplasma/renlnussue) x 100%. Results were 
obtained from 8 cows and are means ± SEM. 
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simple diffusion from plasma, since the renin/albumin ratio was much higher in the eye 
compartments than in plasma. In pigment epithelium-choroid 10 % of renin could be 
explained by contamination with plasma. In retina and anterior uveal this was only 1 and 
4 % respectively. 'Total' renin levels, expressed as enzymatic activity per ml of fluid, 
were approximately equal in vitreous and plasma. In pigment epithelium-choroid and 
anterior uveal tract the 'totaP renin concentration per gram tissue even surpassed that of 
plasma. 
From Fig.4 it can be seen that a concentration gradient exists for prorenin in the 
vitreous, with levels being highest in the posterior vitreous. There was a large difference 
in pro renin between anterior vitreous and aqueous, which was not apparent for total 
protein. 
Discussion 
A critical problem in studying renin in tissue extracts is the distinction between renin and 
other aspartyl proteases that are present in the tissues. These pepsin-like acid proteases 
act optimally at a pH lower than the pH optimum of 'true' renin. Nevertheless they can 
influence the renin assay in which renin-like activity is detected by angiotensin I generation 
from renin substrate. The presence of acid proteases other than renin can cause an 
overestimation of renin content, even when the reaction is performed at pH 7.4.21 That 
the renin~like activity we detected at pH 7.4 in ocular tissues was due to true renin is 
demonstrated by the following findings. We separated ocular tissue renin from acid 
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protease by a-casein-Sepharose affinity chromatography. The peak that contained renin 
activity but not acid protease activity, showed a pH optimum of 6.5~7, which was similar 
to that of activated prorenin from vitreous and also similar to the pH optimum of 
kidney or plasma renin and very different from the pH optimum of purified cathepsin 
D, which is the most important of the angiotensin I generating acid aspartyl proteases in 
tissues. This almost neutral pH optimum already indicates that we are dealing here with 
'true' renin, since renin is the sole AngI generating aspartyl protease known to have a 
near neutral pH optimum. Definitive proof that the renin-like activity in the eye extracts 
is true renin, was obtained by inhibition of enzymatic activity with a specific antiserum 
and with two experimental renin inhibitors, remikiren and CGP 29287, whereas purified 
bovine cathepsin D was inhibited by neither antiserum nor the renin inhibitors. 
Another problem in the present study is that the eye is a highly vascularized organ so 
that ocular tissue extracts are heavily contaminated with plasma. Renin-like activity in 
tissue extracts may therefore be due to kidney·derived renin present in plasma. Obviously 
we could not perform nephrectomy to eliminate this source of renin, so we had to correct 
for plasma renin in the tissues. \Y,le did not wash the tissues for quantification studies in 
order not to lose any tissue renin. Determination of albumin content of the ocular 
speciments and of simultaneously taken plasma showed that plasma renin was of no or 
minor importance, since the renin/albumin ratio in eye structures was much higher than 
in plasma. In the experiments aimed at the identification of renin in the ocular tissues we 
washed the tissues first gently in buffer and in this way we were able to remove some 
80% of the plasma, as estimated by measurement of the albumin concentration. 
Consequently some 80% of plasma renin was removed. The remainder of plasma renin 
in the resulting extracts was negligible relative to tissue renin, i.e. extravascular renin, 
since in the extracts that had not been washed, tissue renin already exceeded plasma 
renin by far. 
Little is known about activation of bovine prorenin. Activation is possible with 
trypsin22 but in tissues this has never been proven to be the optimal method. Moreover 
we were dealing with two kinds of specimens, namely plasma and tissue extracts, which 
were very different in composition and may require different procedures for activating 
prorenin. We examined different methods in order to establish optimal activation 
conditions. Together they cover the activation mechanisms that are known for human 
prorenin. From our results it appears that in bovine materials endogenous activators 
play a less important role in the in-vitro activation of prorenin than in human plasma. In 
bovine plasma it was not possible to activate prorenin maximally by acidification followed 
by a neutral phase. In human plasma this occurs via the factor xnlkallikrein pathway." 
In tissue extracts acidification is supposed to activate acid proteases that in turn will 
activate prorenin. 17 However in the bovine ocular tissue extracts acidification alone did 
not yield optimal restdts. These were obtained when plasmin was added during the neutral 
phase after the acidification step. Plasmin is known to be an effective activator also of 
human prorenin. Acid-pretreatment was a prerequisite for the activation of pro renin by 
plasmin; plasmin alone did not give activation in the ocular tissue extracts. In vitreous, 
155 
CHAPTER 5.2 
however, acidification was not necessary (results not shown), probably because of the 
low content of plasmin inhibitors. 
Some remarks can be made on the observed reninlprorenin ratio's. Little activation 
of pro renin seems to occur during the preparation of the ocular tissue extracts; the 
addition of inhibitors acting on different groups of proteases during preparation of 
these extracts had no effect on the renin/prorenin ratio. Our finding of bovine vitreous 
containing almost exclusively prorenin is consistent with our measurements in human 
vitreous, in that also human vitreous contains much more pro renin than renin. 
Furthermore the renin/prorenin ratio in the various parts of the eye differs from that in 
plasma. This difference suggests that a separate regulation mechanism exists for renin in 
plasma and in the eye and, possibly, that renin in the eye is produced locally. A striking 
analogy exists with the situation in the bovine ovary.22 In follicular fluid the proreninl 
renin ratio is greater than 30, like in vitreous, whereas in the surrounding theca cells this 
ratio is approximately one, as compared to 0.7-4.0 in retina and uveal tract. 
From our results it cannot be said whether renin in the eye is located intra- or 
extracellularly. Nor is it possible to conclude whether renin is synthesized locally in the 
eye or sequestered from plasma. Binding of prorenin to cells has been reported recently'4 
and this would be compatible with sequestration from plasma. However, binding was 
followed by internalization and activation of prorenin. Although this would explain the 
presence of pro renin and renin in the tissues, it would not account for the presence of 
prorenin in the vitreous. The distribution of renin and prorenin at various sites in the eye 
('fable 1) suggests local synthesis. Vitreous, being the large extracellular space in the eye, 
has a high percentage of prorenin, which is in agreement with findings of others that 
extrarenal renin synthesis is accompanied by secretion of exclusively prorenin into the 
extracellular fluid.7.'. 15 Evidence for expression of the renin gene in human choroid and 
retina,25 and in rat anterior uveal tract,26 has been obtained indeed. The higher 
concentration of prorenin in the posterior segment of the vitreous (Fig.4) suggests that 
the origin of vitreous prorenin is located either in the posterior retina or in the posterior 
uveal tract, analogous to the total protein in the vitreous. 27 One problem with the uveal 
tract as a source of vitreous prorenin is that, in order to explain the high levels in vitreous, 
prorenin has to be transferred across the retinal pigment epithelium which, by virtue of 
its tight junctions, is part of the blood-retinal barrier. This barrier is little permeable to 
proteins. Still, the high renin concentrations in the anterior and posterior uvea make this 
tissue a candidate for production of renin. Production in the retina is also conceivable. 
In the brain the same cell types that are present in the retina, both neuronal and glial cells, 
have been shown to synthesize renin.28 Very recently a renin variant has been described 
in neuronal cells that is the result of translation from a renin mRNA variant. 29 This 
variant (designated as renin b) results from different transcription initiation with alternative 
splicing and lacks the pre- and part of the propeptide of prorenin. Apparently it is not 
secreted and hence, again, the presence of pro renin in the vitreous is not explained by 
this renin variant. Immunohistochemical studies have suggested that the retinal Muller 
cells are the source of renin.JO Renin was predominant in the anterior part of these 
macroglial cells that is in intimate contact with the retinal capillaries. Prorenin was located 
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at the posterior pole of the cells. Another group detected prorenin in human ciliary 
body by immuno-staining,31 rather than in the retina. This raises the possibility that 
prorenin produced in the ciliary body is secreted into the aqueous. However, we found a 
large difference between prorenin in anterior vitreous and aqueous. From there it may 
diffuse into the vitreous. However, we found prorenin in aqueous to be much lower than 
in the vitreous, and it is difficult to conceive how pro renin could be transported from a 
lower concentration in aqueous to a higher concentration in the vitreous. Since vitreous 
can be considered the sink of products originating from the retina,32 its high level of 
prorenin might best be explained by production in and secretion from the retina. The 
renin/ pro renin ratio is quite different in uveal tissues on one hand and in retina and 
vitreous on the other hand, suggesting a third option that two distinct renin-producing 
systems exist in uvea and in retina separated by the blood-retinal barrier. 
Reports have been published on components of the renin-angiotensin system in the 
eye. Angiotensin converting enzyme has been found in bovine retina, in both vascular 
and neural fractions. 33 Binding sites of angiotensin II are present in eye-vessels,34 
apparently also on the abluminal side) not in reach of systemic angiotensin II, since 
intravitreal administration of this peptide causes vasoconstriction. 35 Angiotensinogen 
has been detected in the ciliary-epithelium by the sarne group that described the presence 
of prorenin in this tissue.36 Angiotensin II type 1 receptor mRNA appears to be present 
in rat retina.37 Finally, direct angiotensin measurements have been performed. 17• 18 Both 
angiotensin I and II are present in ocular tissues at concentrations that could not be 
explained by admixture of blood, suggesting that both peptides are produced locally. In 
normal porcine eyes virtually no angiotensin was present in vitreous and aqueous fluid) 
which is evidence for the eye being a highly compartmentalized organ. 
The function of a renin-angiotensin system in the eye is not clear. The higher 
concentration of renin in the uveal tract suggests that its major function is exerted there. 
Since the uveal tract is extremely vascular and angiotensin n is a vasoactive peptide it 
may serve a role in local blood supply. Reports are contradictory: one describes an 
important role for angiotensins in the control of the ophthalmic microcircuiation40 in 
perfused porcine eyes. The other presents data that angiotensin II is not a major 
determinant of ocular blood flow in healthy human subjects." Topical administration 
of an angiotensin converting enzyme inhibitor to the eye lowers intraocular pressure.41• 
43 The renin-angiotensin system may therefore playa role in the control of intraocular 
pressure, possibly, in view of the presence of prorenin in the ciliary body," through an 
effect on the production of aqueous humor. The iris sphincter muscle of dogs, located 
near the ciliary body, appears to be responsive to angiotensin II. H Angiotensin II has 
trophic and mitogenic actions on vascular smooth muscle and other cells. 45 We found 
pro renin to be increased in human vitreous from patients with proliferative diabetic 
retinopathy (see preceding chapter). In view of possible angiogenic effects of angiotensin 
1146 the renin-angiotensin system may be a causative factor in proliferative retinopathy. 
In the ovary such a role of renin-angiotensin II has been proposed for the rapid 
vascularization of the developing corpus luteum which occurs after ovulation. 47 Inhibition 
of angiotensin converting enzyme in the isolated perfused feline eye causes changes in 
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the electrophysiological response of the retina to light,48 suggesting that angiotensin II 
may have some neuromodulatory role in the retina. This was also suggested by a study in 
humans." Finally, angiotensin II may have an angiotensin II receptor type 2-specific 
neurotrophic action. 50 
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Pro renin, the enzymatically inactive precursor of the aspartic protease renin, circulates 
in blood plasma at a concentration that, in normal humans, is on average 9 times that of 
renin. It consists of a single polypeptide chain, which, three-dimensionally, is arranged 
into a bilobal renin part covalently connected with the N-terminal 43 amino acid-
propeptide. The two lobes of the renin part are separated by a deep cleft containing the 
enzyme's active site. The propeptide is likely to be folded in the enzymatic cleft, thereby 
obstructing the active site. In vitro, prorenin acquires enzymatic activity, not only by limited 
proteolysis cleaving the propeptide from the renin part, but also non-proteolytically and 
reversibly by incubation at low pH or low temperature. It is unknown whether this non-
proteolytic activation occurs in vivo. 
Proteolytic activation takes place in the kidney mainly in the juxtaglomerular cells, 
but probably also in some extrarenal tissues and cells. In recent years the notion has 
emerged that renin and/or prorenin may exert their actions at the tissue level rather than 
in the circulation. The present thesis adresses some issues concerning the structural aspects 
of the non~proteolytic activation of prorenio, its implications for renin and pro renin 
measurements, the aberrant regulation of circulating levels of prorenin in diabetes mellitus, 
and finally the presence of pro renin in extrarenal tissues. 
Central in chapter 2 is our discovery that remikiren, an active site-directed renin inhibitor, 
is capable of binding to prorenin. By doing so it induces a conformation which is 
recognized by a monoclonal antibody that is specific for an epitope expressed on renin 
but not on native, enzymatically inactive, prorenin. Although the prorenin·remikiren 
complex lacks enzymatic activity, we designate this remikiren·induced process as 
"activation". The observation that the active site of prorenin is accessible to remikiren 
and our study of the kinetics of remikiren·induced prorenin activation indicated the 
existence of an intermediate form of pro renin, which is in rapid equilibrium with the 
native species (chapter 2.1). 
Recently we obtained monoclonal antibodies that were directed at epitopes of the 
prorenin·propeptide. These epitopes are not expressed on native prorenin but are readily 
recognized in prorenin treated by remikiren or incubated at low pH. Proteolytic removal 
of the propeptide by plasmin abolished binding of these monoclonals. Since the process 
of activation at 4 °C is very slow compared to the binding rates of the monoclonals, it 
was possible to follow the kinetics of activation. Enzymatic activity developed at the 
same rate as the unmasking of propeptide and renin epitopes and the maximal activation 
rates were similar with exposure to remikiren and with exposure to low pH, suggesting 
a similar activation mechanism. \Y./e constructed a model of non.proteolytic prorenin 
activation that was based on these observations and on published data on other aspartic 
proteases. In this model prorenin may changes into an intermediate form in which the 
active site is accessible to small ligands but not to natural angiotensinogen. In this 
intermediate conformation the propeptide is presumably still located in the enzymatic 
cleft, since there was no binding to specific propeptide-monoclonals and no enzymatic 
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activity. From this intermediate state pro renin slowly progresses to its active state, in 
which the active site is freely accessible and the propeptide is totally detached from the 
enzymatic cleft, though still covalently connected with the renin part (chapter 2.2). 
Site-directed mutagenesis studies reported by others indicated that substitution of 
the proline residue in the propeptide at position -4 of the start of the renin sequence by 
alanine abolished the proteolytic processing of prorenin into renin in a cell line that, 
after transfection with a wild-type prorenin cDNA containing plasmid, produced renin 
as well as prorenin.1t is possible that proline is essential for the reco;;nition ofthe activation 
site by the (unidentified) processing protease. An alternative hypothesis is that the proline 
residue permits a conformational change of the prosegment through cis-trans 
isomeriution, which is typical for proline residues. This isomeriution might be a necessary 
first step for subsequent processing by the activation protease. We speculated that in this 
case that this conformational change caused by isomerization is the same as the change 
into the intermediate form postulated in the preceding two chapters. This hypothesis 
predicts that this prorenin mutant cannot be activated by remikiren or by cold or by 
incubation at low pH. However, we found that non-proteolytic activation of the mutated 
prorenin occurred at about the same rate as wild-type prorenin. \Vle therefore conclude 
that the proline residue at position -4 is not involved in the first step of proremn activation 
in vitro, as observed in our experiments (chapter 2.3). 
Remikiren was also used to study the kinetics of reversible prorenin activation and 
inactivation at different temperatures. Pure recombinant pro renin acquires up to 15% 
of maximal enzymatic activity upon prolonged (days) incubation at low temperature 
(4°C). This activation is reversible upon incubation at 37°C. We used simple models to 
describe inactivation and inactivation. Enzyme-kinetic assays and immunoradiometric 
assays were used to detect active prorellin. Remikiren promoted activation and retarded 
inactivation. As with remikiren, binding of the natural ligand, angiotensinogen, retarded 
the inactivation of prorenin. Angiotensinogen, however, was not capable of promoting 
prorellin activation. Our kinetic experiments indicate that the activation rate of prorenin 
is relatively independent of temperature and that the inactivation rate is highly temperature-
dependent (chapter 2.4). 
Chapter 3 applies some of the insights obtained by the results of chapter 1 to the 
methodology of renin and prorenin measurements. An immunoradiometric assay we 
often use for renin measurement overestimates renin level when renin levels are low and 
prorenin levels high, as is often the case in patients with diabetes mellitus. TillS is explained 
by co-measurement of 1.5% of prorenin as renin. We hypothesized that this is due to 
activation of prorenin during the long incubation time (24h) of the assay and the incubation 
temperature (22°C). Incubation for 6 hours at 37°C indeed abolished the co-measurement 
of pro renin as renin. Performance of the assay was not adversely affected by incubation 
at 37°C, and the assay proved adequate for renin measurement in the clinical setting 
(chapter 3.1). We also describe a new, immunoradiometric assay ~RMA) of prorenin. It 
is a direct assay, as opposed to indirect assays that first measure renin, then measure 
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renin plus prorenin after activation of prorenin. In such indirect assays the prorenin level 
is calculated as the difference between the results before and after prorenin activation. 
The new IRMA employs a monoclonal directed at the propeptide of prorenin, which 
is expressed after incubation of prorenin with remikiren, as described in chapter 2. This 
antibody is biotinylated and immobilized by linkage to avidin·coated plastic beads. 
Remikiren-treated plasma prorenin is specifically bound by the immobilized antibody 
and subsequently incubated with a radiolabeled antibody against active renin, which is 
the same monoclonal we used in the IRMA of renin. Results of the prorenin IRMA were 
identical to those obtained by the indirect enzyme-kinetic and immunological assays. 
The standard for the direct prorenin IRMA is remikiren-treated recombinant prorenin 
and since this preparation expresses specific renin and prorenin epitopes it can serve as 
a universal standard for both renin and prorenin assays. Performance of the new direct 
prorenin IRMA is excellent in clinical samples, though not superiorto the indirect IRMA 
employing remikiren.lts use will be indispensable to monitor renin and prorenin levels 
in plasmas of patients treated with renin inhibitors, since pro renin is measured by the 
indirect IRMA as renin in these patients (chapter 3.2). 
Chapter 4 aims to investigate the deranged prorenin physiology in diabetes mellitus. It is 
now well established that patients with insulin-dependent diabetes mellitus and 
microvascular complications like retinopathy and nephropathy, have high levels of plasma 
prorenin. We measured serum prorenin in yearly obtained serum samples during a 10-
year follow-up in 199 normoalbuminuric patients with type 1 diabetes mellitus. In 29 
patients who developed microalbuminuria the prorenin level, but not the renin level, 
increased before the onset of microalbuminuria. Microalbuminuria precedes the 
development of diabetic nephropathy. Apparently, renin! prorenin physiology is disturbed 
very early in the course of events thatlead to nephropathy. This, together with the clinical 
observation that pharmacologic interference with the renin-angiotensin system (through 
ACE inhibition) has a beneficial effect on progression of nephropathy, suggests that 
prorenin, either itself or through the formation of renin, is involved in the pathogenesis 
of this diabetic complication. A practical implication is the fact that the measurement of 
prorenin can be used to predict future microalbuminuria. This has potential clinical value 
in the management of diabetic patients (chapter 4.1). 
Our next study was inspired by the fact that only a subset of diabetic patients develops 
nephropathy and by the many reports that predisposition to nephropathy is genetically 
determined. The patient group we studied was from Denmark and has been studied by 
others for association of variation in the angiotensinogen, ACE and angiotensin type 1 
receptor genes with nephropathy. Here we studied plasma renin and prorenin and variation 
in the renin gene in this study group. of the various components of the renin-angiotensin 
system, renin and prorenin are altered. Renin and pro renin are increased, but the increase 
in prorenin is disproportionate with respect to that in renin. The rise in renin is somewhat 
unexpected, since older literature often reported normal or even decreased renin levels 
in diabetic nephropathy. One polymorphic marker in the first intron of the renin gene 
was weakly associated with nephropathy and could have a recessive deleterious effect. 
163 
This strengthens the notion that perhaps increased renin or pro renin is instrumental in 
the development and progression of diabetic nephropathy (chapter 4.2). 
Chapter 5 is concerned with tissue prorenin and renin. \Y/e measured renin and prorenin 
in two distinctive tissue fluids, namely subretinal and vitreous fluid obtained during eye 
surgery. Prorenin and renin were present at levels that could not be explained by plasma 
contamination. Apparently some mechanism exists that causes high local levels of 
prorenin and renin. Whether this mechanism is local synthesis or uptake from plasma is 
not known (chapter 5.1). These findings from pathologic human specimens were 
corroborated by the findings in normal bovine eye tissues. Pro renin was present in 
chorioid and retina tissue, as well as in vitreous and aqueous fluid, at levels that were 
substantially higherthan the levels in plasma. Again the mechanism leading to these high 
concentrations remains unidentified, although various studies report local expression of 
the renin gene (chapter 5.2). Other components of the renin.angiotensin also have been 
identified in the eye, most notably high levels on Angll in the eye tissues. Messenger 
RNA of angiotensinogen, ACE and A TIR, has been found suggesting local synthesis. 
The function of a local renin~angiotensin system in the eye is unknown. Evidence has 
been obtained for a role of Angll in blood flow and intraocular pressure regulation, but 
AnglI may be a neuromodulatory factor too in the retina. The findings of chapter 5 
support the concept oflocal RASs and confirm the predominance of prorenin in these 
local systems. However, whether pro renin has a direct role in these systems remains to 
be determined. 
Where do the results described in this thesis leave us? First, the question of whether 
prorenin fulfills any physiologic role other than being the intrarenal precursor of renin 
remains unanswered and gnawing. In the absence of evidence for proteolytic or non~ 
proteolytic activation of pro renin in the circulation, the most likely site for a role of 
pro renin from blood plasma is at the tissue level, either in the interstitial fluid or at the 
cell surface or in the cells after prorenin has been taken up by the cells. The results of 
chapter 5 and many reports in the literature show that pro renin and renin are present at 
considerable concentrations at diverse tissue sites. \Y/ e know from chapter 2 that non~ 
proteolytic activation is possible at physiologic pH and temperature, provided that 
inactivation of prorenin is precluded. Thus, factors that might cause activation of prorenin 
by inhibiting inactivation should be looked for if non.proteolytic activation is ever to be 
proven to be physiologically important. Recently our group described the binding of 
pro renin to cardiomyocytes. 1 After its binding, prorenin is internalized and activated, 
most probably by limited proteolysis. It has been shown that pro renin is more readily 
activated if it is in the active state with the propeptide out of the enzymatic cleft' . It is 
possible that binding to the putative receptor induces or fixates the enzymatically active 
conformation of prorenin and that this conformation is the substrate for subsequent, 
irreversible, proteolyic activation. 
These new developments may ultimately lead to the acceptance of a hybrid paradigm, 
which implies that 1) the renin-angiotensin system is an endocrine system as far as renin is 
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concerned, 2) prorenin acts both in an endocrine and paracrine fashion, andJ) angiotensin 
II acts in an autocrine or paracrine fashion. The internalization of {pro)renin and the 
emerging reports on intracellular AngIIJ-6 may even lead to a concept of an intracrine 
renin-angiotensin system. All in all it is possible that the termpYOl~ni"-,.eni,,-{/ngiotensi,, system 
will prove to be more appropriate than the term renin·angiotensin system. In my view it 
is essential for acceptance of this concept that the role of angiotensinogeo, until now 
somewhat neglected, be elucidated. 
Our future research on prorenin will be directed at cellular binding and activation of 
pro renin. The monoclonal antibodies that have recently become available and have already 
been useful in the studies of this thesis, will enable us to identify the nature and extent of 
activation steps that occur during and after cell binding. This may ultimately provide an 
answer to the question of whether reversible activation of prorenin is more than an in-
vitro phenomenon. Interest in the reported connections between the plasma contact 
activation system and the activation of prorenin (see first chapter) may be revived, because 
many protease inhibitors of the contact activation system in plasma are probably not 
present at the tissue level. More insight in the phenomenon of (pro)renin binding may 
also teach us about the significance of high prorenin levels at the very early stages of 
diabetic nephropathy. As mentioned above, the role angiotensinogen also needs 
clarification. Although somewhat alien to our expertise we would also like to address 
this issue. Essential for this work is good measurement technology. With the IRMAs 
described in this thesis we are confident that we are well equipped to measure the various 
conformations of prorenin and renin in physiological and pathological conditions. 
The development of a new universal proreninl renin standard, consisting of 
recombinant human prorenin, treated with remikiren, that expresses specific epitopes 
of both renin and prorenin should be undertaken in an international collaboration. If 
this standard can be established, the gain is obvious: after one century of renin research 
there will be at last an opportunity to rigorously compare the results of different 
laboratories. 
The results presented in chapter 4.1 need confirmation in other diabetic populations, 
because they may have important consequences for clinical management. Currently we 
are starting a new project in which we will study a group of patients with type 1 diabetes 
mellitus that have been followed from the start of diabetes to see whether in this group 
elevated prorenin and glycated hemoglobin levels precede microalbuminuria. In this 
group it can also be tested whether the same holds true for the development of 
retinopathy, which, in its proliferative form, is also associated with increased prorenin 
levels. If the findings of chapter 4.1 are confirmed, a study can be envisaged in which 
prorenin and glycated hemoglobin levels are used to identify normoalbuminuric, 
normotensive, patients at risk of microalbuminuria. These can then be aHocated for 
ACE inhibitor treatment. 
Studying the biochemistry of prorenin activation by direct observation through 
spectroscopy is attractive and potentially more powerful than the methodology we have 
used thus far. Raman spectroscopy may be suitable for this goal. Furthermore, in a 
reductionist's view, life's events occur at the cell membrane, with the actions of the renin-
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angiotensin system probably no exception to that.Why not, then, study life or the RAS at 
that level? Again, Raman spectroscopy, combined with confocal microscopy may permit 
to study the processes during the aforementioned cell binding and internalization of 
prorenin. However, we shall have to await further development of these techniques, 
which are still in their infancy for this kind of application. 
In the genetic engineering field, an animal in which the renin gene can be knocked·out 
selectively in any organ at any moment in life provides an opportuniry to study (pro)renin 
deprivation in intact, normally developed, animals. The Cre·lox approach' allows to 
construct such animals (please note the connotation of a deity·like faculty of mankind 
'to construct an animal'). The intrarenal processing of prorenin to renin is still not 
understood. Afterthe identification olthe processing enzyme -let us hope it is only one-
and the cloning of its gene, one may 'construct' knock-out animals for this enzyme. If 
this can be achieved it will be possible to study animals without renin but with 'normal' 
prorenin physiology. Such studies may also indicate whether the prorenin processing 
enzyme is an attractive target for drug therapy in, for instance, hypertension. Only then 
perhaps, we shall be able to refute the statement that prorenin is not worth bothering ... 
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Kort Verslag AAN MIJN OMA, MI/N OVERIGE FA MIllE, en de belasHngbetaler 
Hart- en vaatziekten zijn tegenwoordig goed te voorkomen en behandelen. Toch blijft 
cen gestoorde bloedsomloop, veroorzaakt door hart~en vaatziekten, een van de 
belangrijkste oorzaken van lijden en sterven. Een belangrijke rol in het handhaven, maar 
sams oak in het verstoren van cen goede bloedsomloop speelt het renine·angiotensine 
~steem. Hoewel artsen aI wel beschikken over succesvolle medicijnen die gericht zijn op 
dit systeem, weten we nog maar weinig van dit systeem af. In het nu volgende zal ik u 
verslag doen van het onderzoek dat we uitgevoerd hebben naar een raadselachtig 
onderdeel van dit systeem, prorenine. 
Prorenine is de voorloper van het eiwitsplitsende enzym (erotease) renine, dat wordt 
gemaakt in de nier en daarna in het bloed wordt uitgescheiden. Renine splitst in het 
bloed van het eiwit angiotensinogeen cen stukje af, angiotensine I, dat vervolgens door 
cen anderenzym, angiotensin converting-enzyme (ACE), wordt omgezet in angiotensine 
II. Angiotensine II speelt een belangrijke rol bij het handhaven van de bloeddruk en bij 
het regelen van de hoeveelheid zout en water in het lichaarn. 
\Y./ e weten niet of in het lichaam prorenine net als renine enzymatisch actief is, dat wil 
zeggen cen rol speelt bij de vormingvan angiotensine ll. In een reageerbuisje met prorenine 
en angiotensinogeen gebeurt in ieder gevaI niets bi; 37°C en een normale zuurgraad. 
Waarom dan onze belangstellingvoor prorenine? 
Allereerst, niet aileen reninc wordt uitgescheiden in het bloed, maar oak prorenine. 
De concentratie van prorenine in het bloed van normale mensen is zelfs ongeveer 9 keer 
zo hoog als die van renine. Als dat prorenine weI betrokken zou raken bij angiotensine 
ll-vorming, zou dat een forse stijgingvan het angiotensine II kunnen betekenen. Dit zou 
tot een misschien gevaarlijke verhogingvan de bloeddruk kunnen leiden. Maar ook als 
prorenine maar een klein beetje enzymatische activiteit heeft zou dat belangrijk voor de 
bloeddruk kunnen zijn. 
Een ander rechtvaardiging voor onze belangstelling is dat aile zoogdieren die 
onderzocht zijn, prorenine in hun bloed hebben. Dat is waarschijnlijk niet voor niets 
('onze Lieve Heer heeft daar vast een bedoeling mee gehad'). 
Renine is een eiwit en bestaat uit een keten van aminozuren. Deze keten is zo 
opgevouwen dat een tweelobbig molecuul ontstaat. Bij prorenine zit aan dit renine-
molecuul een keten van 43 aminozuren, die we het propeptide noemen. Dit propeptide 
wordt in de nier afgeknipt zodat rerrine ontstaat. Tussen de twee lobben van het renine-
molecuul bevindt zich een diepe enzymatische spleet, waarin het actieve centrum zich 
bevindt. Dit is de plaats waar het enzym zijn eiwitsplitsende taak uitvoert. Er bevinden 
zich in dit actieve centnlm twee zg. aspartyl aminozuren. \Y/ e rekenen renine dan oak tot 
de zogenaamde aspartyl proteases. Deze hebben aile twee lob ben met een diepe 
enzymatische spleet ertussen met de twee aspartyl groepen. De bekendste voorbeelden 
van andere aspartyl proteasen zijn wei chymosine, dat in het zure stremsel zit waarmee 
kaas wordt gemaakt, en pepsine, dat in het zure maagsap veer de verteringvan eiwitten 
zorgt. In prorenine is het propeptide waarschijnlijk op zodanige wijze in het aktieve 
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(a) (b) (c) 
De verschijningsvonnen van renine en prorenlne. (a),laatrenine zien. De enzymaUsche spleet 
(,spleet') tussen de twee lobben Is open en toegankelijk voor angiotensinogeen. (b) faat prorenine 
zien. Het propeplide sluit de toegang tot het actieve centrum at. (e) laat actief prorenine zien. 
Het propeptide zit neg wei aan het molecuul vast, maar sluU het actieve centrum niet meer at. 
A is een aspartyl groep van het acUeve centrum 
centrum gevouwen dat angiotensinogeen niet hi; het actieve centrum kan kamen. Andere 
aspartyl proteasen kennen ook zo'n inactievevoorloper met cen propeptide. 
In een reageerbuis kan prorenine weI enzymatisch actief worden, niet alleen door het 
propeptide af te knippen, maarook door prorenine bij lage pH (d.w.z. een zure omgeving) 
en lage temperatuur te laten staan. In dat laatste geval blijft het propeptide wel aan het 
molecuul vast zitten maar zwaait het waarschijnlijk naar huiten zodat angiotensinogeen 
wei bij het actievecentrum kan komen. Bij normale pH en een hoge temperatuurverdwijnt 
de activiteit van prorenine weer. Deze eigenschap, dat prorenine onder speciale, met 
name zure omstandigheden ook eiwitsplitsende activiteit kan hebben, is ook bekend van 
voorlopers van andere aspartyl proteasen. Bij die andere aspartyl proteasen is het zelfs 
zo dat zo'n geactiveerde voorloper bij zichzelfhet propeptide kan afknippen. Dit kan 
pro renin echter niet. Het verschijnsel doet wei weer de vraag rijzen of in het lichaam 
omstandigheden voorkomen waarbij prorenine actief is en versterkt ooze belangstelling 
voor proremne. 
Er is in de laatste jaren duidelijk geworden dat prorenine niet aileen in de nieren 
gemaakt wordt maar ook elders in het lichaam. Men denkt ook dat de angiotensine II 
vorming voornamelijk buiten de bloedstroom plaatsvindt in de weefsels. Het zou heel 
goed kunnen zijn dat prorenine, dat ter plaatse wordt gemaakt, daarbij een grote rol 
speelt. 
Een laatste reden voor onze belangstelling v~~r prorenine is dat bij sommige 
aandoeningen prorenine in het bloed erg hoog is. Dit is bijvoorbeeld zo bij suikerziekte, 
waarhij de nieren aangetast zijn. Waarom prorenin zo hoog is, is onbekend. 
In dit proefschrift is een aantal aspecten van prorenine onderzocht, met als doel 
erachter proheren te komen of prorenine, behalve als voorloper van renine, nog een 
andere rol speelt in het renin-angiotensine systeem. Ten eerste (hoofdstuk 2) hebben we 
getracht meer inzicht in de structuur of vorm van prorenine te verkrijgen. Hoe en 
onder welke omstandigheden verandert die vorm en wat zijn de gevolgen voor de 
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enzymatische activiteit van prorenine? Wij hebben ontdekt dat remikirenJ een medicijn 
dat renine remt door in de enzymatische spleet te gaan zitten, ook aan prorenine kan 
binden. We denken dat remikiren in plaats van het propeptide in de spleet gaat zitten. 
Het propeptide zwaait dan uit de enzymatische spIeet, net aIs wanneer prorenine wordt 
aangezuurd of in de kou wordt weggezet (Figuur). AIleen gebeurt de remikiren binding 
ook bij 37 °C en neutrale pH. Verder moeten we aannemen dat onder deze normale 
omstandigheden er een tussenvorm van prorenine bestaat, waarin er nog geen 
enzymatische activiteit bestaat, maar al wei het propeptide een beetje aan de kant 
geschoven is, zodat remikiren kan binden. Prorenine verandert na binding van remikiren 
dan zodanig dat het herkend wordt als renine door antistoffen die aileen maar renine en 
niet prorenine kunnen herkennen. \Xlij hebben dit door remikiren veroorzaakte 
versehijnsel gebruikt om de vormverandering van prorenine die gepaard gaat met 
activering, te bestuderen onderverschillende omstandigheden. Het was daardoor mogelijk 
een model te maken van de aetivering van prorenine. Verder hebben we aannemelijk 
gemaakt dat ook bij normaIe liehaamstemperatuur en -zuurgraad prorenine astief kan 
worden. Er is dan aileen cen extra factor nodig die voorkomt dat prorenine zijn 
enzymatische activiteit weerverliest. Of deze factor bestaat en welke dat is, is niet bekend. 
In het reageerbuisje kan angiotensinogeen in geringe mate ervoor zorgen dat aetief 
gemaakt prorenine (door aanzuren) actief blijft. Dat is wei voor te stellen: als 
angiotensinogeen in de enzymatisehe spleet zit. kan het propeptide er niet in. 
In hoofdstuk 3 wordt een aantal methoden beschreven hoe renine en prorenine het 
beste gemeten kunnen worden. Dit isvan belangom een indruk te krijgen hoe het lichaam 
prorenine en renin reguleert. Door de resultaten van hoofdstuk 2 begrijpen we beter hoe 
prorenine en renine eruit zien en hoe ze van elkaar onderseheiden kunnen worden. We 
do en dat met antistoffen die aIleen maar kunnen binden aan 6f renine en prorenine, 6f 
aan renine aIleen 6f aan prorenine aIleen. Onze nieuwe methoden zijn zeer geschikt voor 
metingen in het bloed. Bovendien kunnen ze gemakkelijk gestandaardiseerd worden, 
wat betekent dat elk laboratorium op de wereld dezelfde Guiste) uitslagen geeft voor 
dezelfde bloedmonsters. Dat laatste is al een eeuw lang een groot probleem in de renine-
wereld: een reninewaarde in een bepaaId monster kan in het ene laboratorium totaal 
anders uitpakken dan in een ander. 
Het vierde en vijfde hoofdstuk gaan over de regulatie van prorenine. Hoofdstuk vier 
behandelt het verband tussen suikerziekte en en prorenine. Bij suikerziekte met 
nieraantasting (diabetische nefropathie) is het prorenine-gehalte van het bloed meestal 
sterk verhoogd. Het Steno Diabetes Centrum, een groat ziekenhuis in Denemarken, 
behandelt aileen mensen met suikerziekte. Deze patienten worden intensief gecontroleerd 
en gegevens en bloedmonsters van deze patienten worden zorgvuldig bewaard. \Xle 
werden in de gelegenheid gesteld ook een grote groep van deze patienten te bestuderen. 
We laten in hoofdstuk 4.1 zien dat prorenine aI stijgt voordat het de dokter duidelijk 
wordt dat de patient een diabetische nefropathie ontwikkelt. Het lijkt er zelfs op dat je 
prorenine kunt gebruiken om het risico op het ontwikkelen van de diabetische nefropathie 
te bepalen. Als prorenine verhoogd is, zau je zelfs kunnen zeggen dat je de suikerziekte 
nog strenger moet proberen te behandelen en zelfs zou je dan kunnen overwegen 
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medicijnen te geven waarvan we weten dat het de nieraantasting door suikerziekte 
voorkomt of vertraagt. 
In hoofdstuk 4.2 hebben we gekeken naar het verband tussen het gm (erfelijke 
informatie voor een eiwit op een chromosoorn) voor prorerune en renine en het ontstaan 
van diabetischc nefropathie. Dit werd ingegeven door het sterke vermoeden dat erfelijke 
factoren een belangrijke rol spelen bij het ontstaan van diabetische nefropathie en door 
het afwijkende prorenine gehalte. Het bleek dat een bepaalde variant van het renine-gen 
een geringe invloed had op het ontstaan van diabetische nefropathie. Die invloed was 
echter zo gering dat je deze variant waarschijnlijk niet kunt gebruiken om nieraantasting 
bij suikerziekte te voorspellen. Verder bleek dat naast prorenin ook het reninegehalte 
verhoogd was. De heersende mening in de medische wereld is echter dat renine aan de 
lage kant is bij suikerziekte. We denken dat deze mening misschien wei herzien moet 
worden. Voorheen werden gebrekkiger methoden gebruikt om renine te meten en de 
resultaten waren toen wellicht minder betrouwbaar. Tenslotte, of (pro)renine de 
nieraantasting veroorzaakt is (nog) niet bekend. 
Het laatste hoofdstuk gaat over renine en prorenine in een weefsel, narnelijk het ~Og. 
De keuze van dit orgaan lijkt misschien wat ongewoon, maar bij oogoperaties is vrij 
gemakkelijk weefselvocht te verkrijgen, dat een afspiegeling is van het vocht dat de cellen 
van het weefsel omringt. Verder hebben we ook koeienogen gebruikt, die gemakkelijk in 
het slachthuis zijn te krijgen. Het blijkt dat renine en prorenine beide voorkomen in 
oogweefseIs, in concentraties die niet zijn te verklaren door bijrnengingvan bloed. In het 
binnenste, heldere, glasvochtlichaam van het oog komt voornamelijk prorenine voor, 
hetgeen zou kunnen bevestigen dat prorenine ter plaatse wordt gemaakt. Welke functie 
prorenin (en renine) zouden kunnen hebben in het oog is nogvolstrekt onduidelijk. Veel 
van de patienten hadden suikerziekte met aantastingvan de ogen. Het is niet uitgesloten 
dat (pro)renine een rol speelt bij deze aandoening. 
Al met al is de vraag of prorenine 'iets doet' nog steeds niet· met zekerheid 
beantwoord. Hoe zou het onderzoek naar prorenine nu verder moeten? Voor de 
patientenzorglijkt verder onderzoek naar het belangvan prorenine metingen bij patienten 
met suikerziekte van belang. Ais men namelijk in een vroeg stadium al het risico op een 
complicatie van suikerziekte kan bepalen, ontstaat ook de mogelijkheid al in een vroeg 
stadium in te grijpen met medicijnen en een striktere regelingvan de bloedsuikers. Of dit 
werkelijk zo werkt, dient bevestigd te worden. 
Dit onderzoek bij patienten met suikerziekte zal echter de hamvraag niet oplossen: 
doet prorenine nu iets of niet? In proefdieren en mensen blijft het moeilijk am onderzoek 
te doen naar prorenine, omdat ook altijd renine aanwezig is. Een mogelijke oplossing is, 
muizen te scheppen Oet op de pretentie van dat woord) die niet meer in staat zijn om 
renine en prorenin te maken of muizen die in de nier van prorenine geen renine meer 
kunnen maken. Het enzym dat voor dat laatste zorgt is nag niet bekend. Heeft men deze 
muizen, dan kunnen de volgende vragen beantwoord worden: Kan een muis zander 
renine? Is een muis dan wellevensvatbaar? Welke afwijkingen treden op? Wordt er nag 
angiotensine gemaakt als er aileen maar prorenine is? Dit soort onderzoek, met genetisch 
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gemanipuleerde dieren, kan veel informatie opleveren, maar is maatschappe1ijk 
omstreden. 
Tenslotte is het theoretisch mogelijk meer inzicht teverkrijgen in de structuur en het 
activatie-mechanisme van prorenine met behulp van spectroscopische technieken. U moet 
zich hierbij voorstellen dat moleculen met lieht of straling worden gebombardeerd. 
Moleculen hebben de eigensehap dat ze dan afhanke!ijk van hun struetuur een ander 
soort lieht of straling ('spectra') terugzenden. Dit kan met speciale apparatuur gemeten 
worden. Ook de recente waarnemingen in ons laboratorium dat prorenine aan cellen 
gebonden kan worden, zou hiermee onderzocht kunnen worden. Dezc technieken staan 
voor deze vraagstelling eehter nog in de kinderschoenen. 
Renine is al in 1898 ontdekt, prorenine in 1971. In de tussenliggende tijd is vee! 
bekend geworden over renine en prorenine, maar het moge duidelijk zijn dat na een 
eeuw, respectievelijk bijna30 jaar, nogvelevragen onbeantwoord blijven. Ik ben benieuwd 
of dat nog zo zal zijn in 2098 of 2071. 
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NAWOORD 
Beleidsmakers geven de indruk dat wetenschappelijk onderzoek zich goed leent voor 
planning, in grote onderzoeksscholen moet plaatsvinden en in ieder geval maatschappelijk 
relevant moet zijn. In dat licht dien je voor een succesvol promotie-onderzoek bij 
voorkeur op cen rijdende trein te springen, Hefst op een TGV. Het traject een aantal 
malen afleggen, telkens in een andere coupe, en je arriveert als doctor. Hogesnelheidslijnen 
zijn rendabel, stipt en hebben belangrijke bestemmingen; er is geen twijfel over nut. Het 
onderzoek dat heeft geleid tot dit proefschrift had nietsvan zo'n TGV-reis. Eerder was 
het een stoomboemeltje in een onbekend oerwoud, waar de reiziger zelf nog het spoor 
moest aanleggen. Langzaam is de weg van A naar B afgelegd, in terugblik zeker niet de 
kortste afstand tussen twee punten. Vaak was er langdurig oponthoud: geen druk op de 
ketel, boom op het SPOOf, een excursie, machinist malaria, geen rails op voorraad, lange 
aarzelingen bij wissels. En aI die tijd stapelden de volgeschoten fotorolletjes zich op. Er 
zijn er nu een paar ontwikkeld en de afdrukken zijn in dit album geplakt. De kleren zijn 
gewassen, vrouw en kinderen gekust. Maarten Schalekarnp heeft als reisleider en directeur 
van de spoorwegmaatschappij de reis tot een avantuur gemaakt, met gelukkig weinig 
aandacht VODr de dienstregeling. Geen comfort van 300 km/uur met air-conditioning, 
maar een daadwerkelijke ervaring van het landschap. Frans Derkx, de mede-reiziger en 
~spoorwegingenieur, Sjors van Kats, Lies Tan, Jeanette van Gool, Rene de Bruin, Jan 
Danser, Ton van den Meiracker, Frans Boomsma, Ellen Maurik, Arie Man in't Veld en aI 
die anderen die ik tijdens de tocht tegenkwam: U was aangenaam en behulpzaam 
gezelschap. Mijn dank daarvoor. Dank ook aan de leescommissie die zo sne! de 
spoorbomen sloot en het sein op groen zette. 
En nu? Promoveren is niet aankomen op een station, maar de mogelijkheid verkrijgen 
om weer op weg te gaan. Nee, niet met cen TGV. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd geboren in Ede. Na het doorlopen van de 
middelbare school volgde hij het propedeutisch jaar van de Vrije Hogeschool te 
Driebergen. In 1980 besloot hij, om onnavolgbare redenen, medicijnen te gaan studeren. 
In 1987legde hij het artsexamen af aan de Erasmus Universiteit te Rotterdam. Na een 
vervangende dienstplicht op de afdeling Interne Geneeskunde I van het Dijkzigt 
Ziekenhuis te Rotterdam, volgde hij van 1989 tot 1995 op deze afdeling de opleiding tot 
internist (opleider: prof. Dr M.A.D.H. Schalekamp). Sinds 1995 is hij alsstaflid verbonden 
aan deze afdeling. Hij is getrouwd met Ellen van der \Val en is vader van Sanne, Bouke en 
Penna. 
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Afkortingenlijst 
AngI, II 
AT1,2R 
AER 
ACE 
aHT 
BSA 
CHO 
CV 
IC" 
CI 
DN 
EKA 
IRMA 
IRP 
Km 
M, 
mAb 
PMSF 
PBS 
PRA 
PRC 
PCR 
PVP 
PI 
PR 
RIA 
RAS 
NaN, 
NIT 
SBTI 
SD 
angiotensin I, II 
angiotensin type 1,2 receptor 
albumin excretion rate 
angiotensin converting enzyme 
antihypertensive therapy 
bovine serum albumin 
chinese hamster ovary 
coefficient of variation 
concentration at which 50% inhibition 
occurs 
confidence interval 
diabetic nephropathy 
enzyme·kinetic assay 
immWloradiometric assay 
international reference preparation 
Michaelis constant 
molecular weight 
monoclonal antibody 
phenylmethylsulfonyl fluoride 
phosphate buffered saline 
plasma renin activity 
plasma renin concentration 
polymerase chain reaction 
polyvinylpyrrolidone 
prognostic index 
prorenin 
radioimmunoassay 
renin.angiotensin system 
sodium azide 
sodium tetratruonate 
soy bean trypsin inhibitor 
standard deviation 
protease 
~ ~ rev in 
remkiren 
.. 
~ 
.... 
.....--
~ 
prorenin closed ~ prorenin intermediary o~ -----PRo '~-.. ~PRe 
angiotensinogen? 
tissue factor? 
Schema van de structuur en activatie van prorenine zoals 
gepresenteerd in dit proefschrift. 'A' staat veor een aspartylgroep 
in de spleet tussen de twee labben van het renine~molecuul. H+ 
staat veor een zuur milieu. (Aangepast vanuit Deinum & 
Schalekamp Renin and prorenin. In Hypertension. Eds. Weber & 
Oparil, New York, 1999, mettoestemming) 
prorenin, open 
enzyrratically active 
PRe 
ERRATUM 
A mistyping occurred in two figures of chapter 5.1, 
In Figure 2 (page 137) and Figure 3 (page 138) the 
title of the x-axis of the lower panel should read 
'Renin substrate ca!culatednmol/L' 
structure and Regulation of ProreninfJ. Deinuml1999 
